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Abstract
Noninvasive imaging technologies, capable of visualizing early carcinoma or dormant or latent metastatic
tumor cells and evaluating the efficacy of cancer therapies are becoming increasingly important. In this
thesis, NIR-emissive polymersomes are engineered for optimal cellular uptake to enable fluorescencebased tumor targeting. A series of benzothiadiazole conjugated porphyrin oligomers with high emission
dipole strength and exceptional large quantum yields in the NIR region are synthesized for optimized
emissive output would be greatly enhanced. Furthermore, this thesis established for the first time a class
of universal chemistry modification methods to directly attach antibody to polymersomes surface with
very high antibody coupling efficiency and precise control of antibody density on polymersomes. These
antibody conjugated NIR-emissive polymersomes exhibit ideal cell-surface adhesion dynamics and
enables future in vivo tracking of labeled tumor cells by NIR fluorescence based imaging. Ultimately,
tracking residual disease in vivo requires biodegradable polymersomes. Towards this goal, we fabricated
analogous nanoscale NIR-emissive, soft-matter-based vesicles based on already FDA-approved materials
poly(caprolactone) (PCL) and poly(trimethylene carbonate ) (PTMC) blocks, and involves copolymer
synthesis, evaluation of vesicle physical properties, and polymersome functionalization. Finally, a new
emissive polymersomes platform is designed by quantitative incorporation of quantum dots into the
polymersomes bilayer membranes, featuring a wide range of applications for in vivo diagnostic and drugdelivery applications. In summary, this synthesis developed functionalized nanoscale NIR-emissive
polymersomes with optimal fluorescence output and ability to detect limited target cell numbers under
clinically relevant diagnostic conditions, and define new tools for the study of metastatic disease.
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ABSTRACT

NIR-EMISSIVE POLYMERSOMAL MARKERS FOR MOLECULAR-LEVEL
DETECTION OF METASTASIS

Wei Qi
Michael. J. Therien

Noninvasive imaging technologies, capable of visualizing early carcinoma or
dormant or latent metastatic tumor cells and evaluating the efficacy of cancer therapies
are becoming increasingly important. In this thesis, NIR-emissive polymersomes are
engineered for optimal cellular uptake to enable fluorescence-based tumor targeting. A
series of benzothiadiazole conjugated porphyrin oligomers with high emission dipole
strength and exceptional large quantum yields in the NIR region are synthesized for
optimized emissive output would be greatly enhanced. Furthermore, this thesis
established for the first time a class of universal chemistry modification methods to
directly attach antibody to polymersomes surface with very high antibody coupling
efficiency and precise control of antibody density on polymersomes. These antibody
conjugated NIR-emissive polymersomes exhibit ideal cell-surface adhesion dynamics and
enables future in vivo tracking of labeled tumor cells by NIR fluorescence based imaging.
Ultimately,

tracking

residual

disease

in

vivo

requires

biodegradable

polymersomes. Towards this goal, we fabricated analogous nanoscale NIR-emissive,
soft-matter-based vesicles based on already FDA-approved materials poly(caprolactone)
V

(PCL) and poly(trimethylene carbonate ) (PTMC) blocks, and involves copolymer
synthesis, evaluation of vesicle physical properties, and polymersome functionalization.
Finally, a new emissive polymersomes platform is designed by quantitative incorporation
of quantum dots into the polymersomes bilayer membranes, featuring a wide range of
applications for in vivo diagnostic and drug-delivery applications.
In summary, this synthesis developed functionalized nanoscale NIR-emissive
polymersomes with optimal fluorescence output and ability to detect limited target cell
numbers under clinically relevant diagnostic conditions, and define new tools for the
study of metastatic disease.
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CHAPTER 1. Introduction to Molecular-Level Detection of
Metastasis and the Specific Aims of the Thesis Dissertation
1.1. Molecular Imaging Sciences
1.1.1. Concept of Molecular Biology and Imaging
Molecular imaging is a new discipline that combines molecular biology and in
vivo imaging. Molecular imaging utilizes new molecular agents with traditional imaging
tools for the visualization, characterization, and measurement of biological processes at
molecular and cellular levels in the body. Molecular imaging differs from traditional
imaging in that new biomarkers are used as imaging probes to help image particular
targets or pathways. Biomarkers interact with their surroundings and in turn produce the
image according to molecular interactions occurring within the area of interest. This
process has significant advantages over the previous imaging methods which primarily
imaged differences in qualities such as density or water content. This ability to image fine
molecular and cellular pathways in vivo opens up an incredible number of exciting
possibilities for medical applications, including earlier detection and characterization of
metastasis by visualizing the cellular function and following up the molecular process in
living organisms without perturbing them. As a result, we will have a better
understanding of biology pathology, prospective evaluation of treatment, and basic
pharmaceutical development. The multiple and numerous potentialities of this field are
applicable to the diagnosis of diseases such as cancer, and neurological and
cardiovascular diseases. This technique also contributes to improving the treatment of
1

these diseases by optimizing the pre-clinical and clinical tests of new medication. They
are also expected to have a major economic impact due to earlier and more precise
diagnosis. Furthermore, molecular imaging allows for quantitative tests, provides
important insights for diagnosis, prognosis, and therapeutic design.
1.1.2. Advantages of Optical Imaging
A number of imaging modalities have current been used in clinical diagnostics,
including image via means of x-ray (x-ray computer tomography or CT), sound
(ultrasound), magnetism (magnetic resonance imaging or MRI), radiolabeled molecules
that produce signals by means of radioactive decay by nuclear imaging (positron
emission tomography or PET, and single-photon emission computed tomography or
PPECT),

and light (optical techniques of bioluminescence and fluorescence).The

transparency of date reduction to form the desired images by using these techniques are
shown in Figure 1.1.

2

A

B

Figure 1.1 A. Comparison of the utility of several commonly available radiological
imaging modalities for anatomical, physiological, and molecular-level investigation. CT
- x-ray computer tomography; US - ultrasonography; MRI - magnetic resonance imaging;
Nuclear - nuclear imaging; Optical - optical imaging. B. Size range of a few common
biology molecules.
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Therefore, among these different strategies, only MRI, nuclear imaging (PET or
PPETC), and optical imaging are suitable for molecular-level investigations. These
imaging technologies differ in five main aspects: (1) spatial resolution; (2) depth
penetration; (3) sensitivity (4) availability of injectable/biocompatible molecular probes;
and (5) tissue safety and facility of use (time and cost), as described in Table 1.1.
Considering the key advantages and disadvantages of these main available imaging
modalities, optical imaging holds the most promise for molecular imaging.
Optical molecular imaging offers significant advantages to nuclear imaging and
MRI‟s capabilities for life science and pre-clinical application. Nuclear imaging requires
the expensive process of creating radioisotopes, delivering these radioisotopes for use
within a very limited time frame to avoid decay, and the use of a very expensive
instrument to examine the results. MRI has the advantages of having very high spatial
resolution and has been widely used at morphological imaging and functional imaging.
However, MRI has a low sensitivity compared to other types of imaging due to the fact
that the difference between atoms in the high energy state and the low energy state in
MRI is very small. Therefore, MRI imaging normally requires long acquisition times of
limited regions of interest.1 This means a priori information is necessary to find and
image the cells of interest, and whole body imaging is not feasible for MRI.
In contrast to both MRI and nuclear imaging which started in the clinic and were
adapted for small animal studies, optical imaging emerged from techniques already
established at the molecular and cellular level. The development of fluorescence-based
optical imaging methods that utilize exogenous fluorescent dyes has gained a great deal
of attention. When introduced within the body, excited with laser diodes, the fluorescent
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dyes emit photons that can be detected externally by photomultiplier tubes (PMTs) or
with highly sensitive charge- coupled device (CCD) cameras.2-13 Optical imaging with
fluorescent light is particular attractive as the detectors are highly sensitive towards the
emitted photons and, hence, require only small amounts of contrast agents (nM) as
compared to with MR imaging (mM). Besides, the instruments and probes for optical
imaging are generally much cheaper, and can be made more mobile, when compared to
those for MRI and nuclear imaging.14 Further, emission of low-energy photons is
concentration-dependent, occurs on the time scale of the fastest molecular processes, and
is inherently dependent upon the emissive environment of the fluorescent agent.9, 10, 14, 15
At shallow depths, picomole quantities of the light emitting source can be detected. There
is also no harmful radiation or strong electromagnetic fields, thereby making it a safe
method for both the operator and study subjects.5-7, 12, 16 Image acquisition times are very
fast, enabling multiple animals to be imaged in one session. Notely, optical imaging can
detect diseases at a very early stage, long before other imaging modalities by allowing
nearly real-time monitering of cellular activity. It therefore holds enormous promise for
faster treatment of disease and better therapeutic outcomes. Longitudinal studies are
easily performed without limitations. Finally, the equipment is very affordable for
universities in comparison to the nuclear and MRI instruments.
As a result, fluorescence-based optical imaging is the overall superior modality
for small animal imaging research as its enables highly sensitive, safe, and affordable
detection of dynamic molecular-level events, with only minimal losses in spatial
resolution and signal attenuation due to short optical path lengths.
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Table 1.1 Comparison of different molecular imaging approaches.
Imaging

EM Radiation

Technique

Spectrum

CT

X-rays

Advantages

Bone

and

Disadvantages

tumor

imaging;

anatomic imaging
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'molecular'

applications;
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soft
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spatial
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Nuclear
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imaging
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molecular
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imaging method; high sensitivity
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near-infrared

nM contrast agent); quantitative
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path lengths.

and

in

spatial
signal

mobile equipment
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1.2. NIR Emissive Polymersomes as Optical Probes for in vivo Imaging
1.2.1. NIR Fluorescence for in vivo Optical Imaging
The goal for optically based method is to collect light emission in a spatially
resolved manner. The energy (E) of each photon of light is inversely proportional to its
wavelength (λ) according to the relationship, E = hλ, where h is Planck's constant. The
penetration of photons through a material such as the tissues in the human body is highly
dependent on the wavelength, or the energy. In vivo imaging with visible fluorophores is
inherently limited to very superficial tissue depths as a result of significant light
scattering and optical absorption. The main absorbing molecules in the tissue include
water, hemoglobin, and deoxyhemoglobin. Absorbance as a function of wavelength for
each of these molecules is depicted in Figure 1.2. With increasing wavelengths, light
scattering decreases appreciably and photon absorption of hemoglobin,

and

deoxyhemoglobin lessens, approaching a nadir over the near-infrared spectrum (600 1000 nm). Therefore, fluorescence-based imaging in this near-infrared spectral has
outstanding signal-to-noise ratios (SNR) due to minimum interference from tissue
autofluorescence, as seen in Figure 1.3. As a result, near-infrared optical imaging can
prospectively be used to resolve molecular events through deep tissue volumes at depths
of up to 12 cm.14 Realization of the full potential for fluorescence-based in vivo imaging
will be dependent upon the design of contrast agents that both absorb and emit in NIR.5, 7,
9, 11, 17
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Figure 1.2 The NIR window is ideally suited for in vivo imaging because of minimal
light absorption by hemoglobin (<650 nm) and water (>900 nm).
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Figure 1.3 Wavelength-dependent autofluorescence of vital organs and bodily fluids.
(a) Immediately after sacrifice, the viscera of a hairless, athymic nu/nu mouse were
exposed.

Tissue

autofluorescence

was

then

imaged

using

three

different

excitation/emission filter sets: (b) blue/green (460–500 nm/505–560 nm); (c) green/red
(525–555 nm/590–650 nm); and (d) NIR (725–775 nm/790–830 nm). The fluence rate
provided by each filter set was adjusted to 2 mW/cm2. To compensate for differences in
emission filter wavelength width and camera sensitivity, exposure times were adjusted
accordingly. Fluorescence images have identical normalization. For orientation, the white
light color image of the animal is shown in (a). Arrows mark the location of the
gallbladder (GB), small intestine (SI) and bladder (Bl).18
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1.2.2. NIR Fluorescence Imaging Probes
The earliest NIR imaging applications utilized fluorochrome indocyanine green
(ICG) for the non-invasive detection of tumors in both animals and patients.5 ICG is a
small molecule (Mw = 775 g/mol) that emits NIR light at 800 nm upon optical excitation
at 780 nm.19 It exhibits strong albumin binding and shows preferential uptake and
retention in tumors as a result of increased vascular permeability through surrounding
leaky blood vessels.20 However, ICG possesses a short circulation half-life due to its
susceptibity to the body's first-pass metabolism, resulted in rapid clearance from the
blood.21 In addition, ICG's spectra are altered22 and its quantum yield significantly
decreases when bound to albumin.23 In order to improve these optical characteristics and
to augment ICG's tumor uptake and contrasting capabilities, dye derivatives that possess
better water solubility, decreased protein binding, and more favorable pharmacokinetics
have been synthesized.23, 24 In general, ICG and its derivatives offer basic physiological
information such as tissue perfusion and accumulation effects with no additional
molecular information.
The energy gap law states that as the energy difference between a fluorophore's
ground and excited state decreases, non-radiative decay pathways increasingly dominate
its excited state relaxation.25 As a result, there is a relative small number of organic-based
NIR fluorophores, while the existing ones such as ICG and derivatives often lack the
ideal properties for generating strong fluorescent signals though deep tissue sections,
necessary for both large animal and clinical imaging applications.
One alternative strategy to solve the problems associated with NIR imaging with
organic fluorophores is to use inorganic semicondutor nanoparticles (i.e. quantum dots)
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Quantum dots are nanocrystals with a core/shell structure comprised of transition metals
(e.g. Cd, Se, S, and/or Zn) surrounded by a water-soluble organic coating.

3, 26-29

By

controlling the size of quantum dots, the band gap can be adjusted and enables tuning of
its narrow fluorescence emission band (25-35 nm) with considerable accuracy.

In

addition to large extinction coefficients and high fluorescence quantum yields, NIRemissive quantum dots also possess high photobleaching thresholds.30 Further, the ready
commercial availability of these agents offers exciting opportunities for detection of
molecular targets both in vitro and in vivo.3,

31-33

However, quantum dots tend to

aggregate in aqueous solution, thereby losing their fluorescence.34 In addition, quantum
dots are normally constructed from toxic elemental materials,35 and the relatively large
sizes of their NIR compositions are too large to be cleared via renal filtration, resulting in
high fluorescence background noise and increased potential for in vivo toxicity.36
1.2.3. Novel NIR Emissive Polymersomes
The ideal NIR agent should possess: (1) Large NIR absorption extinction
coefficients; (2) High NIR fluorescence quantum yields; (3) High photo-bleaching
thresholds; (4) No photo-based cellular toxicity; (5) Good water solubility; (6) Safe and
complete in vivo clearance. Towards this goal, lots of effort has been devoted to NIR
emissive nanocarriers as fluorescence probes, as displayed in Figure 1.4.37
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Figure 1.4 a, A whole range of delivery agents are possible but the main components
typically include a nanocarrier, a targeting moiety conjugated to the nanocarrier, and a
cargo (such as the desired chemotherapeutic drugs). b, Schematic diagram of the drug
conjugation and entrapment processes. The chemotherapeutics could be bound to the
nanocarrier, as in the use of polymer–drug conjugates, dendrimers and some particulate
carriers, or they could be entrapped inside the nanocarrier. 37
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Nanocarriers have been classified based on their physical forms to liposomes,
polymersomes, microspheres, nanoparticles and etc. Among all these different types of
nanocarriers, our lab focused on developing self-assembling polymeric vesicles housing
porphyrin-based NIR fluorophores in the hydrophobic bilayer.38-45 There are significant
advantages of using this porphyrin incorporated NIR emissive polymersomes over
quantum dots or other types of emissive nanocarries.
Porphyrin is an organic molecule containing four pyrrole (C4H5N) rings. The
heme structure of hemoglobin is an example of a porphyrin in biology. Nitrogen atoms of
porphyrin molecules coordinate to complex with metals such as iron by hemoglobin. By
synthesizing porphyrin macromolecules based on conjugating multiple zinc binding
porphyrin chromophores together, we can tune their spectral properties including excitedstate absorptivity, NIR fluorescence, and achieve high quantum yields in the nearinfrared regime.
The most important polymersome feature with regard to fluorophore
incorporation is the thick hydrophobic membrane core for incorporation of a large
amount of fluorescent contrast agents. For example, the 800 nm NIR dye porphyrin
trimer (PZn3) is a nanometric macromolecule at 3.2 nm in length46 which is too large for
incorporation into liposome membranes.39 Polymersomes easily accommodate PZn3 with
little change to the fluorescence spectral properties or polymersome mechanical
properties. Intermolecular fluorophore quenching is minimized by using high polymer to
porphyrin ratios 40:1.
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Properties of polymersomes which make them optimal delivery vehicles also
include the 100% hydrophilic, non-immunogenic PEGylated surfaces with well-proven
shielding capacity against protein opsonization,47 as well as the tunable size from 10 μm
to 50 nm in diameter, lead to longer in vivo circulation times in comparison to liposomes,
the biological counterpart to polymersomes.
In addition to housing fluophores, the vesicular nature of polymersomes makes
them adaptable for making multifunctional reagents. These polymer vesicles are
multifaceted with mechanically robust membranes, have an ability to sequester both
hydrophobic and hydrophilic reagents. Therefore, a second imaging contrast agent could
be encapsulated into the aqueous center yielding a dual modality agent. Alternatively,
drug can be loaded into the hydrophilic core to combine drug delivery with in vivo
monitoring of vesicle biodistributions. Attaching receptor ligands on the PEO brush
would provide in vivo targeted vesicles to the complimentary receptor for diagnostic
purposes. Finally, conjugating tumor targeting antibodies to the exterior brush of the
polymersomal nanoscale vesicles would enable cellular uptake and effectively generate
NIR-emissive cells.

1.3. Principles of Targeted Delivery
1.3.1. Advantages of Targeted Delivery
The development of successful targeting agents will have dramatic impacts for a
number of medical applications, particularly the diagnostic capabilities of imaging agents
and improving the specificity of highly toxic drugs used to treat diseases.48 By far the
greatest benefits occurs with the use of chemotherapeutics to treat cancer. Currently,
general protocols for the treatment of cancer rely on administering chemotherapeutic
14

agents as either single agents or in combination with other drugs. Frequently, the use of
novel therapeutics in medicine is limited by the lack of efficiency in delivery of these
therapeutic agents to the target organs. After a therapeutical agent is administered to the
body, it undergoes even bio-distribution throughout the body. In order to reach the
therapeutical site, these agents have to cross several biological barriers in the body such
as organs, tissues, cells etc., where these agents could be adsorbed, metabolized or
excreted out of the body.49-51 Therefore, to increase the effectiveness of drugs, the doses
for these agents are, in most instances, administered at the drug's maximum tolerated
dose. The unfortunate impact of treating at such high doses is the undesirable side effects
which can be life-threatening. Therefore, most chemotherapeutic agents exhibit very
narrow therapeutic windows due to the drug toxicity and poor therapeutic activity at
nontoxic doses.
Targeted drug delivery can address the above problems by localizing drugs to a
specific target site to provide a major advancement for anti-cancer drug therapy, as it will
allow for more effective treatments to be given at doses that are better tolerated. During
the last three decades there has been intense effort directed towards the development of
targeted drug delivery systems to efficiently transport the drug to its therapeutical site by
the appropriate choice of carrier, route, and target. The use of a carrier system for
delivering drugs to the body provides several opportunities for achieving the goal of drug
targeting. Some potential advantages of targeted drug delivery are: (a) Smaller amounts
of drug dosages and facilitation of administration; (b) Maintenance of constant drug
levels in the therapeutical range; (c )Reduction of drug toxicity and fewer side effects
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when targeted to specific tissues or organs; (d) Protection of biologically active drug
molecules like peptides and proteins from degradation during transport.49, 52
1.3.2. Passive Targeting vs. Active Targeting
Due to its macromolecular nature, nano-sized delivery vehicles such as micelles,
liposomes and polymersomes can accumulate passively in target tissues such as the
reticuloendothelial system (RES) through nonspecific uptake by macrophages, or in
extravascular disease sites including sites of infection, inflammation, and tumors by a
process called the enhanced permeability and retention (EPR) effect.53, 54 The mechanism
of the EPR effect has been summarized according to the following cascade of events: (i)
tumor angiogenesis results in hypervasculature, providing increased blood flow to the
tumor; (ii) tumor vasculature becomes highly permeable for nano-sized delivery vehicles
to escape through blood vessel walls into tissues.; (iii) leaky blood vessels and defective
lymphatic drainage, causing nano-sized delivery vehicles to accumulate in them. These
factors result in larger carriers having decreased renal clearance, thereby taking longer to
be eliminated from the body.55 Through passive targeting, the nano-sized delivery
vehicles accumulation can result in a much larger amount of drug delivery compared to
the injection of the same dose of free drug, protecting healthy tissue and greatly reducing
adverse side effects.56, 57 However, the majority of localized nontargeted delivery vehicles
do not interact with target cells directly, and the therapeutic activity is a consequence of
drug release from nanoparticles within the disease site, a process that does not require
direct binding or association with diseased cells.58
The facilitation of the binding of the delivery vehicles to target cells through the
use of ligands that are capable of recognizing and binding to cells of interest, such as
16

monoclonal antibodies or peptides, to increase localization of drug and target cell is
referred to as active targeting. Active targeting can direct delivery vehicles to tissues
where they would not normally accumulate and increasing drug accumulation in the
desired tissues and organs.59 Active targeting can be combined with passive targeting to
further reduce the interaction of carried drugs with healthy tissue. Nanotechnologyenabled active and passive targeting can also increase the efficacy of a chemotherapeutic,
achieving greater tumor reduction with lower doses of the drug.
Two qualities are important for an active targeting system. One is the specificity
of actively targeted delivery vehicles that is dependent upon the surface ligand's affinity
for a target cell marker. The second is the ability to enable the deliver the required dose
of drug for the required period of time and to overcome biological delivery barriers50, 51,
an important issue for all imaging modalities. Possible solutions60 to this include targeted
local delivery and development of long circulating compounds that provides a more
homogeneous distribution of agent. Therefore, the development of targeted probes are
composed directly against a specific moiety targeted to the molecule, receptor or enzyme
of interest and an imaging component that provides the physical contrast with a
prolonged circulation time of the delivery vehicles in vivo.
1.3.3. Polymer Functionalization for Targeted Delivery
Polymersomes are a great choice as drug carriers for targeted delivery.
Polymersomes have several advantages over other drug delivery systems due to their
biocompatibility, capability of self-assembly, ability for loading hydrophobic and
hydrophilic encapsulates, broad range of tunable physical properties and a wide diversity
of chemistries for polymer modification. These NIR polymersome characteristics led us
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to investigate the application of these optical agents for drug delivery and specific tumor
cell targeting.
It has been shown that a number of drug molecules improved their therapeutic
effects and their targeted delivery in vivo when encapsulated inside polymersomes.61
Such improvement is achieved by (1) retaining the drug molecules inside the
polymersomes, therefore avoiding the exposure to tissues or blood and minimizing the
nonspecific uptake of drug molecules by normal undiseased tissues; (2) selectively
targeting the tissue of interest and releasing the content at the targeted region. These two
criteria have been primary reasons for use of polymersomes as drug delivery cargo. In
order to make the polymersomes selective for certain tissues and cells, it is important to
functionalize the polymersome surface with site-specific ligands.
Functionalized polymersomes provides a versatile carrier platform for the targeted
delivery of therapeutics to the interior of the tumor cell and offers the possibility to
greatly improve treatment outcomes for diseases by enhancing specificity and minimizing
side effects compared to conventional drugs and liposomes.

1.4. Specific Aims of the Thesis Dissertation
The detection of early carcinoma or dormant or latent metastatic tumor cells
remains an elusive but important clinical goal. We seek to develop further revolutionary
new nanotechnology that enables optically based detection of metastatic cancer cells.
Towards this goal, we will further refine design criteria for near infrared (NIR) emissive
polymersomes, a promising new soft matter nanoscale platform for in vivo diagnostic and
drug-delivery applications.

This program will develop (i) nanoscale NIR-emissive

polymersomes having optimized emissive output; (ii) targeted nanoscale (diameter ≤ 100
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nm) NIR-emissive polymersomes; (iii) prototype targeted nanoscale vesicles in which the
polymeric building blocks are based-upon FDA-approved materials; (iv) targeted NIRemissive polymersomes with ideal cell-surface adhesion dynamics; and (v) methods and
technology that provide not only new insights into metastatic disease, but define an
evolvable nanoscale platform for in vivo dormant tumor cell detection, diagnosis, and
treatment. These efforts involve correlating NIR fluorophore structure and photophysics,
polymersome composition of matter, vesicle mechanical and biological properties,
nanoscale NIR-emissive polymersome fluorescence output, and the nature of the cellular
targeting motif, with in vivo function and efficacy. As such, the experimental approach
we pursue is cross-cutting and integrative, encompassing supramolecular chemical
synthesis, photophysical characterization, in vivo imaging, bioengineering, biology, and
medicine. We strive to establish design principles that will ultimately enable real-time
detection and identification of limited target cell numbers under clinically relevant
diagnostic conditions, and define new tools for the study of metastatic disease.
1.4.1. Aim 1- Chapter 2: Engineering and Design of Porphyrin Based Fluorophores
for Optimized NIR Emission Output
The first aim of this thesis dissertation involves the synthesis of high emission
dipole strength porphyrin-based fluorophores with great enhancement of emission
intensity and luminescence quantum yields. A class of quinoidal spacer conjugated
(porphinato)zinc(II) (PZn-(BTD-PZn)n, (PZn)2-(BTD-(PZn)2)n) and

(BTD-(PZn)n-

BTD) complexes that possess intervening conjugated BTD spacer with varying degrees
of porphyrin conjugation have been synthesized. These BTD conjugated porphyrin
species possess large magnitude NIR S1 → S0 fluorescence quantum yields superior to
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the highest reported for NIR laser dyes in the 750−900 nm regime. The synthesis, optical
spectroscopy, potentiometric studies, and electronic structural calculations are reported
and show that the magnitudes of the potentiometric HOMO−LUMO gap (Ep) and
quantum yields in conjugated organic materials can both be modulated.
1.4.2. Aim 2 - Chapter 3: Develop Antibody-Conjugated Polymersomes for
Immunochemical Applications
We aim to develop a series of chemical modification procedures to functionalize
the hydrophilic PEO terminus with selected activated functional groups. These activated
moieties will enable covalent attachment of these species to proteins or antibodies. The
optimized procedures for the maximum antibody conjugation efficiency and
polymersomes yield are established. The impacts of reactive hydrophilic surface
functionality and antibody concentration on maximal loading of targeting antibodies are
also assessed to give controlled antibody conjugation degree on polymersomes surface.
Antibody conjugation to a functionalized NIR-emissive polymersome having a diameter
less than 100 nm provides a nanoscale object targeted to a cell-surface-specific structure.
We aim at test the ability of using these antibody-conjugated NIR-emissive
polymersomes to label cells and measure fluorescence signal intensity in tumor cells. We
will demonstrate the efficiency of these polymersomes to detect metastatic tumor cells
and provide fundamental new information regarding metastasis. These studies will
correlate NIR optical signal intensity with absolute tumor cell numbers. Detection
sensitivity levels will be determined, and the potential for using antibody-conjugated
NIR-emissive polymersomes as a detection system for early tumors, as well as dormant
or latent metastases, will be assessed.
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1.4.3. Aim 3 - Chapter 4: Elaboration of First-Generation Targeted Nanoscale
Emissive Polymersomes on Which the Polymeric Vesicular Building Blocks
are Based-Upon FDA-Approved Biodegradable Polymers
The fouth aim of this thesis dissertation involves the formation of functionalized
polymersomes through self-assembly of an amphiphilic bioresorbable polymer consisting
of previously FDA-approved building blocks: poly(ethyleneoxide) (PEO) , poly(εcaprolactone) (PCL) and poly(1,3-trimethylene carbonate) (PTMC). A varies of PEO-bPCL, PEO-b-PTMC diblock copolymers and PEO-b-P(CL-co-TMC)triblock copolymers
are synthesized and their ability to self-assembly into meso- and nano-scale
polymersomes are examined. Further, we synthesize vinyl sulfone functionalized PEO-bPCl diblock copolymers which can be readily used for peptide conjugation and tumor
targeting. As such, these bioresorbable polymersomes hold promise as nanomaterials for
future imaging, targeting and drug delivery applications.
1.4.4. Aim 4 - Chapter 5: Develop Nanoparticles Incorporated Polymersomes with
Quantitative Membrane Loading
We aim at incorporating various nanoparticles within the thick bilayered
membranes of polymer vesicles for wide-ranging potential applications in cellular
imaging and manipulation. Methodology for the generation of polymer vesicles with
various nanoparticles including different sized CdSe/ZnS quantum dots and gold
nanoparticles loaded in the bilayer membrane through a teflon-based thin-filmrehydration method is established. Quantum dots with no aqueous solubility can be
quantitatively and reproducibly loaded within polymersome membranes at prescribed
molar ratios. The effects of vesicle loading on the absorptive and emissive properties of
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quantum dots, as well as whole polymersomal ensembles, are examined. Nanoparticlesloading-dependent changes on vesicle thermodynamic and mechanical stabilities are
further tested and the results reported.
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CHAPTER 2. Synthesis, Characterization and Properties of
Conjugated

(Porphinato)zinc(II)

Compounds

Featuring

Benzothiadiazole Spacer Units
2.1.

Summary
Imaging in the NIR region (700–1100 nm) have numerous advantages for

biomedical applications because of low background absorption, low scattering and cheap
illumination sources.1,

2

In the design and synthesis of NIR emissive compounds,

problems have been encountered such as aggregation,3 photobleaching,4 and low
fluorescence quantum yields.5 There is a pressing need for the identification of highly
effective NIR emissive materials. Towards this purpose, we report the synthesis, optical,
electrochemical, electronic structural, and transient optical properties of a class of
conjugated (porphinato)zinc(II) complexes with an induced spacer group 1,3benzothiadiazole (BTD) that regulate frontier orbital energy levels and progressively
increase the extent of the quinoidal resonance contribution to the ground and
electronically excited states, augmenting the magnitude of electronic communication and
optimize their optical properties. For (porphinato)zinc(II)-BTD-(porphinato)zinc(II)
(PZn-(BTD-PZn)n

and (PZn)2-(BTD-(PZn)2)n) complexes that featuring the BTD

spacer in-between the porphyrin monomers and dimers, the potentiometrically
determined HOMO-LUMO gaps (E1/20/+ – E1/2–/0) display correspondingly diminished
energy separations with an increasing in the porphyrin conjugation length, with the
emission spectra greatly red-shifts with increasing numbers of conjugated monomeric
units, penetrating well into the NIR. Furthermore, these compounds possess very high
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oscillator strength and extraordinary large NIR fluorescence quantum yields of 17%-38%
in THF, and 18-59% in toluene, while overcoming solvent and stability issues associated
with most other NIR laser dyes.6 The results are remarkable and demonstrate that the S1
→Sn transition manifolds of these species span an unusually broad spectral domain of the
NIR. These data highlight the unusually large quinoidal resonance contribution to the
low-lying electronically excited singlet states of these BTD conjugated porphyrin species.
To better understand how the BTD spacer reduces and tunes energy gaps between
the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular
orbital (LUMO) of such π-conjugated species and increase the quantum yield, we further
design

another

series

of

BTD-(porphinato)zinc(II)-BTD

(BTD-(PZn)n-BTD)

supermolecules with the BTD spacer at the end positions of the conjugated
multiporphyrin oligomers. These BTD conjugated multiporphyrin compounds show
futher red-shifts of the respective x-polarized Q state (S0→S1) transition manifold
maxima in the NIR region relative to the BTD spaced porphyrin oligomers, together with
very high quantum yields. Electronic structural differences, as well as the relative
magnitudes of the optical (Eop) and potentiometric (Ep) band gaps of all these BTD
conjugated porphyrin structures are rationalized within the context of perturbation theory.
The fact that the quantum yields of these BTD conjugated porphyrin possess NIR S1→Sn
manifold absorptions lower in energy with respect to those of classic conducting
polymers, yet with an exceptional high quantum yields, underscore the unusual
electrooptic properties of these conjugated structures.
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2.2.

Introduction
Low band gap organic materials can be used as photonic devices with a wide

range of applications as photovoltaics,7, 8 LEDs,9, 10 electro-optic modulators11, 12, optical
limiters,13, 14, and especially in vivo biomedical imaging probes.15 All these applications
necessitate highly conjugated materials that manifest at least one type of singlet manifold
transition with unusual intensity in the near-infrared (NIR). The excited-states of active
conjugated, low band-gap materials usually have shortened excited-state lifetimes due to
large magnitude Franck-Condon mediated nonradiative decay, congruent with the energy
gap law.16, 17 Most available NIR-emissive fluorophores possess modest quantum yields
with additional undesirable limitations of low chemical and photostability, and a marked
sensitivity to solvent polarity.5, 6 Relative few organic oligomers or polymers have been
identified to possess excited singlet states which absorb strongly in the NIR. To enhance
electrical properties, small band gap materials have become a synthetic goal in
organic/polymer electronics. Construction of either polymers consisting of donor and
acceptors or oligomers that have mid gap states is one means to tune the band gap of
photonic materials. Another possible method is by addition of monomer repeat units to a
monomer unit that possess modest optical, Eop, and electropotential, Epo, band gaps. Upon
addition of monomer repeat units, the band gap sufficiently decreases.
A great candidate for small Eop and Epo oligomer and polymer electronic material
is porphyrins. Porphyrins are a tetrapyrrolic-conjugated macrocycles with large πconjugated ring systems and heteroatoms that give rise to porphyrin-porphyrin πinteractions and possess modest potentiometrically determined HOMO-LUMO gaps (Ep;
E1/20/+ – E1/2–/0), relative to those of the common monomeric aromatic building blocks
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used to construct traditional electronic polymers.

The electronic properties of

(porphinato)metal compounds can be modulated extensively by variation of the
macrocycle peripheral meso- or β-substituents, as well as by selection of the central metal
ion; further, a variety of modes of porphyrinoid-porphyrinoid connectivity provides
sufficiently strong interchromophore electronic interactions to facilitate extensive
electronic delocalization.18-31 In addition, an established means to further reduce the Eop
and Ep gaps of π-conjugated materials involves introducing quinoid-like character into
the conjugation main-chain.32-34 Porphyrin-to-porphyrin bridging motifs involving
ethynes and spacers that induce a quinoidal structural perturbation with appropriately
positioned frontier orbital energy levels, can greatly enhance ground- and excited-state πconjugation, and effect further reduction in Eop and Ep in the corresponding oligomeric
and polymeric structures.35
Our

group

(porphinato)zinc(II)

has

synthesized

(PZn-Sp-PZn)

conjugated

complexes

(porphinato)zinc(II)-spacer-

feature

Sp

moieties

4,7-

diethynylbenzo[c][1,2,5]thiadiazole (E-BTD-E), 6,13-diethynylpentacene (E-PC-E), 4,9diethynyl-6,7-dimethyl[1,2,5]thiadiazolo[3,4-g]quinoxaline

(E-TDQ-E),

and

4,8-

diethynylbenzo[1,2-c:4,5-c„]bis([1,2,5]thiadiazole) (E-BBTD-E). Among these different
spacers, BTD was found to demonstrate the highest quantum yield. Thus, we further
developed a new class of BTD featured porphyrin supermolecules with both BTD spacer
in-between the porphyrin oligomers such as (PZn-(BTD-PZn)n and (PZn)2-(BTD(PZn)2)n), as well as BTD spacer at the end positions of the conjugated multiporphyrin
oligomers (BTD-(PZn)n-BTD). As we expected, all these compounds exhibit very large
quantum yields that are superior to the highest reported quantum yields for organic
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chromophores in the NIR regime.36 The synthesis, optical spectroscopy, potentiometric
studies, and electronic structural calculations are reported and show that the magnitudes
of the potentiometric HOMO−LUMO gap (Ep) and quantum yields in conjugated organic
materials can both be modulated.

2.3.

Experimental Methods

2.3.1.

Materials
All manipulations were carried out under argon previously passed through an O2

scrubbing tower (Schweitzerhall R3-11 catalyst) and a drying tower (Linde 3-Å
molecular sieves) unless otherwise stated. Air sensitive solids were handled in a Braun
150-M glove box.

Standard Schlenk techniques were employed to manipulate air-

sensitive solutions.

Unless otherwise noted, all solvents utilized in this work were

obtained from Fisher Scientific (HPLC grade); tetrahydrofuran (THF) was distilled from
K/4-benzoylbiphenyl under N2. Diisopropylamine, Triethylamine, MeOH, CHCl3 and
CH2Cl2 were distilled from CaH2 under N2. Pyridine and piperidine was also dried over
CaH2 and distilled under reduced pressure. The catalysts tetrakis (triphenylphosphine)
palladium

Pd(PPh3)4,

bis(triphenylphosphine)

palladium

chloride

Pd(PPh3)2Cl2,

tris(dibenzylideneacetone) dipalladium(0) Pd2dba3, copper iodide CuI, triphenylarsine
AsPh3 and triphenylphosphine P(o-tol)3 were purchased from Strem Chemicals and used
as

received.

4-bromo-benzo[c][1,2,5]thiadiazole,

4,7-

Dibromobenzo[c][1,2,5]thiadiazole,37 were prepared by literature methods. All NMR
solvents were used as received. The supporting electrolyte used in the electrochemical
experiments, tetra-n-butylammonium hexafluorophosphate, was recrystallized twice from
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ethanol and dried under vacuum at 70 ˚C overnight prior to use. All the other chemicals
were used as received.
Chemical shifts for 1H NMR spectra are relative to tetramethylsilane (TMS)
signal in the deuterated solvent (TMS = 0.00 ppm). All J values are reported in Hertz.
Flash and size exclusion column chromatography were performed on the bench top, using
respectively silica gel (EM Science, 230–400 mesh) and Bio-Rad Bio-Beads SX-1 as
media. MALDI-TOF spectroscopic data were obtained with a Perspective Voyager DE
instrument in the Laboratory of Dr. W. Degrado (Department of Biophysics, University
of Pennsylvania); samples for these experiments were prepared as micromolar solutions
in THF or CH2Cl2, and dithranol in THF or cyano-4-hydroxycinnamic acid in
CH2Cl2/isopropyl alcohol (4:1) were utilized as the matrix.
2.3.2.

Instrumentation
Electronic absorption spectra were recorded on a Shimazu UV/vis/near-IR

spectrophotometry system that is based on the optics of a Cary 14 spectrophotometer.
NMR spectra were recorded on 500 MHz DMX-300 Brüker spectrometers. Cyclic
voltammetric measurements were carried out on an EG&G Princeton Applied Research
model 273A Potentiostat/Galvanostat.

The electrochemical cell used for these

experiments utilized a platinum disk working electrode, a platinum wire counter electrode,
and a saturated calomel reference electrode (SCE).

The reference electrode was

separated from the bulk solution by a junction bridge filled with the corresponding
solvent/supporting electrolyte solution. The ferrocene/ferrocenium redox couple was
utilized as an internal potentiometric standard.
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Figure 2.1 Structures of the BTD conjugated porphyrin compounds.
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2.3.3.

Synthesis
Previously made porphyrin compounds see supplemental of literatures.38, 39
4,7-Bis[(10,20-bis[2’,6’-bis(3’’,3’’-dimethyl-1’’-

butyloxy)phenyl]porphinato)zinc(II)-5-ylethynyl]benzo[c][1,2,5]thiadiazole (PZnEBTD-EPZn)

(1).

(5-Ethynyl-10,

butyloxy)phenyl]porphinato)zinc(II)

(0.100g,

20-bis[2‟,6‟-bis(3,3-dimethyl-11.05×10-4

mol),

4,7-

dibromobenzo[c][1,2,5]thiadiazole (12.9 mg, 4.4×10-5 mol) were charged into a Schlenk
Flask with Pd2dba3 (12.1 mg, 1.32×10-5 mol) and AsPh3 (32.3 mg, 1.05×10-4 mol). THF:
iPr2NH (9:1 ml) solvent mixture was degassed with an Ar purge for 30 min prior to
solvent transfer. Once solvent was transferred, the reaction mixture was stirred at 50 ºC
overnight under Ar. After the solvent was evaporated, the residue was chromatographed
on silica gel using 5:1 hexanes:THF as the eluant. Yield = 82 mg (91.6 % based on 12.9
1

mg of the dibromobenzo[c][1,2,5]thiadiazole starting material).

H NMR (500 MHz,

CDCl3): 10.12 (d, 4H, J = 4.4 Hz, β-H), 10.04 (s, 2H, meso-H), 9.21 (d, 4H, J = 4.4 Hz,
β-H), 9.06 (d, 4H, J = 4.5 Hz, β-H), 8.92 (d, 4H, J = 4.3 Hz, β-H), 8.37 (s, 2H, Ph-H),
7.74 (t, 4H, J = 8.6 Hz, Ph-H), 7.04 (d, 8H, J = 8.6 Hz, Ph-H), 3.94 (t, 16H, J = 7.2 Hz, O-CH2-C), 0.87 (t, 16H, J = 7.6 Hz, -O-C-CH2-C), 0.24 (s, 72H, -C-CH3). MALDI-TOF
MS m/z : 2029.98 (M+) (calcd 2028.884).

(5-[7’-Bromobenzo[c][1,2,5]thiadiazole-

ethyn-4’-yl]

bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)
bis[2‟,6‟-bis(3,3-dimethyl-1-butyloxy)phenyl]porphinato)zinc(II)

-10,20-bis[2’,6’-

(2).

(5-Ethynyl-10,20-

(0.100g,

1.05×10-4

mol), 4, 7-dibromobenzo[c][1,2,5]thiadiazole (123.7 mg, 4.21×10-4 mol) were charged
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into a Schlenk Flask with Pd2dba3 (14.4 mg, 1.57×10-5 mol) and AsPh3 (38.5 mg,
1.26×10-4 mol). THF: iPr2NH (9:1 ml) solvent mixture was degassed with an Ar purge
for 30 min prior to solvent transfer. Once solvent was transferred, the reaction mixture,
was stirred at 50 ºC overnight under Ar. After the solvent was evaporated, the residue
was chromatographed on silica gel using 5:1 hexanes:THF as the eluant. Yield = 0.118 g
(96.6 % based on 100 mg of the porphyrin starting material). 1H NMR (500 MHz,
CDCl3): 10.06 (s, 1H, meso-H), 10.01 (d, 2H, J = 4.4 Hz, β-H), 9.22 (d, 2H, J = 4.4 Hz,
β-H), 9.02 (d, 2H, J = 4.5 Hz, β-H), 8.91 (d, 2H, J = 4.5 Hz, β-H), 8.07 (d, 1H, J = 7.4 Hz,
Ph-H), 8.01(d, 1H, J = 7.5 Hz, Ph-H), 7.71 (t, 2H, J = 8.6 Hz, Ph-H), 7.01 (d, 4H, J = 8.6
Hz, Ph-H), 3.90 (t, 8H, J = 7.3 Hz, -O-CH2-C), 0.87 (t, 8H, J = 7.0 Hz, -O-C-CH2-C),
0.22 (s, 36H, -C-CH3).

(5,

15-Bis[7’-([10’’’,20’’’-bis[2’’’’,6’’’’-bis(3’’’’’,3’’’’’-dimethyl-1’’’’’-

butyloxy)phenyl]porphinato)zinc(II)-5’’-ylethynyl]benzo[c][1,2,5]thiadiazole-ethyn4’-yl]-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)
(PZnE-BTD-EPZnE-BTD-EPZn) (3). Compound 2 (0.100g, 8.59×10-5 mol), (5, 15diethynyl-10, 20-bis[2‟,6‟-bis(3,3-dimethyl-1-butyloxy)phenyl]porphinato)zinc(II) (34.9
mg, 3.58×10-5 mol) were charged into a Schlenk Flask with Pd2dba3 (9.83 mg, 1.07×10-5
mol) and P(o-tol)3 (26.1 mg, 8.59×10-5 mol). THF: TEA (9:1 ml) solvent mixture was
degassed with an Ar purge for 30 min prior to solvent transfer. Once solvent was
transferred, the reaction mixture was stirred at 60 ºC overnight under Ar. The reaction
mixture was then poured down a short silica gel column using CHCl3: MeOH (49:1 mL)
as the eluent. A large band was collected and the solvent stripped and then the residue
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was taken up in THF and put down a size exclusion column (BioRad Biobeads, SX-1)
and chromatographed gravimetrically. The first band was collected and solvent removed
via vacuum and the residue was purified by silica gel chromatography using CHCl3:
MeOH (49:1 mL) as the eluent. Yield = 114 mg (58% based on diethynyl starting
material). 1H NMR (500 MHz, CDCl3): 10.02 (d, 4H, J = 4.4 Hz, β-H), 9.94 (d, 4H, J =
4.5 Hz, β-H), 9.86 (s, 2H, meso-H), 9.08 (d, 4H, J = 4.2 Hz, β-H), 8.96 (d, 4H, J = 4.3 Hz,
β-H), 8.86 (d, 4H, J = 4.5 Hz, β-H), 8.81(d, 4H, J = 4.2 Hz, β-H), 8.26 (s, 4H, Ph-H),
7.70 (t, 6H, J = 8.6 Hz, Ph-H), 7.02 (d, 6H, J = 4.6 Hz, Ph-H), 7.00 (d, 6H, J = 4.7 Hz,
Ph-H), 3.89 (m, 24H, -O-CH2-C), 0.87 (m, 24H, -O-C-CH2-C), 0.34 (s, 36H, -C-CH3),
0.30 (s, 72H, -C-CH3). MALDI-TOF MS m/z: 3136.72 (M+) (calcd 3133.32).

(5-Ethynyl-15-[7’-Bromobenzo[c][1,2,5]thiadiazole-

ethyn-4’-yl]

-10,20-

bis[2’,6’-bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II) (4). (5-Ethynyl15-Triisopropylsilylethynyl-10,20-bis[2‟,6‟-bis(3,3-dimethyl-1butyloxy)phenyl]porphinato)zinc(II)

(0.100g,

0.94×10-4

mol),

4,

7-

dibromobenzo[c][1,2,5]thiadiazole (110.7 mg, 3.77×10-4 mol) were charged into a
Schlenk Flask with Pd2dba3 (12.9 mg, 1.40×10-5 mol) and AsPh3 (34.5 mg, 1.13×10-4
mol). THF: iPr2NH (9:1 ml) solvent mixture was degassed with an Ar purge for 30 min
prior to solvent transfer. Once solvent was transferred, the reaction mixture, was stirred
at 50 ºC overnight under Ar. After the solvent was evaporated, the residue was
chromatographed on silica gel using 5:1 hexanes:THF as the eluant. Yield = 0.117 g
(92.4 % based on 100 mg of the porphyrin starting material). 1H NMR (500 MHz,
CDCl3): 9.85 (d, 2H, β-H), 9.57 (d, 2H, J = 4.6 Hz, β-H), 8.83 (d, 2H, J = 4.5 Hz, β-H),
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8.79 (d, 2H, J = 4.7 Hz, β-H), 7.69 (t, 2H, J = 8.5 Hz, Ph-H), 7.56 (m, 1H, Ph-H), 7.29 (m,
1H, Ph-H), 6.98 (d, 4H, J = 8.6 Hz, Ph-H), 1.43(m, 42H, -SiCH(CH3)2), 3.88 (t, 8H, J =
7.4 Hz, -O-CH2-C), 0.87 (t, 8H, J = 7.3 Hz, -O-C-CH2-C), 0.24 (s, 36H, -C-CH3).

5, 15-Bistriisopropylsilylethynyl- (5, 15-Bis[7’-([10’’’,20’’’-bis[2’’’’,6’’’’bis(3’’’’’,3’’’’’-dimethyl-1’’’’’-butyloxy)phenyl]porphinato)zinc(II)-5’’ylethynyl]benzo[c][1,2,5]thiadiazole-ethyn-4’-yl]-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl1’’butyloxy)phenyl]porphinato)zinc(II) (5). Coumpound 4 (0.100g, 7.44×10-5 mol), (5,
15-diethynyl-10,

20-bis[2‟,6‟-bis(3,3-dimethyl-1-butyloxy)phenyl]porphinato)zinc(II)

(30.3 mg, 3.10×10-5 mol) were charged into a Schlenk Flask with Pd2dba3 (8.52 mg,
0.93×10-5 mol) and P(o-tol)3 (22.6 mg, 7.44×10-5 mol). THF: TEA (9:1 ml) solvent
mixture was degassed with an Ar purge for 30 min prior to solvent transfer. Once solvent
was transferred, the reaction mixture was stirred at 60 ºC overnight under Ar. The
reaction mixture was then poured down a short silica gel column using CHCl3: MeOH
(49:1 mL) as the eluent. A large band was collected and the solvent stripped and then the
residue was taken up in THF and put down a size exclusion column (BioRad Biobeads,
SX-1) and chromatographed gravimetrically. The first band was collected and solvent
removed via vacuum and the residue was purified by silica gel chromatography using
CHCl3: MeOH (49:1 mL) as the eluent. Yield = 56.4 mg (52% based on diethynyl
starting material). 1H NMR (500 MHz, CDCl3): 10.02 (d, 4H, J = 4.4 Hz, β-H), 9.94 (d,
4H, J = 4.5 Hz, β-H), 9.86 (s, 2H, meso-H), 9.08 (d, 4H, J = 4.2 Hz, β-H), 8.96 (d, 4H, J
= 4.3 Hz, β-H), 8.86 (d, 4H, J = 4.5 Hz, β-H), 8.81(d, 4H, J = 4.2 Hz, β-H), 8.26 (s, 4H,
Ph-H), 7.70 (t, 6H, J = 8.6 Hz, Ph-H), 7.02 (d, 6H, J = 4.6 Hz, Ph-H), 7.00 (d, 6H, J = 4.7
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Hz, Ph-H), 3.89 (m, 24H, -O-CH2-C), 1.42 (m, 42H, -SiCH(CH3)2), 0.87 (m, 24H, -O-CCH2-C), 0.34 (s, 36H, -C-CH3), 0.30 (s, 72H, -C-CH3). MALDI-TOF MS m/z: 3136.72
(M+) (calcd 3133.32).

5,

15-Ethynyl-

(5,

15-Bis[7’-([10’’’,20’’’-bis[2’’’’,6’’’’-bis(3’’’’’,3’’’’’-

dimethyl-1’’’’’-butyloxy)phenyl]porphinato)zinc(II)-5’’ylethynyl]benzo[c][1,2,5]thiadiazole-ethyn-4’-yl]-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl1’’butyloxy)phenyl]porphinato)zinc(II) (6). Compound 5 (100 mg, 2.63×10-5 mol)
were dissolved in THF and cooled down to 0 ºC under Ar. TBAF (0.526 mL, 0.1 M
TBAF in THF solution, 5.26×10-5 mol) was then added dropwise and the reaction
mixture was allowed to stir for 15 min at 0 ºC. The reaction mixture was then directly
poured down a short silica gel column using CHCl3 as the eluent. Yield = 75 mg (82.3%
based on compound 5). 1H NMR (500 MHz, CDCl3): 10.05 (d, 4H, J = 4.4 Hz, β-H), 9.96
(d, 4H, J = 4.5 Hz, β-H), 9.02 (d, 4H, J = 4.2 Hz, β-H), 8.96 (d, 4H, J = 4.3 Hz, β-H),
8.87 (d, 4H, J = 4.5 Hz, β-H), 8.80 (d, 4H, J = 4.2 Hz, β-H), 8.26 (s, 4H, Ph-H), 7.72 (t,
6H, J = 8.6 Hz, Ph-H), 7.02 (d, 6H, J = 4.6 Hz, Ph-H), 7.00 (d, 6H, J = 4.7 Hz, Ph-H),
4.13 (s, 2H), 3.89 (m, 24H, -O-CH2-C), 0.87 (m, 24H, -O-C-CH2-C), 0.34 (s, 36H, -CCH3), 0.30 (s, 72H, -C-CH3).

(5, 15-Bis[7’’-([10’’’’,20’’’’-bis[2’’’’’,6’’’’’-bis(3’’’’’’,3’’’’’’-dimethyl-1’’’’’’butyloxy)phenyl]porphinato)zinc(II)-5’’’-ylethynyl]benzo[c][1,2,5]thiadiazole-ethyn4’’-yl]

-(5,

15-Bis[7’-([10’’’,20’’’-bis[2’’’’,6’’’’-bis(3’’’’’,3’’’’’-dimethyl-1’’’’’-

butyloxy)phenyl]porphinato)zinc(II)-5’’-ylethynyl]benzo[c][1,2,5]thiadiazole-ethyn-
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4’-yl]-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)
(PZnE-BTD-EPZnE-BTD-EPZn-

BTD-EPZnE-BTD-EPZn)

(7).

Compound

2

(0.100g, 8.59×10-5 mol), compound 6 (114.1 mg, 3.58×10-5 mol) were charged into a
Schlenk Flask with Pd2dba3 (9.83 mg, 1.07×10-5 mol) and P(o-tol)3 (26.1 mg, 8.59×10-5
mol). THF: TEA (9:1 ml) solvent mixture was degassed with an Ar purge for 30 min
prior to solvent transfer. Once solvent was transferred, the reaction mixture was stirred at
60 ºC overnight under Ar. The reaction mixture was then poured down a short silica gel
column using CHCl3: MeOH (49:1 mL) as the eluent. A large band was collected and the
solvent stripped and then the residue was taken up in THF and put down a size exclusion
column (BioRad Biobeads, SX-1) and chromatographed gravimetrically. The first band
was collected and solvent removed via vacuum and the residue was purified by silica gel
chromatography using CHCl3: MeOH (49:1 mL) as the eluent. Yield = 61.2 mg (32%
based on compound 6). 1H NMR (500 MHz, CDCl3): 10.02 (d, 4H, J = 4.4 Hz, β-H), 9.94
(d, 4H, J = 4.5 Hz, β-H), 9.86 (s, 2H, meso-H), 9.08 (d, 4H, J = 4.2 Hz, β-H), 8.96 (d, 4H,
J = 4.3 Hz, β-H), 8.86 (d, 4H, J = 4.5 Hz, β-H), 8.81(d, 4H, J = 4.2 Hz, β-H), 8.26 (s, 4H,
Ph-H), 7.70 (t, 6H, J = 8.6 Hz, Ph-H), 7.02 (d, 6H, J = 4.6 Hz, Ph-H), 7.00 (d, 6H, J = 4.7
Hz, Ph-H), 3.89 (m, 24H, -O-CH2-C), 0.87 (m, 24H, -O-C-CH2-C), 0.34 (s, 36H, -C-CH3),
0.30 (s, 72H, -C-CH3). MALDI-TOF MS m/z: 5366.7 (M+) (calcd 5353.51).

(5,

15-Bis[benzo[c][1,2,5]thiadiazole-ethyn-4’-yl]

-10,20-bis[2’,6’-bis(3,3-

dimethyl-1-butyloxy)phenyl]porphinato)zinc(II) (BTD-EPZnE-BTD) (8). (5, 15Diethynyl-10,20-bis[2‟,6‟-bis(3,3-dimethyl-1-butyloxy)phenyl]porphinato)zinc(II) (50.0
mg, 5.13×10-5 mol), 4-bromobenzo[c][1,2,5]thiadiazole (26.5 mg, 1.23×10-4 mol) were
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charged into a Schlenk Flask with Pd2dba3 (14.1 mg, 1.54×10-5 mol) and AsPh3 (37.7 mg,
1.23×10-4 mol). THF: iPr2NH (9:1 ml) solvent mixture was degassed with an Ar purge
for 30 min prior to solvent transfer. Once solvent was transferred, the reaction mixture,
was stirred at 50 ºC overnight under Ar. After the solvent was evaporated, the residue
was chromatographed on silica gel using 5:1 hexanes:THF as the eluent. Yield = 57.2 mg
(90.2 % based on 50 mg of the porphyrin starting material). 1H NMR (500 MHz, CDCl3):
9.82 (d, 4H, J = 4.5 Hz, β -H), 8.85 (d, 4H, J = 4.5 Hz, β-H), 7.97 (d, 2H, J = 6.4 Hz, PhH), 7.68 (t, 2H, J = 8.5 Hz, Ph-H), 7.47 (m, 2H, Ph-H), 7.71 (t, 2H, J = 8.6 Hz, Ph-H),
6.98 (m, 6H, Ph-H), 3.86 (t, 8H, J = 7.3 Hz, -O-CH2-C), 0.77 (t, 8H, J = 7.3 Hz, -O-CCH2-C), 0.19 (s, 36H, -C-CH3). CI MS m/z: 1239.53 [(M+H)+] (calcd 1240.44)

4-(Trimethylsilyl)ethynylbenzo[c][1,2,5]thiadiazole

(9).

4-

Bromobenzo[c][1,2,5]thiadiazole (0.378 g, 1.76×10-3 mol), Pd(PPh3)4 (0.125 g,
1.68×10-4 mol), CuI (0.014 g, 7.4×10-5 mol), THF (20 ml), diisopropylamine (1.00 ml)
and (trimethylsilyl)acetylene (1.00 ml, 7.1×10-3 mol) were added to a 50-ml Schlenk tube.
N2 was bubbled through the mixture for 5 min, following which the reaction was stirred
at 45 ºC for 20 h under N2. After cooling, the solvent was evaporated and the residue was
chromatographed on silica gel with 1:1 hexanes:CHCl3 as the eluant. Yield = 0.398 g
(97.3 % based on 0.378 g of 4-bromobenzothiadiazole).

1

H NMR (500 MHz, CDCl3):

7.88 (m, 1H, Ph-H), 7.67 (m, 1H, Ph-H), 7.45 (m, 1H, Ph-H), 0.33 (s, 9H, -Si-CH3).

4-Ethynylbenzo[c][1,2,5]thiadiazole

(10).

4-

(Trimethylsilyl)ethynylbenzo[c][1,2,5]thiadiazole (0.100 g, 4.30×10-4 mol), K2CO3 (78.6
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mg, 5.71×10-4 mol), THF (3ml), MeOH (2 ml) were added to a 25-ml Schlenk tube. N2
was bubbled through the mixture for 5 min, following which the reaction was stirred at
room temperature for 1.5 h under N2. The reaction mixture was then filtered and the
filtrate was evaporated. The residue was chromatographed on silica gel with 5:1
hexanes:THF as the eluant.

Yield = 63 g (91.4% based on 0.100 g of 4-

(trimethylsilyl)ethynylbenzothiadiazole). 1H NMR (500 MHz, CDCl3): 8.01 (m, 1H, PhH), 7.78 (m, 1H, Ph-H), 7.56 (m, 1H, Ph-H), 3.56 (s, 1H, -CC-H).

(5-Bromo-15-[benzo[c][1,2,5]thiadiazole-

ethyn-4’-yl]

-10,20-bis[2’,6’-

bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II) (11). (5, 15-Dibromo10,20-bis[2‟,6‟-bis(3,3-dimethyl-1-butyloxy)phenyl]porphinato)zinc(II)

(0.200g,

1.84×10-4 mol), 4-ethynylbenzo[c][1,2,5]thiadiazole (14.8 mg, 8.22×10-5 mol) were
charged into a Schlenk Flask with Pd(PPh3)4 (26.6 mg, 2.30×10-5 mol) and CuI (8.8 mg,
4.62×10-4 mol). THF: piperidine (9:1 ml) solvent mixture was degassed with an Ar purge
for 30 min prior to solvent transfer. Once solvent was transferred, the reaction mixture,
was stirred at 50 ºC overnight under Ar. After the solvent was evaporated, the residue
was chromatographed on silica gel using 5:1 hexanes:THF as the eluant. Yield = 0.076 g
(64.9 % based on the 4-ethynylbenzothiadiazole starting material). 1H NMR (500 MHz,
CDCl3): 9.75 (d, 2H, β-H), 9.57 (d, 2H, J = 4.6 Hz, β-H), 8.88 (d, 2H, J = 4.5 Hz, β-H),
8.81 (d, 2H, J = 4.7 Hz, β-H), 8.00 (m, 1H, Ph-H), 7.69 (t, 2H, J = 8.5 Hz, Ph-H), 7.56 (m,
1H, Ph-H), 7.29 (m, 1H, Ph-H), 6.98 (d, 4H, J = 8.6 Hz, Ph-H), 3.88 (t, 8H, J = 7.4 Hz, O-CH2-C), 0.87 (t, 8H, J = 7.3 Hz, -O-C-CH2-C), 0.24 (s, 36H, -C-CH3).
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(5-Triisopropylsilylethynyl-15-[benzo[c][1,2,5]thiadiazole-

ethyn-4’-yl]

-

10,20-bis[2’,6’-bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II) (12). (5Bromo-15-triisopropylsilylethynyl-10,20-bis[2‟,6‟-bis(3,3-dimethyl-1butyloxy)phenyl]porphinato)zinc(II)

(0.200g,

1.69×10-4

mol),

4-

ethynylbenzo[c][1,2,5]thiadiazole (32.5 mg, 2.03×10-4 mol) were charged into a Schlenk
Flask with Pd(PPh3)4 (29.3 mg, 2.53×10-5 mol) and CuI (9.6 mg, 5.06×10-5 mol). THF:
piperidine (9:1 ml) solvent mixture was degassed with an Ar purge for 30 min prior to
solvent transfer. Once solvent was transferred, the reaction mixture was stirred at 50 ºC
overnight under Ar. After the solvent was evaporated, the residue was chromatographed
on silica gel using 5:1 hexanes:THF as the eluant. Yield = 164.4 mg (76.8 % based on the
porphyrin starting material). 1H NMR (500 MHz, CDCl3): 9.87 (d, 2H, β-H), 9.61 (d, 2H,
J = 4.5 Hz, β-H), 8.86 (d, 2H, J = 4.5 Hz, β-H), 8.80 (d, 2H, J = 4.5 Hz, β-H), 8.07 (m,
1H, Ph-H), 7.67 (t, 2H, J = 8.5 Hz, Ph-H), 7.60 (m, 1H, Ph-H), 7.49 (m, 1H, Ph-H), 6.98
(d, 4H, J = 8.5 Hz, Ph-H), 3.88 (t, 8H, J = 7.4 Hz, -O-CH2-C), 1.41 (m, 21H, -Si(CH(CH3)2)3), 0.88 (t, 8H, J = 7.3 Hz, -O-C-CH2-C), 0.27 (s, 36H, -C-CH3).

(5-Ethynyl-15-[benzo[c][1,2,5]thiadiazole-

ethyn-4’-yl]

-10,20-bis[2’,6’-

bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II) (13). Compound 12 (160
mg, 1.26×10-4 mol) were dissolved in THF under Ar. TBAF (2.5 mL, 0.1 M TBAF in
THF solution, 2.5×10-4 mol) was then added dropwise and the reaction mixture was
allowed to stir for 5 min at room temperature. TLC analysis (5:1 Hexanes: THF) showed
complete formation of the product and consumption of the starting material. The reaction
mixture was then quenched with 10ml water, extracted with CHCl3 and evaporated. The
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residue was chromatographed on silica gel using 5:1 hexanes:THF as the eluant. Yield =
125.5 mg (89.5% based on compoud 12). 1H NMR (500 MHz, CDCl3): 9.86 (d, 2H, β-H),
9.57 (d, 2H, J = 4.1 Hz, β-H), 8.85 (d, 2H, J = 4.8 Hz, β-H), 8.81 (d, 2H, J = 4.5 Hz, β-H),
8.03 (m, 1H, Ph-H), 7.69 (t, 2H, J = 8.5 Hz, Ph-H), 7.56 (m, 1H, Ph-H), 7.49 (m, 1H, PhH), 6.98 (m, 4H, Ph-H), 4.07 (S, 1H, -CC-H), 3.88 (t, 8H, J = 7.4 Hz, -O-CH2-C), 0.87 (t,
8H, J = 6.8 Hz, -O-C-CH2-C), 0.29 (s, 36H, -C-CH3).

1,2-Bis[(15-(benzo[c][1,2,5]thiadiazole- ethyn-4’-yl)-10,20-bis[3’,5’-bis(3’’,3’’dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)-5-yl]ethyne (BTD-EPZnE-PZnEBTD) (14): Compound 11 (50.0 mg, 4.30×10-5 mol), Compound 13 (57.0 mg, 5.16×10-5
mol) were charged into a Schlenk Flask with Pd2dba3 (5.9 mg, 6.45×10-6 mol) and AsPh3
(15.8 mg, 5.16×10-5 mol). THF: TEA (9:1 ml) solvent mixture was degassed with an Ar
purge for 30 min prior to solvent transfer. Once solvent was transferred, the reaction
mixture was stirred at 60 ºC overnight under Ar. The reaction mixture was then poured
down a short silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A large
band was collected and the solvent stripped and then the residue was taken up in THF and
put down a size exclusion column (BioRad Biobeads, SX-1) and chromatographed
gravimetrically. The first band was collected and solvent removed via vacuum and the
residue was purified by silica gel chromatography using CHCl3:MeOH (49:1 mL) as the
eluent. Yield = 45 mg (47.8% based on 50 mg of compound 11). 1H NMR (500 MHz,
CDCl3): 10.19 (d, 4H, J = 4.4 Hz, β-H), 9.85 (d, 4H, J = 4.3 Hz, β-H), 8.88 (d, 4H, J =
4.4 Hz, β-H), 8.84 (d, 4H, J = 4.5 Hz, β-H), 8.10 (d, 2H, J = 6.1 Hz, Ph-H), 8.37 (m, 2H,
Ph-H), 7.66 (t, 4H, J = 8.6 Hz, Ph-H), 7.00 (d, 8H, J = 8.6 Hz, Ph-H), 3.89 (t, 16H, J =
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7.5 Hz, -O-CH2-C), 0.82 (t, 16H, J = 6.6 Hz, -O-C-CH2-C), 0.32 (s, 72H, -C-CH3).
MALDI-TOF MS m/z: 2182.14 (M+) (calcd 2186.88).

(5,

15-Bis[15’-benzo[c][1,2,5]thiadiazole-ethyn-4’-yl-(10’’’,20’’’-

bis[2’’’’,6’’’’-bis(3’’’’’,3’’’’’-dimethyl-1’’’’’butyloxy)phenyl]porphinato)zinc(II)ethyn-5’-yl]-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl1’’butyloxy)phenyl]porphinato)zinc(II)

(BTD-EPZnE-PZn-EPZnE-BTD)

(15).

Coumpound 13 (60 mg, 5.42×10-5 mol), (5, 15-dibromo-10, 20-bis[2‟,6‟-bis(3,3dimethyl-1-butyloxy)phenyl]porphinato)zinc(II) (24.5 mg, 2.26×10-5 mol) were charged
into a Schlenk Flask with Pd2dba3 (6.2 mg, 6.78×10-6 mol) and P(o-tol)3 (16.5 mg,
5.42×10-5 mol). THF: TEA (9:1 ml) solvent mixture was degassed with an Ar purge for
30 min prior to solvent transfer. Once solvent was transferred, the reaction mixture was
stirred at 60 ºC overnight under Ar. The reaction mixture was then poured down a short
silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A large band was
collected and the solvent stripped and then the residue was taken up in THF and put down
a size exclusion column (BioRad Biobeads, SX-1) and chromatographed gravimetrically.
The first band was collected and solvent removed via vacuum and the residue was
purified by silica gel chromatography using CHCl3:MeOH (49:1 mL) as the eluent. Yield
= 48.4 mg (68.2% based on dibromo starting material). 1H NMR (500 MHz, CDCl3):
10.16 (d, 4H, J = 4.4 Hz, β-H), 10.14 (d, 4H, J = 4.3 Hz, β-H), 9.81 (d, 4H, J = 4.4 Hz, βH), 8.87 (d, 4H, J = 4.4 Hz, β-H), 8.85 (d, 4H, J = 4.4 Hz, β-H), 8.81 (d, 4H, J = 4.4 Hz,
β-H), 8.02 (d, 2H, J = 6.0 Hz, Ph-H), 7.90 (d, 2H, J = 8.7 Hz, Ph-H), 7.63 (m, 8H, Ph-H),
6.96 (m, 12H, J = 4.6 Hz, Ph-H), 3.89 (m, 24H, -O-CH2-C), 0.81 (m, 24H, -O-C-CH2-C),
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0.28 (s, 36H, -C-CH3), 0.26 (s, 72H, -C-CH3). MALDI-TOF MS m/z: 3136.80 (M+)
(calcd 3133.32).

(5,15-Bis[(15’-triisopropylsilylethynyl-10’,20’-bis[2’’’,6’’’-bis(3’’’’,3’’’’dimethyl-1’’’’butyloxy)phenyl]porphinato)zinc(II)ethyn-5’-yl]-10,20-bis[2’,6’bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)

(16):

(5-bromo-15-

triisopropylsilylethynyl-10,20-bis[2‟,6‟-bis(3‟‟,3‟‟-dimethyl1‟‟butyloxy)phenyl]porphinato)zinc(II) (120 mg, 1.01×10-4 mol) and (5,15-diethynyl10,20-bis[2‟,6‟-bis(3‟‟,3‟‟dimethyl-1‟‟-butyloxy)phenyl]porphinato)zinc(II)

(41.1 mg,

4.21×10-5 mols) were charged into a Schlenk flask with AsPh3 (30.9 mg, 1.01×10-4 mols)
and Pd2dba3 (11.6 mg, 1.26×10-5 mol). THF: TEA (9:1 mL) solvent mixture was
degassed with an Ar purge for 30 min and then transferred to the reaction flask. The
reaction mixture was stirred at 60 ºC under Ar overnight. The reaction mixture was then
poured down a short silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A
large band was collected and the solvent stripped and then the residue was taken up in
THF and put down a size exclusion column (BioRad Biobeads, SX-1) and
chromatographed gravimetrically. The first band was collected and solvent removed via
vacuum and the residue was purified by silica gel chromatography using CHCl3: MeOH
(49:1 mL) as the eluent. Yield = 114 mg (85% based on diethynyl starting material). 1H
NMR (500 MHz, CDCl3): 10.35 (d, 8H, β-H), 9.64 (d, 4H, β-H), 9.01 (d, 8H, β-H), 8.86
(d, 4H, β-H), 7.72 (d, 6H, β-H), 7.05 (d, 12H, J = 4.6 Hz, Ph-H), 3.98 (m, 24H, -O-CH2C), 1.40 (m, 42, -SiCH(CH3)2), 0.89 (m, 24H, -O-C-CH2-C), 0.40 (s, 36H, -C-CH3), 0.37
(s, 72H, -C-CH3).
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(5,15-Bis[(15’-ethynyl-10’,20’-bis[2’’’,6’’’-bis(3’’’’,3’’’’-dimethyl1’’’’butyloxy)phenyl]porphinato)zinc(II)ethyn-5’-yl]-10,20-bis[2’,6’-bis(3’’,3’’dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II) (17): Compound 16 (114 mg,
3.58×10-5 mol) were dissolved in THF and cooled down to 0 ºC under Ar. TBAF (0.716
mL, 0.1 M TBAF in THF solution, 7.16×10-5 mol) was then added dropwise and the
reaction mixture was allowed to stir for 15 min at 0 ºC. The reaction mixture was then
directly poured down a short silica gel column using CHCl3 as the eluent. Yield = 101.2
mg (98.4% based on compound 16). 1H NMR (500 MHz, CDCl3): 10.35 (d, 8H, β-H),
9.64 (d, 4H, β-H), 9.01 (d, 8H, β-H), 8.86 (d, 4H, β-H), 7.72 (d, 6H, β-H), 7.05 (d, 12H, J
= 4.6 Hz, Ph-H), 4.11 (s, 2H), 3.98 (m, 24H, -O-CH2-C), 0.89 (m, 24H, -O-C-CH2-C),
0.40 (s, 36H, -C-CH3), 0.37 (s, 72H, -C-CH3).

[5,15-Bis(15’’’-[(15’’’’’’-

benzo[c][1,2,5]thiadiazole-ethyn-4’’’’’’’-yl

-

10’’’’’’,20’’’’’’-bis[2’’’’’’’,6’’’’’’’-bis(3’’’’’’’’,3’’’’’’’’dimethyl-1’’’’’’’’butyloxy)phenyl]porphinato)zinc(II)-ethyn-5’’’’’’-yl]-10’’’,20’’’bis[2’’’’,6’’’’bis(3’’’’’,3’’’’’-dimethyl-1’’’’’-butyloxy)phenyl]porphinato)zinc(II)-ethyn-5’’’-yl)10,20-bis[2’,6’-bis(3’’,3’’-dimethyl-1’’-butyloxy)phenyl)phenyl]porphinato]zinc(II)
(BTD-EPZnE-PZn-EPZnE-PZn-EPZnE-BTD) (18): Coumpound 11 (50 mg, 4.13×105

mol), compound 17 (47.4 mg, 1.65×10-5 mol) were charged into a Schlenk Flask with

Pd2dba3 (5.7 mg, 4.95×10-6 mol) and P(o-tol)3 (12.1 mg, 3.96×10-5 mol), CuI (0.31mg, 1.
65×10-6 mol). THF: TEA (9:1 ml) solvent mixture was degassed with an Ar purge for 30
min prior to solvent transfer. Once solvent was transferred, the reaction mixture was
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stirred at 60 ºC overnight under Ar. The reaction mixture was then poured down a short
silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A large band was
collected and the solvent stripped and then the residue was taken up in THF and put down
a size exclusion column (BioRad Biobeads, SX-1) and chromatographed gravimetrically.
The first band was collected and solvent removed via vacuum and the residue was
purified by silica gel chromatography using CHCl3:MeOH (49:1 mL) as the eluent. Yield
= 55 mg (68.2% based on compound 17). 1H NMR (500 MHz, CDCl3): 10.39 (m, 8H, βH), 10.35 (m, 8H, β-H), 9.84 (d, 4H, β-H), 9.04 (m, 16H, β-H), 8.88 (d, 4H, β-H), 7.77 (d,
2H, Ph-H), 7.74 (m, 12H, Ph-H), 7.55 (d, 2H, Ph-H), 7.07 (m, 20H, Ph-H), 4.03 (m, 40H,
-O-CH2-C), 0.89 (m, 40H, -O-C-CH2-C), 0.38 (m, 180H, -C-CH3). MALDI-TOF MS m/z:
5016.80 (M+) (calcd 5026.19).

(5-

Triisopropylsilylethynyl-15-[10’,20’-bis[2’’’,6’’’-bis(3’’’’,3’’’’-dimethyl-

1’’’’butyloxy)phenyl]porphinato)zinc(II)-ethyn-5’-yl]

-10,20-bis[2’,6’-bis(3’’,3’’-

dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)

(19).

(5-Bromo-15-

triisopropylsilylethynyl-10,20-bis[2‟,6‟-bis(3,3-dimethyl-1butyloxy)phenyl]porphinato)zinc(II) (74.8 mg, 6.31×10-5 mol), (5-ethynyl-10,20bis[2‟,6‟-bis(3,3-dimethyl-1-butyloxy)phenyl]porphinato)zinc(II) (50 mg, 5.26×10-5 mol)
were charged into a Schlenk Flask with Pd2dba3 (7.2 mg, 7.89×10-6 mol) and AsPh3 (19.2
mg, 6.31×10-5 mol). THF: TEA (9:1 ml) solvent mixture was degassed with an Ar purge
for 30 min prior to solvent transfer. Once solvent was transferred, the reaction mixture
was stirred at 60 ºC overnight under Ar. Once solvent was transferred, the reaction
mixture was stirred at 60 ºC overnight under Ar. The reaction mixture was then poured
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down a short silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A large
band was collected and the solvent stripped and then the residue was taken up in THF and
put down a size exclusion column (BioRad Biobeads, SX-1) and chromatographed
gravimetrically. The first band was collected and solvent removed via vacuum and the
residue was purified by silica gel chromatography using CHCl3:MeOH (49:1 mL) as the
eluent.

Yield = 82 mg (75.8 % based on the 50 mg of 5-Bromo-15-

triisopropylsilylethynyl porphyrin starting material). 1H NMR (500 MHz, CDCl3): 10.43
(d, 2H, J = 4.6 Hz, β-H), 10.42 (d, 2H, J = 4.4 Hz, β-H), 10.03 (s, 1H, meso-H), 9.65 (d,
2H, J = 4.5 Hz, β-H), 9.23 (d, 2H, J = 4.4 Hz, β-H), 9.10 (d, 2H, J = 4.6 Hz, β-H), 8.99 (d,
2H, J = 4.4 Hz, β-H), 8.95 (d, 2H, J = 4.4 Hz, β-H), 8.86 (d, 2H, J = 4.4 Hz, β-H), 7.73
(m, 4H, Ph-H), 7.05 (m, 8H, Ph-H), 3.98 (m, 16H, -O-CH2-C), 1.43 (m, 21, SiCH(CH3)2), 0.89 (m, 16H, -O-C-CH2-C), 0.45 (s, 36H, -C-CH3), 0.42 (s, 36H, -C-CH3).

(5-Ethynyl-15-[10’,20’-bis[2’’’,6’’’-bis(3’’’’,3’’’’-dimethyl1’’’’butyloxy)phenyl]porphinato)zinc(II)-ethyn-5’-yl]
dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)

-10,20-bis[2’,6’-bis(3’’,3’’-

(20). Compound 19 (80 mg,

3.89×10-5 mol) were dissolved in THF and cooled down to 0 ºC under Ar. TBAF (0.778
mL, 0.1 M TBAF in THF solution, 7.78×10-5 mol) was then added dropwise and the
reaction mixture was allowed to stir for 15 min at 0 ºC. The reaction mixture was then
directly poured down a short silica gel column using CHCl3 as the eluent. Yield = 65 mg
(87.9% based on compound 16). 1H NMR (500 MHz, CDCl3): 10.43 (d, 2H, J = 4.6 Hz,
β-H), 10.42 (d, 2H, J = 4.4 Hz, β-H), 10.03 (s, 1H, meso-H), 9.65 (d, 2H, J = 4.5 Hz, βH), 9.23 (d, 2H, J = 4.4 Hz, β-H), 9.10 (d, 2H, J = 4.6 Hz, β-H), 8.99 (d, 2H, J = 4.4 Hz,
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β-H), 8.95 (d, 2H, J = 4.4 Hz, β-H), 8.86 (d, 2H, J = 4.4 Hz, β-H), 7.73 (m, 4H, Ph-H),
7.05 (m, 8H, Ph-H), 4.10 (s, 2H), 3.98 (m, 16H, -O-CH2-C), 0.89 (m, 16H, -O-C-CH2-C),
0.45 (s, 36H, -C-CH3), 0.42 (s, 36H, -C-CH3).

4,7-Diiodobenzo[c][1,2,5]thiadiazole (21). Benzo[c][1,2,5]thiadiazole (3.20 g,
2.35×10-2 mol), I2 (13.2 g, 5.20×10-2 mol), Ag2SO4 (7.34 g, 2.35×10-2 mol) were added
to a 100-ml three neck round bottom flask. 35ml concentrated H2SO4 was added to the
mixture and the reaction mixture was stirred at 110 ºC for 14 hours under N 2. After
cooling, the reaction mixture was poured into ice water and the precipitate was collected
by filtration. This precipitate was washed with CHCl3. The organic solution was then
washed with saturated NaHSO3 aqueous solution and brine respectively for three times,
and dried over Na2SO4. The product was then chromatographed on silica gel with 1:1
hexanes:CHCl3 as the eluant.

Yield = 3.95 g (43.3 % based on 3.20 g of

benzothiadiazole). 1H NMR (500 MHz, CDCl3): 7.75 (s, 12H, Ph-H).

4,7-Bis[(15-(10’,20’-bis[2’’,6’’-bis(3’’’,3’’’-dimethyl-1’’’butyloxy)phenyl]porphinato)zinc(II)

ethyn-5’-yl)-10,20-bis[2’,6’-bis(3’’,3’’-

dimethyl-1’’-butyloxy)phenyl]porphinato)zinc(II)-5ylethynyl]benzo[c][1,2,5]thiadiazole

(PZn-EPZnE-BTD-EPZnE-PZn)

(22).

Compound 20 (50.0 mg, 2.63×10-5 mol), Compound 21 (4.27 mg, 1.10×10-6 mol) were
charged into a Schlenk Flask with Pd2dba3 (3.03 mg, 3.31×10-7 mol) and AsPh3 (8.05 g,
2.63×10-5 mol). THF: iPr2NH (9:1 ml) solvent mixture was degassed with an Ar purge
for 30 min prior to solvent transfer. Once solvent was transferred, the reaction mixture
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was stirred at 60 ºC overnight under Ar. The reaction mixture was then poured down a
short silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A large band was
collected and the solvent stripped and then the residue was taken up in THF and put down
a size exclusion column (BioRad Biobeads, SX-1) and chromatographed gravimetrically.
The first band was collected and solvent removed via vacuum and the residue was
purified by silica gel chromatography using CHCl3:MeOH (49:1 mL) as the eluent. Yield
= 35 mg (80.6 % based on 4.27 mg of compound 21). 1H NMR (500 MHz, THF-d8):
10.33 (d, 4H, J = 7.3 Hz, β-H), 10.28 (d, 4H, J = 7.0 Hz, β-H), 10.07 (d, 4H, J = 8.3 Hz,
β-H), 9.90(s, 2H, meso-H), 9.13 (d, 4H, J = 7.0 Hz, β-H), 9.06 (d, 4H, J = 7.4 Hz, β-H),
8.94 (m, 8H, β-H), 8.88 (d, 4H, J = 4.2 Hz, β-H), 8.40 (s, 2H, Ph-H), 7.79 (m, 8H, Ph-H),
7.17 (m, 16H, Ph-H), 4.01 (m, 32H, -O-CH2-C), 0.87 (m, 32H, -O-C-CH2-C), 0.41 (d,
72H, J = 5.2 Hz, -C-CH3), 0.36 (d, 72H, J = 5.1 Hz, -C-CH3). MALDI-TOF MS m/z:
3942.10 (M+) (calcd 3937.79).

1,2-Bis[(15-triisoprpylsilylethynyl-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl1’’butyloxy)phenyl]porphinato)zinc(II)-5-yl]ethyne

(23):

(5-Bromo-15-

triisopropylsilylethynyl-10,20-bis[2‟,6‟-bis(3‟‟,3‟‟-dimethyl1‟‟butyloxy)phenyl]porphinato)zinc(II) (150 mg, 1.26 x 10-4 mol) and (5-ethynyl-15triisopropylsilylethynyl-10,20-bis[2‟,6‟-bis(3‟‟,3‟‟-dimethyl1‟‟butyloxy)phenyl]porphinato)zinc(II) (106 mg, 9.40×10-5 mol) were charged into a
Schlenk flask with AsPh3 (46.3 mg, 1.51×10-4 mol) and Pd2dba3 (17 mg, 1.89×10-5 mol).
THF: TEA (9:1 mL) solvent mixture was degassed with an Ar purge for 30 min and then
transferred to the reaction flask. The reaction mixture was stirred at 60 ºC under Ar
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overnight. The reaction mixture was then poured down a short silica gel column using
CHCl3: MeOH (49:1 mL) as the eluent. A large band was collected and the solvent
stripped and then the residue was taken up in THF and put down a size exclusion column
(BioRad Biobeads, SX-1) and chromatographed gravimetrically. The first band was
collected and solvent removed via vacuum and the residue was purified by silica gel
chromatography using CHCl3: MeOH (49:1 mL) as the eluent. Yield = 164mg (78.1%
based on 106 mg 5-ethynyl-15-triisopropylsilylethynyl porphyrin starting material). 1H
NMR (500 MHz, CDCl3): 10.36 (d, 4H, β-H), 9.67 (d, 4H, β-H), 9.00 (d, 4H, β-H), 8.88
(d, 4H, β-H), 7.75 (m, 4H, Ph-H), 7.06 (m, 8H, Ph-H), 3.98 (m, 16H, -O-CH2-C), 1.46 (m,
21H, -SiCH(CH3)2), 0.91 (m, 16H, -O-C-CH2-C), 0.38 (d, 72H, -C-CH3).

1,2-Bis[(15-ethynyl-10,20-bis[2’,6’-bis(3’’,3’’-dimethyl1’’butyloxy)phenyl]porphinato)zinc(II)-5-yl]ethyne (24): Compound 23 (150 mg,
6.71×10-5 mol) was charged in a Schlenk Fask and dissolved in THF and cooled to 0 ºC
while under Ar. Tetrabutylammonium fluoride (TBAF) (1.34 mL, 0.1 M TBAF solution
in THF, 1.34×10-4 mol) was added dropwise to the reaction mixture and allowed to stir
for 15 min at 0 ºC under Ar. At 15 min the reaction mixture was poured down a prepacked CHCl3 silica gel plug and the first band was collected and solvent removed via
vacuum. Yield = 115 mg (89.1% based on compound 23). 1H NMR (500 MHz, CDCl3):
10.32 (d, 4H, β-H), 9.58 (d, 4H, β-H), 8.96 (d, 4H, β-H), 8.84 (d, 4H, β-H), 7.73 (m, 4H,
Ph-H), 7.06 (m, 8H, Ph-H), 4.10 (s, 2H), 3.96 (m, 16H, -O-CH2-C), 0.91 (m, 16H, -O-CCH2-C), 0.40 (d, 72H, -C-CH3).
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(5-(10’,20’-Bis[2’’,6’’-bis(3’’’,3’’’-dimethyl1’’’butyloxy)phenyl]porphinato)zinc(II)-ethyn-5’-yl)-15-[7’bromobenzo[c][1,2,5]thiadiazole- ethyn-4’-yl] -10,20-bis[2’,6’-bis(3’’,3’’-dimethyl1’’butyloxy)phenyl]porphinato)zinc(II) (25). Compound 20 (0.200g, 1.05×10-4 mol), 4,
7-dibromobenzo[c][1,2,5]thiadiazole (123.8 mg, 4.21×10-4 mol) were charged into a
Schlenk Flask with Pd2dba3 (14.4 mg, 1.57×10-5 mol) and AsPh3 (38.6 mg, 1.26×10-4
mol). THF: TEA (9:1 ml) solvent mixture was degassed with an Ar purge for 30 min
prior to solvent transfer. Once solvent was transferred, the reaction mixture, was stirred
at 50 ºC overnight under Ar. After the solvent was evaporated, the residue was then
poured down a short silica gel column using CHCl3: MeOH (49:1 mL) as the eluent. A
large band was collected and the solvent stripped and then the residue was taken up in
THF and put down a size exclusion column (BioRad Biobeads, SX-1) and
chromatographed gravimetrically. The second band was collected and solvent removed
via vacuum and the residue was purified by silica gel chromatography using CHCl3:
MeOH (49:1 mL) as the eluent. Yield = 108 mg (48.7 % based on 0.200 mg of the
porphyrin starting material). 1H NMR (500 MHz, CDCl3): 10.43 (d, 2H, J = 4.6 Hz, β-H),
10.42 (d, 2H, J = 4.4 Hz, β-H), 10.03 (s, 1H, meso-H), 9.65 (d, 2H, J = 4.5 Hz, β-H), 9.23
(d, 2H, J = 4.4 Hz, β-H), 9.10 (d, 2H, J = 4.6 Hz, β-H), 8.99 (d, 2H, J = 4.4 Hz, β-H),
8.95 (d, 2H, J = 4.4 Hz, β-H), 8.86 (d, 2H, J = 4.4 Hz, β-H), 8.10 (d, 1H, J = 6.1 Hz, PhH), 7.73 (m, 5H, Ph-H), 7.05 (m, 8H, Ph-H), 3.98 (m, 16H, -O-CH2-C), 1.43 (m, 21, SiCH(CH3)2), 0.89 (m, 16H, -O-C-CH2-C), 0.45 (s, 36H, -C-CH3), 0.42 (s, 36H, -C-CH3).
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1,2-Bis(4-[10,20-bis[2’,6’-bis(3’’,3’’-dimethyl-1’’butyloxy)phenyl]porphinato)zinc(II)-5-ylethynyl],7-[(15-(10’,20’-bis[2’’,6’’bis(3’’’,3’’’-dimethyl-1’’’-butyloxy)phenyl]porphinato)zinc(II)ethyn-5’-yl)-10,20bis[2’,6’-bis(3’’,3’’-dimethyl-1’’-butyloxy)phenyl]porphinato)zinc(II)-5ylethynyl]benzo[c][1,2,5]thiadiazole

(PZn-EPZnE-BTD-EPZn-E-PZnE-BTD-

EPZnE-PZn) (26). Compound 25 (181.4 mg, 8.59×10-5 mol), compound 24 (68.9 mg,
3.58×10-5 mol) were charged into a Schlenk Flask with Pd2dba3 (9.83 mg, 1.07×10-5 mol)
and P(o-tol)3 (26.1 mg, 8.59×10-5 mol). THF: TEA (9:1 ml) solvent mixture was
degassed with an Ar purge for 30 min prior to solvent transfer. Once solvent was
transferred, the reaction mixture was stirred at 60 ºC overnight under Ar. The reaction
mixture was then poured down a short silica gel column using CHCl3: MeOH (49:1 mL)
as the eluent. A large band was collected and the solvent stripped and then the residue
was taken up in THF and put down a size exclusion column (BioRad Biobeads, SX-1)
and chromatographed gravimetrically. The first band was collected and solvent removed
via vacuum and the residue was purified by silica gel chromatography using CHCl3:
MeOH (49:1 mL) as the eluent. Yield = 68.9 mg (32% based on diethynyl starting
material). 1H NMR (500 MHz, CDCl3): 10.02 (d, 4H, J = 4.4 Hz, β-H), 9.94 (d, 4H, J =
4.5 Hz, β-H), 9.86 (s, 2H, meso-H), 9.08 (d, 4H, J = 4.2 Hz, β-H), 8.96 (d, 4H, J = 4.3 Hz,
β-H), 8.86 (d, 4H, J = 4.5 Hz, β-H), 8.81(d, 4H, J = 4.2 Hz, β-H), 8.26 (s, 4H, Ph-H),
7.70 (t, 6H, J = 8.6 Hz, Ph-H), 7.02 (d, 6H, J = 4.6 Hz, Ph-H), 7.00 (d, 6H, J = 4.7 Hz,
Ph-H), 3.89 (m, 24H, -O-CH2-C), 0.87 (m, 24H, -O-C-CH2-C), 0.34 (s, 36H, -C-CH3),
0.30 (s, 72H, -C-CH3). MALDI-TOF MS m/z: 6017.79 (M+) (calcd 6006.49).
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Figure 2.2 1H NMR (500 MHz) of PZnE-BTD-EPZn in CDCl3. The designations s and x
denote solvent and impurity peaks, respectively.

54

Figure 2.3 1H NMR (500 MHz) of PZnE-BTD-EPZnE-BTD-EPZn in CDCl3 with 1 drop
of pyridine-d5. The designations s and x denote solvent and impurity peaks, respectively.
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Figure 2.4 1H NMR (500 MHz) of PZnE-BTD-EPZnE-BTD-EPZnE- BTD-EPZnEBTD-EPZn in CDCl3 with 1 drop of pyridine-d5. The designations s and x denote solvent
and impurity peaks, respectively.
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Figure 2.5 1H NMR (500 MHz) of BTD-EPZnE-BTD in CDCl3. The designations s and
x denote solvent and impurity peaks, respectively.
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Figure 2.6 1H NMR (500 MHz) of BTD-EPZnE-PZnE-BTD in CDCl3 with 1 drop of
pyridine-d5. The designations s and x denote solvent and impurity peaks, respectively.
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Figure 2.7 1H NMR (500 MHz) of BTD-EPZn-EPZnE-PZnE-BTD in CDCl3 with 1
drop of pyridine-d5. The designations s and x denote solvent and impurity peaks,
respectively.
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Figure 2.8 1H NMR (500 MHz) of BTD-EPZnE-PZn-EPZnE-PZn-EPZnE-BTD in
CDCl3 with 1 drop of pyridine-d5. The designations s and x denote solvent and impurity
peaks, respectively.
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Figure 2.9 1H NMR (500 MHz) of PZnE-EPZnE-BTD-EPZnE-PZn in CDCl3 with 1
drop of pyridine-d5. The designations s and x denote solvent and impurity peaks,
respectively.
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Figure 2.10 1H NMR (500 MHz) of PZn-EPZnE-BTD-EPZnE-PZnE-BTD-EPZnE-PZn
in CDCl3 with 1 drop of pyridine-d5. The designations s and x denote solvent and
impurity peaks, respectively.
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2.3.4.

Fluorescence Quantum Yield Determination
The fluorescence quantum yields ϕf of these species were determined by the

reference method,40 using the relation:
∫
∫
where ∫

and ∫

are the respective, total integrated fluorescence intensities of the

unknown and emission standard, AX and AS are the corresponding wavelength-specific
absorbances

of

the

unknown

and

standard,

respectively,

and

is

the

acceptedfluorescence quantum yield value for the standard chromophore. The quantity
(nx/ns)2represents the solvent refractive index correction. The concentrations of all
samples were adjusted such that their absorbance was between 0.005 and 0.05 at the
excitation wavelength to minimize complications due to reabsorption effects.
Fluorescence spectra obtained for the (porphinato)metal complexes, as well as the
chromophores used as emission standards, were corrected to account for the wavelengthdependent efficiency of the detection system which was determined using the spectral
output of a calibrated light source. All samples were degassed via purging with a stream
of argon gas for ten minutes. Secondary corrections to the emission spectra used to
determine ϕf (such as energy-dependent intensity corrections necessitated by the variable
band pass/constant wavelength resolution data acquisition mode of the grating
monochromator) were performed as outlined by Fery-Forgues. Quantum yields were
determined using freebase tetraphenylporphyrin (ϕf = 0.13 in benzene5) as a standard
benchmark. The standard error in quantum yields determined by this method is typically
taken as ± 10% of the reported value. The ϕf entries correspond to the average of values
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obtained from at least six independent measurements; corresponding standard deviations
from the mean are also listed.

2.4.

Results and Discussion

2.4.1.

Synthesis
Structures of the BTD conjugated porphyrin supermolecules are shown in Figure

2.1. These BTD conjugated porphyrin species were synthesized by palladium (Pd)mediated cross-coupling reactions involving appropriately substituted (porphinato)zinc(II)
(PZn) compounds and BTD units. The PZn-containing structures exploit 2‟,6‟-bis(3,3dimethyl-1-butyloxy)phenyl groups as 10- and 20-meso-porphyrin substituents, which
facilitate excellent solubility and straightforward assignment of 1H-NMR spectra.22,
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4,7-Diethynylbenzo[c][1,2,5]thiadiazole (E-BTD-E) were used as proquinodal spacer
units.
The nature of the functionalized PZn and BTD moieties used in the synthesis of
the corresponding BTD conjugated porphyrin complexes varied with porphyrin
conjugation degree. In our first attempt, PZn-(BTD-PZn)n structure featuring a E-BTDE spacer unit in-between porphyrin monomers was synthesized (Scheme 2.1). The
synthesis of BTD spaced porphyrin dimer PZnE-BTD-EPZn was via a Pd-mediated
coupling reaction between PZnE and Br-BTD-Br. The synthesis of BTD spaced
porphyrin trimer PZnE-BTD-EPZnE-BTD-EPZn can be done using two different
routes: coupling of PZnE-BTDE and Br-PZn-Br or coupling of PZnE-BTD-Br and
EPZnE. The first method has a lower yield than the second method due to the low
stability of the PZnE-BTDE compound. For the synthsis of the BTD spaced porphyrin
pentamer PZnE-BTD-EPZnE-BTD-EPZnE-BTD-EPZnE-BTD-EPZn, there are many
64

possible routes such as coupling two equivalent of BTD-porphyrin dimer to one
equivalent of BTD-porphyrin monomer, or coupling two equivalent of BTD-porphyrin
monomer to one equivalent of BTD-porphyrin trimer. The experimental results indicated
that the optimized route was to conjugate small porphyrin oliogomers to large porphyrin
oligomers. Considering the stability of the starting materials, the coupling reaction was
performed between Br-BTD-EPZn monomer and EPZnE-PZn-EPZnE trimer with a 32%
yield of PZnE-BTD-EPZnE-BTD-EPZnE-BTD-EPZnE-BTD-EPZn, while the yield
from other synthetic routes was significantly lower (8-10%).
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Scheme 2.1 Synthesis of PZn-(BTD-PZn)n compounds.
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Next, we synthesized BTD-(PZn)n-BTD compounds featuring the BTD spacer
unit at the two ends of conjugated porphyrin oligomers (Scheme 2.2). The synthesis of
BTD-EPZnE-BTD monomer was by coupling Br-BTD to EPZnE, considering that EBTD has a very poor stability. The synthesis of BTD-EPZnE-PZnE-BTD dimer was by
BTD-EPZnE conjugation with Br-PZnE-BTD. Moreover, the synthesis of BTD-EPZnEPZn-EPZnE-BTD trimer was by coupling BTD-EPZnE to Br-PZn-Br which has a better
reaction yield compare to a similar coupling reaction of BTD-EPZn-Br and EPZnE. For
synthesis of BTD-EPZnE-PZn-EPZnE-PZn-EPZnE-BTD pentamer, as suggested by
our previous results that conjugating small porphyrin monomers to large porphyrin
oligomers offers a better reaction yield, the optimized route was to conjugate BTD-EPZnBr with EPZnE-PZn-EPZnE.
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Scheme 2.2 Synthesis of BTD-(PZn)n-BTD compounds.
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Finally, (PZn)2-(BTD-(PZn)2)n with BTD spacer in-between diporphyrin
oligomers were synthesized (Scheme 2.3). Different from our previous synthetic strategy
of coupling small porphyrin monomers to large porphyrin oligomers, the synthesis of
PZn-EPZnE-BTD-EPZnE-PZn internal tetramer was by adding two equivalents of
large porphyrin dimer oligomers to a small BTD monomer. The reason for using this
synthetic route rather than conjugating two equivalent of EPZn monomer to one
equivalent of Br-PZnE-BTD-EPZn-Br dimer was due to the difficulty of synthesize BrPZnE-BTD-EPZn-Br dimer which involved very difficult separation steps and low
reaction yields. Therefore, Br-BTD-Br monomer was used to react with the PZn-EPZnE
to produce the desired PZn-EPZnE-BTD-EPZnE-PZn internal tetramer. Similarly, for
synthesis of PZn-EPZnE-BTD-EPZnE-PZnE-BTD-EPZnE-PZn internal hexamer,
PZn-EPZnE-BTD-Br was coupled to EPZnE-PZnE. This reaction scheme was found to
involve the least reaction steps and the highest reaction yield out of all possible synthetic
routes.
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Scheme 2.3 Synthesis of (PZn)2-(BTD-(PZn)2)n compounds.
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2.4.2.

Electronic Absorption and Emission Spectra
Figure 2.11 displays the representative electronic absorption and emission spectra

of the BTD conjugated porphyrin compounds PZn-(BTD-PZn)n, (PZn)2-(BTD-(PZn)2)n
and BTD-(PZn)n-BTD. These BTD spaced (porphinato)zinc(II) oligomers have
electronic spectra that are not components of their respective monomer building blocks,
due to the large ground state electronic coupling through the cylindrically π-symmetric
BTD moiety.
There are several noteworthy characteristics and trends of the Soret region (Bband 300-500 nm) of the electronic spectra: (i) The Soret region shifts to the red with
extension of π-conjugation along the x-axis (x being the long molecular axis); (ii) The Bband shows exciton splitting due to the x and y polarizations of the neighboring
molecules. The Bx transition has a significant disparity in oscillator strength than the By
band due to the polarization along the molecular axis. For PZn-(BTD-PZn)n oligomers,
the By-state (high energy portion of the B-band) is dominant. For BTD-(PZn)n-BTD
oligomers, the By band is diminished and there is an enhanced Bx (low energy portion of
the B-band) state. Finally, for (PZn)2-(BTD-(PZn)2)n oligmers, the Bx and By band is
further separated and have much less structure than the other two series of oligomers.
The Q-band region (500 - 900 nm) represents the π-π derived transition of the
macrocycle and also has several notable characteristics: (i) the Q-band maximum shifts to
the red with increasing conjugation length. However, there is not much increasing in the
Q-band oscillator strength. This may be due to the broadening of both the B- and Q-band
manifold, due to variations in inter porphyfin dihedral angles or due to aggregation; (ii)
The lowest energy manifold represents the Qx-polarization along the molecular axis. The

71

Qy-polarization remains unchanged with increasing conjugation and resides underneath
the blue edge of the Q-band manifold; (iii) the broad blue edge of the Q-band is due to
the large number of rotational conformers that can be accessible at room temperature,
which causes a broadening of the Q-band.
The S1→ S0 emission spectra for the series of PZn-(BTD-PZn)n, (PZn)2-(BTD(PZn)2)n and BTD-(PZn)n-BTD compounds are also shown in Figure 2.11. Reflecting
the extended conjugation in PZnn, the emission spectra red-shift to the NIR region with
increasing numbers of conjugated monomeric units. Upon increasing the number of
porphyrins repeat units, a noticeable saturation of the red-shifting begins to develop. The
detailed emission data are listed in Table 2.3. The decreasing of FWHM and stokes shift
with increasing conjugation length for PZn-(BTD-PZn)n compounds implying a
correlation between the electron-vibrational coupling and chain length. Increasing the
conjugation length limits the vibrational activity, therefore decreases the nonradioactive
decay process and cause a slow relaxation of the porphyrin oligomer to the lowest
vibration S1 state. However, for BTD-(PZn)n-BTD compounds, the trend is opposite that
the FWHM and stokes‟ shift increases with increasing conjugation length. One possible
explanation for this trend is that these BTD-(PZn)n-BTD compounds are more coplanar
and offered good effective conjugation in the π-linked porphyrin compounds, thus tend to
aggregate more than the PZn-(BTD-PZn)n. This aggregation will causes the energy of
the excited state decreasing and results a long-wavelength shift in fluorescence spectrum,
as well as increasing stokes‟ shift with increased conjugation length. For (PZn)2-(BTD(PZn)2)n compounds, they have similar structures to PZn-(BTD-PZn)n compounds, but
with more porphyrin π-conjugation. Therefore, the conjugation length effect and the
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aggregation effect balances to give a slight increasing of FWHW while a slight
decreasing of stokes‟ shift. More solvent and time resolved studies will be performed for
better understanding of the excited state differences between these compounds.
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Figure 2.11 Electronic absorption and emission spectra of: PZnE-BTD-EPZn (DA);
PZnE-BTD-EPZnE-BTD-EPZn

(TA);

PZnE-BTD-EPZnE-BTD-EPZn-EPZnE-BTD-

EPZn (PA); BTD-EPZnE-BTD (MB); BTD-EPZnE-PZnE-BTD (DB); BTD-EPZnEPZn-EPZnE-BTD (TB); BTD-EPZnE-PZn-EPZnE- PZn-EPZnE-BTD (PB); PZnEPZnE-BTD-EPZnE-PZn

(ITA);

PZn-EPZnE-BTD-EPZnE-PZnE-BTD-EPZnE-PZn

(IHA).
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Table 2.1 Comparative integrated oscillator strengths and absorptive domains of the blue
and red spectral regions of the BTD conjugated porphyrin compounds.a

Compound

FWHMb
B-band region
[cm–1, (nm)]

Oscillator
Strength
B-band
regiond

FWHMe
Q-band region
[cm–1, (nm)]

Oscillator
Strength
Q-band
regionf

Total
Oscillator
Strength

PZnE-BTD-EPZn

2323

(426)c

2.11

1180

(689)

0.72

3.52

PZnE-BTD-EPZnEBTD-EPZn
PZnE-BTD-EPZnEBTD-EPZnE-BTDEPZnE-BTD-EPZn
BTD-EPZnE-BTD

2777

(428)c

2.90

1059

(752)

0.75

3.65

4235

(429)c

3.21

1227

(780)

0.97

4.18

1850

(469)c

2.00

654

(674)

0.35

2.34

BTD-EPZnE-PZnEBTD
BTD-EPZnE-PZnEPZnE-BTD
BTD-EPZnE-PZnEPZnE-PZn-EPZNEBTD
PZn-EPZnE-BTDEPZnE-PZn
PZn-EPZnE-BTDEPZnE-PZnE-BTDEPZnE-PZn

2704
1069
4538

(468)
(495)c
(492)c

3.60

1222

(765)

0.89

4.49

2.99

1597

(811)

0.84

3.83

3700

(498)c

3.33

1689

(844)

1.05

4.38

3920
1083
3887
1566

(415)
(488)c
(416)
(489)c

7.64

1904

(778)

1.62

9.26

6.21

1654

(816)

1.65

7.87

a

From electronic absorption spectra recorded in THF solvent.
Taken as twice value of half the spectral width of the B-band region at half the height of the
absorption noted.
c
Entries correspond to the spectral breadth of the transition envelope centered at the wavelength
in parentheses.
d
Oscillator strengths calculated over the following wavelength domains: PZnE-BTD-EPZn (380
~ 600 nm); PZnE-BTD-EPZnE-BTD-EPZn (380 ~ 600 nm); PZnE-BTD-EPZnE-BTD-EPZnEPZnE-BTD-EPZn (380 ~ 600 nm); BTD-EPZnE-BTD (360 ~560 nm); BTD-EPZnE-PZnEBTD (360 ~ 560 nm); BTD-EPZnE-PZn-EPZnE-BTD (360 ~ 560 nm); BTD-EPZnE-PZnEPZnE- PZn-EPZnE-BTD (360 ~ 560 nm); PZn-EPZnE-BTD-EPZnE-PZn (360 ~ 610 nm);
PZn-EPZnE-BTD-EPZnE-PZnE-BTD-EPZnE-PZn (360 ~ 610 nm).
e
Entries correspond to the spectral breadth of the transition envelope centered at the wavelength
in parentheses.
f
Oscillator strengths calculated over the following wavelength domains: PZnE-BTD-EPZn (600
~ 760 nm); PZnE-BTD-EPZnE-BTD-EPZn (600 ~820 nm); PZnE-BTD-EPZnE-BTD-EPZnEPZnE-BTD-EPZn (600 ~ 900 nm); BTD-EPZnE-BTD (560 ~720 nm); BTD-EPZnE-PZnEBTD (560 ~ 850 nm); BTD-EPZnE-PZn-EPZnE-BTD (560 ~ 910 nm); BTD-EPZnE-PZnEPZnE- PZn-EPZnE-BTD (560 ~ 1050 nm); PZn-EPZnE-BTD-EPZnE-PZn (610 ~ 860 nm);
PZn-EPZnE-BTD-EPZnE-PZnE-BTD-EPZnE-PZn (610 ~ 920 nm).
b
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Table 2.2 Prominent absorption band wavelength, energies, and extinction coefficients of
BTD conjugated porphyrin compounds in THF solvent.

UV-region

B-band region

Q-band region

nm)

(cm–1)

log()

nm)

(cm–1)

log()

nm)

(cm–
1
)

log()

PZnE-BTD-EPZn

313

31,949

(4.39)

426
465

23,474
21,505

(5.16)
(4.79)

PZnE-BTDEPZnE-BTD-EPZn

311

32,154

(4.50)

428
489

23,364
20,449

(5.24)
(4.82)

PZnE-BTDEPZnE-BTDEPZnE-BTDEPZnE-BTD-EPZn
BTD-EPZnE-BTD

316

31,645

(4.59)

429

23,310

(5.20)

314
322

31,847
31,056

(4.45)
(4.48)

434
469

23,041
21,321

(4.90)
(5.21)

BTD-EPZnEPZnE-BTD

310
323

32,258
30,959

(4.60)
(4.60)

468
495

21,367
20,202

(5.20)
(5.40)

BTD-EPZnE-PZnEPZNE-BTD

308
323

32,467
30,960

(4.49)
(4.48)

426
492

23,474
20,325

(4.93)
(5.20)

BTD-EPZnE-PZnEPZnE-PZnEPZNE-BTD
PZn-EPZnE-BTDEPZnE-PZn
PZn-EPZnE-BTDEPZnE-PZnEBTD-EPZnE-PZn

303

33,003

(4.72)

421
498

23,753
20,080

(4.95)
(5.25)

307

32,573

(5.04)

302

33.112

(4.85)

415
488
416
489

24,096
20,491
24,038
20,450

(5.42)
(5.67)
(5.29)
(5.55)

524
566
689
525
573
634
689
752
525
643
716
780
592
619
674
585
638
705
765
592
621
811
595
681
844
562
778
816

19,083
17,667
14,514
19,047
17,452
15,772
14,513
13,297
19,047
15,552
13,966
12,820
16,892
16,155
14,837
17,094
15,674
14,184
13,072
16,891
16,103
12,330
16,807
14,684
11,848
17,793
12,853
12,254

(4.55)
(4.34)
(4.81)
(4.75)
(4.30)
(4.27)
(4.56)
(5.05)
(4.83)
(4.43)
(4.70)
(5.07)
(3.85)
(4.02)
(4.91)
(4.26)
(4.21)
(4.73)
(5.04)
(4.10)
(4.03)
(4.94)
(4.32)
(4.37)
(4.94)
(4.77)
(5.23)
(5.28)
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Table 2.3 Spectroscopic Parameters of the porphyrin compounds in THF.

max(S0S1)
[nm]a

g
@
max(S0S1)
[M-1 cm -1]

max(S1S0)
[nm]a

Stokes‟
shift
(cm-1)

fb

Fc
[ns]

PZnE-BTD-EPZn

689(1180)

121 000

741(1605)

1018

0.37
(0.015)

1.6

PZnE-BTD-EPZnEBTD-EPZn
PZnE-BTD-EPZnEBTD-EPZnE-BTDEPZnE-BTD-EPZn
BTD-EPZnE-BTD

752(1059)

112 000

784(977)

543

1.1

780(1227)

118 000

811(846)

490

0.36
(0.015)
0.29
(0.015)

674(654)

81 000

687(727)

281

0.17
(0.005)

1.3

BTD-EPZnE-PZnEBTD
BTD-EPZnE-PZnEPZNE-BTD
BTD-EPZnE-PZnEPZnE-PZn-EPZNEBTD
PZn-EPZnE-BTDEPZnE-PZn
PZn-EPZnE-BTDEPZnE-PZnE-BTDEPZnE-PZn

765(1222)

109 000

787(802)

365

1.4

811(1597)

87 000

846(872)

510

844(1689)

87 100

888(1008)

587

0.33
(0.006)
0.25
(0.015)
0.20
(0.025)

778(1904)

169 000

822(926)

688

0.6

816(1654)

190 000

857(1154)

586

0.26
(0.011)
0.22
(0.01)

0.8

0.8
0.6

0.5

a

Numbers in parentheses are spectral breadths (FWHM) of the respective transitions in
units of cm-1.
b
Quantum yields were determined relative to H2TPP in benzene (f = 0.13); parenthetical
values represent standard deviations from the mean.
c
All compounds were excited at 405 nm, except TB, PB, ITA, and IHA, which were
excited at 780 nm. The lifetime is determined with single exponential fitting using
Hamamatsu HPD-TA software with single-photon counting mode. The fitting module is
used for fitting analysis with deconvolution method. For the deconvolution method,
scattering sample (cream dissolved in water) is used to acquire the instrument response
function.
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2.4.3.

Quantum Yields
The quantum yields (f) of these BTD conjugated porphyrin compounds were

measured both in THF and toluene solvent as shown in Table 2.4. The quantum yields
for these compounds are exceptional high in the NIR region, which are 18-38% in THF
and 18-59% in toluene. The excited-state lifetimes (τf) were also determined which vary
from 0.5 ps to 1.6 ns. Trends in φf and τf are consistent with the expected dependences
upon the magnitudes of radiative (kr) and nonradiative (knr) rate processes, where knr
includes contributions due to internal conversion (kic) and intersystem crossing (kisc) rate
constants. Except for BTD-EPZNE-BTD, the quantum yield and life time decreases with
increasing conjugation length in each series of BTD conjugated porphyrin compounds,
derives from a larger magnitude kr, congruent with the Strickler-Berg relation,41 which
predicts that kr is proportional to the integrated oscillator strength of the lowest-energy
ground-state absorption band. The decreasing of the S0→S1 energy gap with the
argument of conjugation length will cause an increasing of the S0→S1 internal conversion
rate (kic) and therefore the diminishing of the quantum yield and life time. The reason for
the low quantum yield of BTD-EPZNE-BTD is possible due to the balance of increased
number of T1 state at shorter conjugation length, which causes more S0→S1 intersystem
crossing (kisc) decay and thus a low quantum yield. These results highlight the close
correlation of fluorescence quantum yields with S0 → S1 integrated oscillator strength,
and demonstrate the ability of broad NIR spectral domain fluorescence energy
modulation, where φf magnitudes follow a simple Strickler−Berg relationship.
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Table 2.4 Comparative quantum yields of conjugated porphyrins in THF and Toluene.

f (THF)

f (Toluene)

PZnE-BTD-EPZn

0.39

0.49

PZnE-BTD-EPZnE-BTD-EPZn

0.37

0.49

PZnE-BTD-EPZnE-BTD-EPZnE-BTD-EPZnE-BTD-EPZn

0.29

0.44

BTD-EPZnE-BTD

0.17

0.18

BTD-EPZnE-PZnE-BTD

0.33

0.45

BTD-EPZnE-PZn-EPZnE-BTD

0.25

0.46

BTD-EPZnE-PZn-EPZnE-PZn-EPZNE-BTD

0.21

0.48

PZn-EPZnE-BTD-EPZnE-PZn

0.27

0.59

PZn-EPZnE-BTD-EPZnE-PZnE-BTD-EPZnE-PZn

0.22

0.58

79

2.4.4.

Electrochemical Properties.
Table 2.5 report the solution electrochemically determined oxidation (HOMO

energy level) and reduction (LUMO energy level) levels. As seen with the optical data,
the π→π* derived transition shifts to lower energy with increasing conjugation length,
the potentiometrically determined band gap, Epo, become destabilized and stabilized
respectively with increasing number of porphyrins (ie the band gap becomes smaller with
larger oligomers in agreement with optical and emission data).
It is also important to note that the optical band gaps (Eop values) of these BTD
conjugated porphyrin compounds track closely with their corresponding Eps. These data,
coupled with the facts that the steady state absorption spectra indicate that the visible and
NIR polarized excitations evince extensive mixing of PZn- and BTD-derived electronic
states suggest that the quinoidal resonance contribution to the low lying singlet
electronically excited states exceeds greatly that for the ground-state, thus giving rise to
the expectation that the excited singlet wavefunctions of these BTD conjugated porphyrin
compounds should feature unusual degrees of electronic delocalization.
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Table 2.5 Optical HOMO–LUMO gaps (Eops) and potentiometrically determined
HOMO–LUMO gaps (Eps) of the BTD conjugated porphyrins.

a

Eop(max)
Eop(edge)b
Epc

DA

TA

PA

MB

DB

TB

PB

ITA

IHA

1.80
1.69
1.88

1.65
1.54
1.58

1.59
1.48
1.51

1.84
1.77
1.87

1.62
1.54
1.75

1.53
1.43
1.70

1.47
1.34
1.62

1.59
1.46
1.76

1.52
1.38
1.69

a

Optical HOMO–LUMO gap determined from the lowest absorption maximum
measured in THF.
b
Optical HOMO–LUMO gap determined from the absorption edge measured in THF.
The absorption edge was determined as the intersection of the two tangent lines involved.
c
Potentiometrically determined HOMO–LUMO gap (E1/20/+ – E1/2–/0) measured in CH2Cl2.
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2.5.

Conclusions
Quinoidal spacer conjugated (porphinato)zinc(II) (PZn-(BTD-PZn)n, (PZn)2-

(BTD-(PZn)2)n) and (BTD-(PZn)n-BTD) complexes that possess intervening conjugated
BTD spacer with varying degrees of porphyrin conjugation have been synthesized by
palladium-catalyzed cross coupling reactions. The performance of electronic and optical
devices based on these conjugated species is optimized by reducing and tuning energy
gaps between the highest occupied molecular orbital (HOMO) and the lowest unoccupied
molecular orbital (LUMO). Electronic absorption spectra show significant red-shifts of
the x-polarized Q state (S0→S1) transition manifold maxima into NIR region. Likewise,
the potentiometrically determined HOMO-LUMO gaps (E1/20/+ – E1/2–/0) display
correspondingly exceptional low band gap. These BTD conjugated porphyrin species
possess large magnitude NIR S1 → S0 fluorescence quantum yields superior to the
highest reported value for NIR laser dyes in the 700-1000 nm regime. Notely, these
emitters do not suffer from commonly cited drawbacks of poor photostability and
substantial φf sensitivity to solvent polarity for NIR chromophores. These facts
underscore the tremendous potential of these species as electrooptic materials in a range
of photonic applications.
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CHAPTER 3. Antibody Conjugated Near-Infrared Emissive
Polymersomes for Active Targeting
3.1. Summary
Polymersomes have emerged as versatile carrier systems for delivering active
molecules in the organism, and demonstrated enhanced efficiency compared to
conventional drugs and liposomes. The design of immunopolymersomes (IPs) for
targeted cancer therapies by endocytosis of the targeting molecule and delivery of
therapeutic agents to the interior of the tumor cell remains an ongoing research goal. This
is accomplished by highly specific chemical modifications to the bilayers of the
polymersomes for the attachment of antibodies that recognize and bind specifically to
target cells. Therefore, active, targeting antibodies conjugated near infrared (NIR)
emissive polymer vesicles will be a perfect system for in vivo diagnostic and drugdelivery applications. The efficiency, stability of the resulting antibody to polymersomes
bond, and biocompatibility are essential criteria for such conjugation chemistry. To this
end, various techniques have been developed, including covalent and noncovalent
approaches, with emphasis on the major differences between the coupling reactions, on
their advantages and drawbacks, on the surface functionalization degree effect, antibody
concentration effect, polymersome recovery yields and the coupling efficiencies obtained.
The optimized coupling method was by using 5% maleimide functionalized PEO(3600)b-PBD(6800) (PEO80-b-PBD125: OB18) mixture with PEO(1300)-b-PBD(2500) (PEO30b-PBD46: OB2) to preform polymersomes, followed by addition of thiol-activated
antibody at mole ratio of 1:40 IgG antibody to functionalized polymer, resulted in ~ 64
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IgG antibody per 100 nm polymersomes with conjugation efficiency as high as 80.6%.
Furthermore, the antibody-conjugated polymersomes were characterized by confocal
microscope, cryogenic transmission electron microscopy (Cryo-TEM), Enzyme-linked
immunosorbent assay (ELISA), and Licor-Odyssey imaging experiments. All of these
characterizations showed direct province of successful antibody conjugation to the
polymersome surface.
Based on the functionalization techniques we developed for direct conjugation of
antibodies to the polymersome surface, anti-ErbB2 NIR emissive IPs were developed to
enable efficient delivery to HER2 breast cancer cells. Flow cytometry and confocal
microscopy analysis indicated that anti-ErbB2 IPs delivery to HER2 cells was
concentration dependent, and resulted in punctate intracellular localization. The extent of
anti-ErbB2 IPs delivery was estimated to be 86,000 ± 2,500 vesicles per BT474 cell with
uptake efficiency as high as 37%. In summary, we developed NIR emissive IPs based on
universal chemical modification methods for targeted delivery and optically based
detection of metastatic cancer cells in vivo.

3.2. Introduction
In recent years, an increasing number of studies have been devoted to the
development of drug delivery methods that are aimed at targeting cancer
chemotherapeutics to tumors. Systemic administration of chemotherapeutic agents results
in indiscriminate drug distribution and severe toxicity, so specific targeting to tumor cells
is a great advantage. The first attempt toward this goal was accomplished by utilization of
antibody coupled anti-tumor drugs.1 However, one major difficulty was to preserve of
both pharmacological and immunological activities of the antibody-drug conjugates.
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Only a relatively low amount of drug can be coupled to the antibody to maintain the
binding activity, which is often insufficient to obtain the desired therapeutic effect.
Therefore, other strategies for targeted delivery have been developed by the entrapment
of drugs into liposomes or nanoparticles. Liposomes offer a suitable means for drug
delivery by protecting encapsulated drugs from enzymatic degradation and rapid
clearance in vivo, thereby improving drug pharmacokinetics, and leading to increased
accumulation of the drug at the tumor site. However, phospholipids have their
physicochemical limitations, and hence limited options are available to tailor their
properties.
Polymersomes are a new class of self-assembled vesicles based on amphiphilic
block copolymers with thicker and tougher membranes than lipids, with critical strains
before rupture as much as seven times larger than those for lipid vesicles, and with
toughnesses up to 50 times that of phopholipid vesicles.2-4 The sizes of polymersomes can
be easily tuned to 100-200 nm scale following self-assembly by techniques such as
sonication, freeze-thaw cycles and extrusion through appropriately sized membranes.5 At
this length scale the polymersomes can most effectively leverage the Enhanced
Permeability and Retention (EPR) effect and leave the bloodstream at the site of tumors. 6
In addition, polymersomes also offer the advantage of prolonged circulation in vivo,
resulted in increased biological stability, slow uptake by phagocytic cells of the
reticuloendothelial system (RES)7-9 and thus strong targeting specificity.10-12 Moreover,
the physical and chemical properties of polymersomes including particle size, drug
loading, surface modification, and even prolonged circulation in vivo behavior may be
broadly tunable through rich diversity of block copolymer chemistries.2, 3, 13-15 Another
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advantage of polymersomes is their unique ability to encapsulate hydrophobic
components, owing to the hyperthickness of the polymersome membrane. The most
compelling example of this is the encapsulation of hydrophobic light emitting
porphyrinic dyes, ranging in size from 1.1 to 5.5 nm in length, to yield NIR emissive
polymersomes that have exceptional potential to facilitate deep-tissue fluorescence-based
imaging for in vivo diagnostic and drug-delivery applications.16
These polymersomal vesicles are promising systems to be used as molecular
imaging

modalities16,

17

,

targeted

drug-delivery

devices18-21,

biosensors,

and

nanoreactors.22-29 The attachment of targeting ligands to the polymersomes is of crucial
importance in these applications. By tethering ligands that are specific to receptors
overexpressed on the surface of diseased cells to the delivery vehicles, it is possible to
achieve specific binding between delivery vehicles and target cells. 30 Developing
polymersomes that have targeting vectors attached to the bilayer surface has attracted
increasing attention.31 These vectors have included ligands such as peptides, enzymes and
proteins. However, very few studies have focused on antibody conjugates. Developing
antibody-polymersome conjugation techniques is very important since procedures for
producing highly specific monoclonal antibodies are well established, and the antibodypolymersomes conjugates will become immunogenic which is ideal for various
immunochemical and diagnostic purposes.
IPs are polymersomes that have been specially designed for active targeting to a
given type of tissue or organ that the polymersome is able to recognize by its molecular
fingerprint. This is accomplished by conjugating an antibody or an antibody fragment
which is responsible for cell recognition to the bilayer surface of the polymersomes.
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Antibodies are immunoglobulins, which are glycoproteins produced by the body‟s
immune system. Therefore, the attachment of specific antibodies to the surface of the
polymersomes enables them to bind to cells bearing antigens, and subsequently be
internalized into the cells for the immuno-specific delivery of drugs or other materials to
the antigenic target cells. To note, the liposome-based antigen delivery is more
immunogenic than the antigen alone. This effect is attributed to the particulate nature of
liposomes which more closely mimic the uptake of viruses or bacteria.32 It is possible that
polymersomes would possess this adjuvant quality as well.
There are two basic approaches to the attachment of ligands to polymersomes.
The first involves the direct attachment of a ligand to a preformed polymersome that will
contain functionalized headgroups which are predisposed to react with the ligand. The
major advantage of this approach is that it allows the use of any polymersomes
preparation procedure, and avoids exposure of the ligand to the conditions of
polymersome preparation. The second type of approach involves functionalization of
block copolymers at their hydrophilic chain end with ligands such as carbohydrates,
peptides and proteins and subsequently self-assembly into polymer vesicles with surface
functionalization.33-43 This strategy allows the functionalized copolymer to be purified and
fully characterized as a non-aggregated species. Thus, the ligands density on polymersomes
surface can be better controlled by simply adjusting the ratio of functionalized to nonfunctionalized block copolymer prior to vesicle formation. However, the assembly behavior
of the block copolymers might be affected by the end-functionalization, so that their ability to
form vesicles has to be confirmed by experimental data. Also, the protein may be denatured
or deactivated during the polymersomes self-assembling process which normally involves
harmful organic solvent or sonication, and thus carefully chosen of polymersomes formation
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method is required. Finally, only about half of the ligand that is conjugated to the polymer
will be positioned in the inner membrane of the polymer vesicles during self-assembly and
will not be accessible for targeting; therefore, this method has a low ligand coupling
efficiency on the outer surface of the polymersomes and is not suitable for costly proteins.

For the conjugation of a targeting ligand to polymersomes particles, there are two
main options: non-covalent linkage, such as the avidin-biotin interaction,19,

23, 44-48

or

covalent binding. The noncovalent avidin-biotin linkage has been exploited for
conjugating polymersomes with a biotinylated ligand, e.g. a peptide or antibody. Avidin
is a tetrameric protein with a molecular weight of 68 kDa which can strongly bind to four
biotins. By using noncovalent avidin-biotin conjugation, a polymer vesicle carrying
biotin functionalities is first incubated with avidin. In a second step, the avidinpolymersomes conjugate is incubated with biotinylated ligands. Although this method is
simple and effective, the introduction of avidin into the conjugate has certain drawbacks.
First, conjugation of avidin to polymersomes will considerably increase its size and
thereby alter its pharmacokinetics. More importantly, avidin is known49 to be rapidly
cleared by the liver. In fact, this property of avidin has been exploited to chase and clear
antibodies50 and MRI contrasting agents from the circulation.51
Covalently linking the ligand to the polymersome directly would lead to a smaller
conjugate, which has more favorable pharmacokinetic properties. Covalent conjugation
of ligands to polymersomes is achieved with several methods. Roughly, these methods
can be divided in the formation of (i) a triazole bond, between alkyne groups and azide
groups as so called “click chemistry”,

27, 52-55

(ii) a C-S bond, between N-

hydroxysuccinimidyl ester or vinyl sulfone and thiol groups,
between aldehyde groups and amino groups,

57

13, 56

(iiii) an imine bond,

(iv) a hydrazone bond, between two
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different amide groups.

58

To avoid possible interactions between targeting ligands and

cargo (drugs, RNA, etc.) and to prevent interference with self-assembly, attachment of
ligands is normally take place after vesicle formation. Several approaches to attach
ligands have been reported as shown above, for example biotin-streptavidin binding or
azide-alkyne click chemistry. Although these approaches have proven feasible, they
exhibit problems in terms of application in therapy, including human intolerance to
streptavidin and toxic effects due to possible copper residues used to catalyze the alkyneazide click reaction. Therefore, the challenge was to devise a biocompatible conjugation
chemistry that would facilitate precise control of antibody density on polymersomes
surface and stable chemical bonding while avoiding toxic reaction additives and catalysts.
Also, in most of these coupling methods, the block copolymer vesicle surfaces are
functionalize by chemical means with small ligands such as adhesion moieties23, 44, 57, 59,
carbohydrates33, 34, fluorophores41, 42, 55, 58, 60 and peptides35-40, 43, 56. Very few works have
been done on large motieties such as antibody conjugation to polymersomes. In addition,
previous work on conjugating antibodies to polymersomes has either resulted in low
antibody conjugation efficiency58 or lacks systematic information to study the factors that
affect the antibody conjugation efficiency.13, 58
Toward this goal, OB18 diblock copolymers with five different functionalities at
the hydrophilic terminus (Scheme 3.1) are synthesized for antibody conjugation. The
schemetic structure of functionalized polymersome system for targeted drug delivery and
imaging is shown in Scheme 3.2. The polymersomes are comprised of a mixture of
functionalized OB18 diblock copolymer and nonfunctionalized OB2 diblock copolymer
with highly NIR emissive fluorescent hydrophobic porphyrin fluorophores incorporated
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in the bilayer membrane. The longer functionalized OB18 will be in both the inner and
outside surface of the polymersomes bilayer membrane, and the schemetic structure only
displays them as on the outside of the polymersomes bilayer membrane. The thick
polymersome hydrophobic bilayer membrane enables the incorporation of NIR emissive
porphyrin dyes for optical based NIR molecular imaging; the functionalized
polymersome surface enables the antibody conjugation for specific cell targeting; and the
large aqueous inner core of the polymersomes facilitates hydrophilic drug encapsulation
for drug delivery. All these features of this antibody conjugated NIR emissive
polymersomes suggest a promising new soft matter nanoscale platform for in vivo
diagnostic and drug-delivery applications.

93

Scheme 3.1 Schematic structures of OB18 diblock copolymers with different
functionalities.
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Scheme 3.2 Schematic structures of antibody conjugated NIR emissive polymersomes.
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The functionalized end groups of OB18 can react with amino groups on
antibodies or thio-activated antibodies. In summary, these five different functionalized
end groups features the four chemistries of forming (i) a ester bond, between 4-Fluoro-3nitrobenzoic ester (FNB) functionalized polymers and amino antibodies; (ii) a biotinavidin bond, between biotin functionalized polymers and avidin, followed by addition of
biotinlated antibodies; (iii) a urea bond or hydrazine bond, between isocyante groups and
amino antibodies or amide groups and amide-activated antibodies, (iiii) a thioester bond,
between maleimide and thiol. Six coupling procedures have been developed from the five
functionalized polymers described above, and all these coupling method were evaluated,
compared and optimized in terms of antibody conjugation efficiency and polymersome
recovery yield. The number of exposed functionalities on the surface was controlled by
varying the molar percentage of the functional OB18 polymer. The antibody
concentration effect was also studied by varying the mole ratio of antibody concentration
and polymersomes concentration. Among all these approaches for antibody conjugation,
the maleimide method is found to give the highest protein conjugation yield and is
broadly applicable. To apply this maleimide method, the ligand should contain a free
thiol group, necessary for bond formation. Proteins, antibody and peptides exposing a
free cysteine group can directly be used for coupling to maleimide. For proteins that
don‟t have cysteine, thiol groups can be introduced by different thiolation methods such
as: (1) reducing the disulfide crosslinks of cystines in proteins by using dithiothreitol
(DTT).61 However, the reduction will alter the protein conformation and may result in
loss of protein activity or specificity; (2) thiolating the amines with succinimidyl 3-(2pyridyldithio)-propionate (SPDP), followed by reduction with DTT;

62

(3) thiolating the
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amines with succinimidyl acetylthioacetate (SATA), followed by deprotection generating
sulfhydryl groups in the biopolymer.63 This reagent is most useful when disulfides are
essential for activity. And it also circumvents the separation step of the ligand-SH with
other reagents and to allow a "one-pot" conjugation method. In this work, an alternate
thiolation agent, 2-iminothiolane (Traut's reagent) is used to modify primary amines by
adding a small spacer arm (8.1 Å) terminated by a free sulfhydryl group while
maintaining charge properties similar to the original amino group for immediate use.
Traut‟s reagents have several advantages over the other described thiolation reagents in
light of its simplicity, specificity, flexibility and solubility.64-67 It is a one-step conversion
of amines to sulfhydryls with selective and spontaneous modification of primary amines
at pH 7-10. And it incorporates a space arm to reduce steric hindrance. Moreover, it
preserves the original positive charge to preserve protein solubility. Finally, the thiol
containing ligands is utilized to react with maleimide-containing particles and form a
covalent thioether linkage.
After the attachment of the antibody to NIR emissive polymersomes, the
morphology and immunogenic effect were also characterized by using confocal
microscopy, cryogenic transmission electron microscopy (Cryo-TEM), Enzyme-linked
immunosorbent assay (ELISA) experiments, and Licor-Odyssey imaging experiments.
The results indicate successful antibody conjugation on polymersomes surface, as well as
highly specific and selective activity of these antibody conjugated IPs towards other
antigens or antibodies.
Using the estabilished functionalization methods, we further developed IPs to
combine the tumor-targeting properties and delivery advantages of long circulating
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polymersomes. The IPs system we studied was the anti-ErbB2 NIR emissive
polymersomes. HER2 (also known as ErbB2) is a member of the epidermal growth factor
receptor family that has been found to be overexpressed or amplified in approximately
20-30% of breast cancers.68 Overexpression of this receptor in breast cancer is associated
with increased disease recurrence and worse prognosis. Because of its prognostic role,
breast tumors are routinely checked for overexpression of HER2. Overexpression also
occurs in other cancer such as ovarian cancer, stomach cancer, and biologically
aggressive forms of uterine cancer, such as uterine serous endometrial carcinoma.69 As a
target antigen, HER2 is a readily accessible cell surface receptor for selective
immunotargeting of tumor cells when overexpressed. By conjugating anti-ErbB2
antibody to the surface of NIR-emissive polymersomes, we were able to use these IPs for
HER2 cell targeting and imaging.
Confocal microscope imaging experiments indicates that the anti-ErbB2 IPs bind
specifically to HER2 overexpressed tumor cell lines BT474, SKBR3, HCC1569, and
showed minimal binding towards low HER2 expressing tumor cell line MCF7 (the ErbB2
receptors per MCF7 cell is two to three orders of magnitude less than the ErbB2
overexpression cell lines). Nonconjugated polymersomes and irrelevant rat-IgG
conjugated polymersomes were used as negative controls towards those tumor cells and
all of them showed minimal binding to the cells. In addition, the anti-ErbB2 IPs
demonstrated intense focus of fluorescence both at the ErbB2 overexpression tumor cell
surface and intracellularly.
In order to maximize the intracellular uptake of polymersomes necessary for
optimal cellular labeling, the effects of varying both the polymersome concentration and
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incubation time on polymersomes uptake were examined. Flow cytometry and LicorOdyssey imaging were used to measure the intensity of cellular-associated PZn3 based
fluorescence following cell incubation and washing in vitro. These experiments evaluated
the uptake of both anti-ErbB2 IPs and nonconjugated polymersomes controls in order to
distinguish the impact of antibody conjugation on intracellular delivery. The results
indicate that a single BT474 cell can be effectively labeled with 86000 ± 2500 IPs, and
800 ± 50 control polymersomes. For MCF7 cells, they can only be labeled with 1700 ±
130 IPs per cell, and 830 ± 200 control polymersomes per cell. The maximum IP uptake
percentage for BT474 cells is 37.9 ± 1.8%, and 0.60 ± 0.18% for MCF7 cells; while the
maximum control polymersomes uptake percentage for BT474 cells is 0.19 ± 0.03%, and
0.19 ± 0.05% for MCF7 cells. The incubation times of one hour and overnight have also
been studied. We found for overnight incubation, the IP uptake slightly increased while
the control polymersomes uptake greatly increased. This indicates a higher level of
nonspecific binding with increased incubation time.

3.3. Experimental Methods
3.3.1. Polymer Functionalization
3.3.1.1. Synthesis of FNB Modified Polymer

Scheme 3.3 Reaction scheme for terminal hydroxyl derivatization to 4-Fluoro-3nitrobenzoic ester.
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The PEO terminal hydroxyl of the copolymer was derivatized with 4-Fluoro-3nitrobenzoic acid (FNB) as presented in Scheme 3.3 and as previously drecribed.48
Briefly, in round bottom flask, 100 mg OB18 was added to 1.1 equivalents of 4-fluoro-3nitrobenzoic acid (Sigma-Aldrich, St. Louis, MO), with catalytic dimethylaminopyridine
(Sigma-Aldrich), followed by the addition of 35 mL dry methylene chloride (Fisher). To
a dried septum-seal vial we added 1.1 equivalents of dicyclohexylcarbodiimide (SigmaAldrich) and 5 mL methylene chloride, which was then injected into round bottom flask
with the polymer. The reaction was allowed to proceed for 48 hours, and the resulting
solution was purified by filtration and high-performance liquid chromatography (HPLC).
The final product was vacuum dried and stored under argon gas at -20°C until use. The
extent of derivatization of the polymer was determined by 1H NMR to be 88%.
3.3.1.2. Synthesis of Biocytin Modified Polymer

Scheme 3.4 Reaction scheme for terminal hydroxyl derivatization to biocytin.
The terminal end of the PEO block was modified to display biocytin through a two-step
synthesis. 4-fluoro-3-nitrobenzoic acid was attached to the hydroxyl polymer terminus
through an esterification in methylene chloride as described in 3.3.1. After filtration and
HPLC purification, biocytin was attached to the modified polymer through a nucleophilic
aromatic substitution in 50% THF / 50% DI water (by volume) at 5 mM in a glass screw
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top vial. FNB functionalized polymer, biocytin and triethylamine were combined at
1:1.5:10 (molar ratio, FNB-polymer : biocytin : triethylamine). Reaction proceeded at 3740 °C, while stirring for 24 hours. The mixture was dried by rotary evaporation to remove
water and THF, resolvated in 100% THF at 0.1 mg mL-1, and then filtered and purified
by HPLC. Characterization of the biotin functionalization percentage in the final polymer
was quantified via the established extinction coefficients (5449 M-1 cm-1) of the
biotinylated PEG at 428 nm70 and was calculated to be 68%. The reaction scheme is
shown in Scheme 3.4.
3.3.1.3. Synthesis of Amine Modified Polymer

Scheme 3.5 Reaction scheme for terminal hydroxyl derivatization to amine.
As shown in Scheme 3.5, methanesulfonyl chloride (5.4 mg, 50 μmol) in 1 mL
methylene chloride were mixed at 0°C with 100 mg (10 μmol) OB2 and 2 mg (20 mmol)
triethylamine dissolved in 1 mL methylene chloride. The reaction mixture was then
stirred overnight under Ar at room temperature, and the product was purified by filtration
and HPLC. Yield was 88 mg. 1H NMR showed 94% functionalization. The mesylated
OB18 (88 mg, 8 μmol) and hexamethylenediamine (10 mg, 80 μmol) were dissolved in
benzene (5 mL) with a suspension of 15 mg anhydrous sodium carbonate. This mixture
was stirred at reflux for 3 days, and then the product was purified by filtration and HPLC.
Yield was 69 mg, 1H NMR showed an overall of 54% substitution.
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3.3.1.4. Synthesis of HyNic Modified Polymer

Scheme 3.6 Reaction scheme for terminal hydroxyl derivatization to HyNic.
50 mg amine functionalized OB18 diblock copolymer was dissolved in 1ml
methylene chloride, and 1.5 mL of 10 mg mL-1 (100 μmol) succinimidyl 6hydrazinonicotinate acetone hydrazone (S-HyNic) in anhydrous DMSO were added.
After reaction overnight at room temperature, the hydrazine functionalized polymers
were purified by HPLC. The functionalization degree calculated by 1H NMR was 63%.
3.3.1.5. Synthesis of Maleimide Modified Polymer

Scheme 3.7 Reaction scheme for terminal hydroxyl derivatization to maleimide.
100 mg OB18 diblock copolymer was dried under vacuum and dissolved under
nitrogen in 2 mL of methylene chloride at room temperature, after which 6 mg (5 mM)
catalyst dibutylin dilaurate (DBTDL) was added. p-maleimidophenyl isocyanate (PMPI)
(20 mg; Pierce Chemical Co., Rockford, IL) was dissolved in 2 mL of anhydrous DMSO
and then added to the diblock copolymer solution. The reaction was performed under Ar
in the dark overnight. The solution was filtered and puried by HPLC to remove any
residual traces of DMSO and catalyst, dried at room temperature under Ar, and stored at 20 °C. The functionalization degree was calculated by 1H NMR to be 72%.
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3.3.2. Preparation and Characterization of OB18 and OB2 Mixed Polymersomes
All Near-infrared fluorophores incorporated polymersomes were prepared as
described by Ghoroghchian et al.16 A schematic vesicle formation via thin film
rehydration is shown in Scheme 3.8. In brief, a different ratio of OB18 and OB2 diblock
copolymer (Polymer Source Inc., Montreal, Quebec) was mixed at a mole ratio of 0%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% and 100%. The mixed diblock
copolymer and porphyrin fluorophore trimer (PZn3) were dissolved in methylene chloride
at a 40:1 molar ratio of polymer to NIRF. The solution was then plated onto a roughened
Teflon film and dried under vacuum overnight. Polymersomes were formed upon the
addition of DI water and sonicated (1 h) in a bath sonicator. A narrow size distribution of
nano-sized polymersomes was achieved with serial extrusion using a Liposofast Basic
hand-held extruder equipped with 400-, 200- and 100-nm polycarbonate membranes
(Avestin Inc., Ottawa, Ontario). The morphology of polymersomes samples was observed
by Cryo-TEM as described in 3.3.8.
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Scheme 3.8 Schematic formation of polymersomes by thin film rehydration.
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3.3.3. Functionalized Polymersomes Formulation
The formation of functionalized polymersomes is similar to the procedures
described in 3.3.2. Functionalized OB18 diblock copolymer was mixed with OB2 diblock
copolymer and porphyrin fluorophore trimer (PZn3). The polymer and porphyrin were
codissolved in methylene chloride at a 40:1 molar ratio of polymer to porphyrin, plated
on a square roughened Teflon film and dried under vacuum overnight. FNB
functionalized polymersomes were formed upon the addition of 290 mOsm 0.1M pH 8.5
sodium borate buffer; biocytin, amine and HyNic functionalized polymersomes were
formed upon the addition of 290 mOsm 0.1M pH 7.4 phosphate buffered saline (PBS)
buffer solution; and the maleimide functionalized polymersomes were formed in 290
mOsm pH 4.0 2-(N-morpholino)ethanesulfonic acid (MES) buffer solution. Heating at 60
ºC for 24 hours yielded micron-sized polymersomes while sonication (1 h) in a bath
sonicator yielded nanoscale polymersomes. For nanosized polymersomes, a narrow size
distribution of nano-sized polymersomes was achieved with serial extrusion using a
Liposofast Basic hand-held extruder equipped with 400-, 200- and 100-nm polycarbonate
membranes (Avestin Inc., Ottawa, Ontario). The morphology of polymersomes samples
was observed by Cryo-TEM as described in 3.3.8.
3.3.4. Protein Conjugation to Functionalized Polymersomes by Different Coupling
Procedures
3.3.4.1. Synthesis of ANHP Modified Polymers and Self-Assemble into Polymersomes
The terminal end of the PEO block was modified with ANHP peptide (a 1.5KDa
anti-HER2-neu peptide mimic designed by Murali et al.)71 through a two-step syntheses.
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4-fluoro-3-nitrobenzoic acid was attached to the hydroxyl polymer terminus through an
esterification in methylene chloride as described in 3.3.2.1. After filtration and HPLC
purification, ANHP was attached to the modified polymer through a nucleophilic
aromatic substitution in 50% THF (HPLC grade, Sigma-Aldrich) / 50% DI water (by
volume) at 5 mM in a glass screw top vial. FNB functionalized polymer, ANHP and
triethylamine (Sigma-Aldrich) were combined at 1:2:10 (molar ratio, FNB-polymer :
ANHP : triethylamine). Reaction proceeded at 37-40 °C, while stirring for 48 hours. The
mixture was dried by rotary evaporation to remove water and THF, resolvated in 100%
THF at 0.1 mg mL-1, and then filtered and purified by HPLC. Characterization of the
final polymer using 1H NMR showed that 42.4% of the polymer was modified with
ANHP. The ANHP functionalized 100 nm polymersomes were then prepared from a
mixture of ANHP functionalized OB18 and OB2 at mole ratio of 1:99, 5:95 and 10:90 as
described in 3.3.3. The polymersomes samples were then examined by Cryo-TEM (as
described in 3.3.8) and DLS (as described in 3.3.9).
3.3.4.2. ANHP Peptide Conjugation to Preformed FNB Functionalized Polymersomes
100 nm FNB functionalized polymersomes were formed from a mixture of FNB
functionalized OB18 and OB2 at mole ratio of 5:95, 10:90 and 30:70 as described above
in 3.3.3. ANHP peptides were added to the preformed FNB functionalized polymersomes
at a mole ratio of 1:10 in 0.1M Sodium borate buffer, PH 8.5. After reaction under Ar at
37°C for 48 hours, the free ANHP peptide was separated by passing the mixture through
a Sephacryl S-500 column (GE Healthcare Biosciences, Piscataway, NJ) with pH 7.4
PBS as eluent. The polymersomes samples were then examined by Cryo-TEM (as
described in 3.3.8) and DLS (as described in 3.3.9).
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3.3.4.3. Protein Conjugation to FNB Functionalized Polymersomes
100 nm FNB functionalized polymersome samples were prepared from a mixture
of FNB functionalized OB18 and OB2 at mole ratio of 5:95 as described in 3.3.3. FNB
functionalized 100 nm polymersomes were then mixed with streptavidin (Jackson
ImmunoResearch Laboratories, PA) at a mole ratio of 10:1 functionalized polymer to
streptavidin, or with rat-IgG antibody (Jackson ImmunoResearch Laboratories, PA) at a
mole ratio of 40:1 functionalized polymer to rat IgG in 0.1M sodium borate buffer, pH
8.5. After reaction under Ar at 37°C for 48 hours, the unbound antibody is separated by
passing the mixture down a Sephacryl S-500 column with pH 7.4 PBS as eluent. The
protein coupling efficiency to polymersomes was quantified by BCA protein assay as
described in 3.3.7.
3.3.4.4. Antibody Conjugation to Biotin Functionalized Polymersomes

Scheme 3.9 Reaction scheme for biotinylated antibody conjugation to streptavidin
polymersomes.
100 nm biotin functionalized polymersome samples were prepared from a mixture
of biotin functionalized OB18 and OB2 at mole ratio of 1:99 as described in 3.3.3. The
polymersomes were diluted to 0.5 mg mL-1, mixed with streptavidin at a mole ratio of 1:
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10 functionalized polymer to streptavidin in PBS buffer, pH 7.4 and stirred at room
temperature for 1 hour. After reaction, the unreacted streptavidin is separated by passing
the mixture down a Sephacryl S-500 column with pH 7.4 PBS as eluent. The streptavidin
concentration was quantified by BCA protein assay as described in 3.3.7. For biotinylated
antibody conjugation (Scheme 3.6), biotin-rat-IgG antibody (Jackson ImmunoResearch
Laboratories, PA) is added to the streptavidin conjugated polymersomes at a mole ratio of
10:1 biotin-rat-IgG antibody to streptavidin conjugated polymersomes. After reaction
under Ar at room temperature for 1 hour, the unbound biotin-rat-IgG antibody is
separated by passing through a Sephacryl S-500 column with pH 7.4 PBS as eluent. The
protein coupling efficiency to polymersomes was quantified by BCA protein assay as
described in 3.3.7.
For micron-sized biotin functionalized polymersomes, they were also prepared
from a mixture of biotin functionalized OB18 and OB2 at mole ratio of 1:99 as described
in 3.3.3. The meso-scale polymersome samples were mixed with FITC-streptavidin
(Jackson ImmunoResearch Laboratories, PA) at a mole ratio of 1: 10 biotin
functionalized polymer to FITC-streptavidin in pH 7.4 PBS buffer containing 3% bovine
serum albumin (BSA). The vesicles were allowed to bind 1 hour at room temperature, the
unreacted FITC-streptavidin was separated by using a 1000 KDa dialysis tube (Spectrum
Laboratories, Inc.). The morphology of FITC-streptavidin conjugated μm-sized NIR
emissive polymersomes was observed by confocal laser scanning microscope.
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3.3.4.5. Protein
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Scheme 3.10 Reaction scheme for antibody conjugation via TDIC linkage.
To 2 ml of 20 nM 100 nm amine functionalized polymersomes prepared from a
mixture of amine functionalized OB18 and OB2 at mole ratio of 5:95 as described in
3.3.3, 200 μl of a 2% solution of TDIC in p-dioxane was added. The reaction mixture was
incubated at room temperature for 2 hours with stirring. The resulting supernatant was
then mixed with 50 μl of streptavidin (10 mg/ml in PBS) or 200 μl of rat-IgG solution (2
mg/ml in PBS) and incubated at 37°C for 2hr to produce antibody-modified
polymersomes. To separate noncovalently bound antibody, the polymersome solution
was then passed down a sephacryl S-500 HPLC column with pH 7.4 PBS as eluent. The
protein coupling efficiency to polymersomes was quantified by BCA protein assay as
described in 3.3.7.
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3.3.4.6. Antibody Conjugation via Sulfo-SMCC Linkage to Amine Functionalized
Polymersomes

Scheme 3.11 Reaction scheme for antibody conjugation via sulfo-SMCC linkage.
To 2 ml of 20 nM 100 nm amine functionalized polymersomes prepared from a
mixture of amine functionalized OB18 and OB2 at mole ratio of 5:95 as described in
3.3.3, 1 ml of 5 mg/ml sulfo-SMCC in PBS buffer was added. Reaction was continued at
RT for 1 hour. Excess sulfo-SMCC was removed by passing the reaction mixture through
a sephacryl S-500 HPLC column with pH 7.4 PBS as eluent. Streptavidin or rat-IgG
antibody was thiolated using 2-iminothiolane (Traut's reagent). 2-iminothiolane was
dissolved at 2mg/ml in pH 8 0.1M sodium borate buffer containing 5mM EDTA. The
molar ratio of 2-iminothiolane added to antibody was 40:1.13,
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The reaction was

performed at RT for 1 hour under Ar. The thiol modified antibody was then desalted into
conjugation buffer (pH 7.4, PBS buffer). The thiolated streptavidin or rat-IgG was then
incubated with concentrated sulfo-SMCC polymersomes overnight with stirring under Ar
flow at room temperature. The molar ratio of thiolated streptavidin to maleimide was

110

1:10 and thiolated rat-IgG to maleimide was 1:40. The reaction mixture was then applied
to a sephacryl S-500 HPLC column and eluted with 0.01 M PBS buffer (pH 7.4) to
remove unbound antibody. The protein coupling efficiency to polymersomes was
quantified by BCA protein assay as described in 3.3.7.
3.3.4.7. Antibody Conjugation to HyNic Functionalized Polymersomes

Scheme 3.12 Reaction scheme for antibody conjugation via hydrazone linkage.
Streptavidin and rat-IgG antibody were passed through a 40k desalting column
(Thermofisher) before modification. 1.0 mg succinimidyl 4-formylbenzoate (SFB) was
dissolved in 100 μl anhydrous DMF. The required volume of SFB (20 mole
equivalents/mole antibody, and the percentage of DMF (vol/vol) in the final SFB
modification reaction was maintained below 5% of the total reaction volume) was added
to the antibody solution in modification buffer (2-4 mg/ml concentration, 0.1 M PBS, 150
mM NaCl, pH 7.4) and mixed thoroughly. The reaction was incubated at room
temperature for 1.5 hour. The SFB modified antibody was purified by desalting into
conjugation buffer (100 mM phosphate, 150 mM NaCl, pH 6.0) using a 40k desalting
column.
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Polymersome-antibody conjugate was synthesized by adding SFB modified
streptavidin or rat-IgG to 100nm HyNic modified polymersomes prepared from a mixture
of HyNic functionalized OB18 and OB2 at mole ratio of 5:95 as described in 3.3.3, at
mole ratio of 10:1 functionalized polymer: streptavidin or 40:1 functionalized polymer:
rat-IgG. The non-conjugated antibody was subsequently removed by a sephacryl S-500
HPLC column with pH 7.4 PBS as eluent. The protein coupling efficiency to
polymersomes was quantified by BCA protein assay as described in 3.3.7.
3.3.4.8. Antibody Conjugation to Maleimide Functionalized Polymersomes
Streptavidin, rat-IgG or Goat-Anti-Mouse IgG (5 nm Gold conjugated) antibody
(Ted-pella Inc, Redding, CA) were thiolated using 2-iminothiolane. 2-iminothiolane as
described in 3.3.4.6. The 100 nm maleimide functionalized polymersomes were prepared
from a mixture of maleimide functionalized OB18 and OB2 at mole ratio of 5:95 as
described in 3.3.3 at pH 4.0 in MES buffer. The pH of maleimide functionalized
polymersomes was adjusted to pH 6.5 by adding NaOH dropwise. The thiolated
streptavidin or rat-IgG was incubated with maleimide functionalized polymersomes
overnight with stirring under Ar flow at room temperature. The molar ratio of thiolated
streptavidin to maleimide was 1:10 and thiolated rat-IgG or Goat-Anti-Mouse IgG (5 nm
Gold conjugated) antibody to maleimide was 1:40. The reaction mixture was then applied
to a sephacryl S-500 HPLC column and eluted with pH 7.4 PBS buffer. The protein
coupling efficiency to polymersomes was quantified by BCA protein assay as described
in 3.3.7. The morphology of Goat-Anti-Mouse IgG (5nm Gold conjugated) antibody
conjugated polymersomes was observed by TEM, negative staining TEM and Cryo-TEM
as described in 3.3.8.
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For micron-sized maleimide functionalized polymersomes, they were also
prepared from a mixture of maleimide functionalized OB18 and OB2 at mole ratio of
5:95 as described in 3.3.3. The pH of the maleimide functionalized polymersome samples
were adjusted to 6.5 and then mixed with thiol activated FITC-rat IgG (Jackson
ImmunoResearch Laboratories, PA) at a mole ratio of 1: 40 maleimide functionalized
polymer to thiol-activated FITC-rat IgG. The vesicles were allowed to bind overnight at
room temperature; the free unbound FITC-rat IgG was separated by using a 1000 KDa
dialysis tube. The morphology of FITC-rat IgG conjugated μm-sized NIR emissive
polymersomes was observed by confocal laser scanning microscope.
3.3.5. Antibody Conjugation Efficiency with Different Functionalization Degree
Streptavidin

and

rat-IgG

antibody

were

conjugated

to

functionalized

polymersomes by both FNB coupling method and Maleimide method at different
functionalized polymer degrees. For FNB coupling method, 0.05%, 0.1%, 0.5%, 1%, 2%,
3% and 4% FNB functionalized polymersomes were conjugated with streptavidin at mole
ratio of 2:1; while 0.1%, 0.2%, 0.3%, 0.5%, 0.75% and 1%

FNB functionalized

polymersomes were conjugated with rat-IgG antibody at mole ratio of 2:1. For
Maleimide coupling method, 0.5%, 1%, 2%, 3%, 4% and 5% Maleimide functionalized
polymersomes were conjugated with thiolated streptavidin at mole ratio of 2:1; while
0.2%, 0.3%, 0.5%, 0.75%, 1%, 2% and 3% FNB functionalized polymersomes were
conjugated with thiolated rat-IgG antibody at mole ratio of 2:1. Conjugated antibody
concentration per polymersome was quantified by BCA protein assay.
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3.3.6. Antibody Conjugation Efficiency with Different Antibody Concentration
5% Maleimide functionalized polymersomes were conjugated with thiolated ratIgG antibody at mole ratio of 80:1, 40:1, 20:1 and 10:1 maleimide functioanlzied
polymer to antibody. Conjugated antibody concentration per polymersome was quantified
by BCA protein assay. Antibody (AB) conjugation efficiency was calculated using the
equation below:
AB conjugation efficiency = AB conjugated / AB initially added
3.3.7. Quantification of Protein concentration by BCA protein assay
Bicinchoninic acid (BCA) protein assay (ThermoScientific, USA) was used to
quantify the extent of protein coupling to the polymersomes. First, we constructed a
protein calibration curve by preparing a serial dilution of antibodies in PBS and analyzing
each solution for protein content with the BCA protein assay kit. Next, the protein
concentrations of protein-conjugated polymersome sample and the blank polymersome
sample were both measured by using the BCA assay. The blank polymersomes sample
was prepared by mixing the same amount of nonfunctionalized polymersomes with
protein, followed by passing down the sephacryl S-500 column. The amount of protein
that was covalently coupled to the polymersomes was determined by subtracting the
calculated amount of the blank polymersomes sample from the protein conjugated
polymersomes sample. The experiment was repeated three times with three different
polymersomes samples prepared on different days to get the average value of protein
concentration. The number of antibodies per 100nm polymersomes was then calculated
as below: computations assume a 1 nm2 projected area per PBD block composing the
polymersome‟s bilayer membrane, therefore each 100nm polymersomes is composed of
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~62,800 PEO-b-PBD polymer.73 There are approximate 4*1014 peptides per ug ANHP,
1*1013 proteins per ug streptavidin, 4 *1012 antibodies per ug rat IgG antibody, and
9.6*10

12

polymersomes per umol polymer. The polymer concentration was directly

related to the porphyrin concentration by the initial molar ratio deposited as a thin film
(40:1 polymer:porphyrin).16, 74 The concentration of the PZn3 porphyrin emitterS in the
polymersomal membrane was quantified via the established extinction coefficients of the
far red absorbance of these species PZn3 (λ = 795 nm). Upon measurement of
fluorophore absorbance in solution, the concentration of PZn3 was obtained using Beer's
Law and previously established extinction coefficients (PZn3 λ795nm ε = 25000 M-1cm-1).17,
75-78

The concentration of protein is quantified by BCA assay, therefore, we could

calculate the number of protein per 100nm polymersome using the method described here.
3.3.8. Transmission Electron Microscopy (TEM)
TEM
Nanometric polymersomes were formulated as described above. A droplet of
solution (5 μl) was deposited on TEM grid, any excess solution was removed with filter
paper. Sample grids were examined in a FEI Tecnai G²Twin transmission electron
microscope operating at 200 kV, and images were recorded with a Gatan 724 multiscan
digital camera.
Negative staining TEM
For the negative staining, a droplet of sample solution, DI water and
phosphotungstic acid (Ted Palla, USA) were deposited on a parafilm. The TEM grid was
insert into the sample drop (30 s), then in a distilled water drop for washing (10 s) and
finally in a phosphotungstic acid (PTA) drop for staining (10 s). Any excess solution was
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removed with filter paper. Sample grids were examined in a FEI Tecnai G² Twin
transmission electron microscope operating at 200 kV, and images were recorded with a
Gatan 724 multiscan digital camera.
Cryogenic Transmission Electron Microscopy (Cryo-TEM)
Vitreous samples were prepared within a controlled environment vitrification
system (Vitrobot). A droplet of solution (10 μl) was deposited on a copper TEM grid
coated with a porous polymer film. A thin film (< 300 nm) was obtained by blotting with
filter paper. After allowing the sample sufficient time to relax from any residual stresses
imparted during blotting (30 s), the grid was plunge cooled in liquid ethane at its freezing
point (-180 °C), resulting in vitrification of the aqueous film. Sample grids were
examined in a FEI Tecnai G²Twin transmission electron microscope operating at 200 kV,
and images were recorded with a Gatan 724 multiscan digital camera.
3.3.9. Dynamic Light Scattering (DLS)
Dynamic light scattering was performed using a DynaPro Titan dynamic lightscattering instrument (Wyatt Technology Inc.) that applied vertically polarized laser light
of wavelength 829 nm. The DLS instrument was calibrated with BSA standard (2 mg ml1

in PBS buffer, 25 ºC). Light-scattering studies were carried out in the concentration

range of 0.1-0.5 mg mL-1 polymersomes in DI H2O. Prior to DLS, The quartz cell was
rinsed several times with filtered water and then filled with the filtered sample solution.
The data obtained in each case were the average of 50 runs, each of 10 s duration. The
temperature was maintained at 25 ºC. Data were collected and analyzed using the
DYNAMICS software for the DynaPro Titan instrument (Wyatt Technology Inc.)
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3.3.10. Confocal Laser Scanning Microscopy
Fluorescence scanning confocal microscope images were obtained with a Leica
SP5 Confocal Microscope (Oberkochen, Germany) equipped with a CApochromat
40×/1.2 W objective. Both FITC and PZn3 excitation were achieved with a 488 nm
Argon laser. Fluorescence emission was captured using either 505-530 nm band pass
(FITC) or 650 nm long-pass (YZ112) filters. Polymersomes were imaged by directly
plating 10 μL on a glass slide and covering with coverslip. Images were modified for
contrast and brightness using Leica SP5 software.
3.3.11. Enzyme-linked Immunosorbent Assay (ELISA) Experiments
Equilibrium binding of conjugated rat IgG polymersomes by maleimide method
to recombinant goat-anti-rat IgG antigen was determined by a modified ELISA assay.
ELISA was performed at room temperature. NUNC MaxiSorpTM High Protein-Binding
Capacity ELISA plates (NUNC, Rochester, NY, USA) were coated with goat-anti-rat IgG
antibody (100 µg mL-1) and incubated overnight at 4°C. After rinsing the plates three
times with PBS buffer, blocking was performed with 3% bovine serum albumin (BSA) in
the washing buffer for 1 h at RT. After being washed, different concentrations of test
samples (Rat-IgG antibody conjugated polymersomes) and control samples (nonconjugated polymersomes) were incubated for 1 hour at RT. The wells were washed, and
1/5000 diluted Goat-anti-Rat HRP was then incubated for 1 h at RT. After a final wash,
the enzyme substrate (100 µg mL-1 TMB12 in 100mM sodium acetate, PH 6.0, with 10 µl
of 30% hydrogen peroxide added to 50ml of this solution directly before use) was added
and incubated for 10 min at RT. The reaction was then stopped by the addition of 1 N
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HCl. The absorbance was read at 520 nm using an ELISA plate reader (Dynatech, MR5000, Chantilly, Va., USA).
3.3.12. Licor-Odyssey Experiments to Measure Polymersomes Binding Sensitivity
Binding of streptavidin conjugated polymersomes by maleimide coupling method
to biotinylated 96 well plates were determined by direct Licor-Odyssey imaging.
Purified streptavidin conjugated polymersomes or unconjugated polymersomes alone
(1.68-200 fmol polymersomes/well) were immobilized on a biotinlated plate (Pierce)
with a 2 times serial dilution per well for l hr at room temperature in PBS. Commercially
available DyLight 680 conjugated streptavidin and DyLight 800 conjugated streptavidin
were used at the same concentration as the streptavidin conjugated polymersomes for
comparision. Excess polymersomes or DyLight streptavidin samples were then washed 3
times by using excessive PBS buffer. Images were acquired by excite using a solid-state
diode laser at 685nm or 785 nm and collected with a dichroic mirror filter below 750nm
(700 nm chanel) and above 810nm (800 nm chanel) with an Odyssey Infrared Imaging
System (LI-COR, Lincoln, NE). Emission readings (700 nm and 800 nm chanel) of the
samples were determined by integration of the image intensity.
3.3.13. Preparation of anti-ErbB2 IPs
Anti-ErbB2 antibody (Abcam, USA) was thiolated using 2-iminothiolane as
described in 3.3.4.6. The maleimide functionalized polymersomes prepared from
maleimide functionalized OB18 diblock copolymer mixture with OB2 diblock copolymer
at a mole ratio of 5:95 as described in 3.3.3 was incubated with the thiolated antibody
overnight under Ar flow at room temperature. The molar ratio of the thiolated anti-ErbB2
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antibody to maleimide was 1:40. The reaction mixture was then applied to a sephacryl S500 HPLC column and eluted with 0.1 M PBS buffer (pH 7.4).
3.3.14. Cell Culture and Harvest
The human breast cancer cell lines BT474, HCC1569 cells, SKBR3, and MCF7
were purchased from the American Type Tissue Culture Collection. BT474 cells and
HCC1569 cells were cultured in Roswell Park Memorial Institute medium (RPMI) with
penicillin:streptomycin (PenStrep), 10% fetal bovine serum (FBS), 1% glutamine and 10
μg/mL of insulin. SKBR3 cells were cultured in Dulbecco's modified eagle's medium
(DMEM) growth medium supplemented with 10% fetal bovine serum, 1% penicillin,
10,000 μg/mL streptomycin, 2 mM L-glutamine and 1 mM pyruvate. MCF7 cells were
cultured in DMEM with PenStrep and 10% FBS and 1% glutamine. Cells were grown in
a humidified incubator (HERA Cell 150, Thermo Scientific, Germany) at 37 °C in a 5%
CO2 atmosphere. The medium was replenished every two days and the cells were
harvested as follows. Following removal of the growth medium, cells were first washed
with 5 mL of phosphate buffered saline (PBS). PBS was removed and the cells were
disassociated with 2 mL PBS containing 2 mM ethylenediamine tetraacetate (EDTA) and
subcultured by trypsinization.
3.3.15. Internalization of Anti-ErbB2 IPs in Cells
Human breast cancer cells BT474, HCC1569 cells, SKBR3, and MCF7 were
seeded at a density of 1 × 106 cells per well in a 6-well plate and incubated for 24 h to
allow attachment of cells to the plate prior to the uptake experiments. Both live cells and
fixed cells (fixed by using 4% formaldehyde at room temperature for 15 mins and then
washed 3 times with PBS buffer) were incubated with anti-ErbB2 810 nm emissive
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polymersomes with and without conjugated anti-ErbB2 antibody, or with conjugated
irrelevant rat-IgG antibody. For fixed cells, 4 nM polymersomes were incubated with the
cells for 30 mins at room temperature.

For live cells, 1 nM polymersomes were

incubated with the cells for 4 hours at room temperature. Following incubation, cells
were washed 3 times with PBS buffer to remove non-internalized polymersomes. The
cells were analyzed for the uptake of polymersomes with and without conjugated antiErbB2 antibody with confocal laser scanning microscopy.
3.3.16. Cell Imaging by Laser Confocal Scanning Microscopy
Cells pre-treated with 810 nm emissive polymersomes with and without
conjugated anti-ErbB2 antibody were incubated with nuclei staining Hoechest dye 33258
followed by 3 PBS washes before imaging. The cell suspensions were visualized with a
confocal laser scanning microscope (Leica SP5) equipped with 40× oil lens (Olympus).
The measurements were performed in sequential mode, and the intensity of each
fluorescent dye was adjusted individually: both FITC and PZn3 excitation were achieved
with a 488 nm Argon laser. Fluorescence emission was captured using either 505-530 nm
band pass (FITC) or 650 nm long-pass (YZ112) filters. Images were modified for
contrast and brightness using Leica SP5 software.
3.3.17. Quantification of IP Uptake
BT474 cells and MCF7 cell lines were passaged when confluency reached 70%.
These adherent cells were detached from culture plates with addition of 0.05% trypsin
and 2 mM EDTA and incubation at 37C for 5 min. The single cell suspensions were
counted to have a cell concentration of 1 × 106 cells/mL. The cells were fixed by using 4%
formaldehyde at room temperature for 15 mins, followed by washing 3 times with PBS
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buffer. The cell suspensions were then incubated with either PBS buffer (control), NIR
emissive polymersomes, or ErbB2-NIR emissive polymersomes at controlled
concentrations (0.22 nM to 3.52 nM polymermersomes) for 1 hour at RT or overnight at
4°C. Following incubation, cells were collected using three PBS washes with an
additional volume of PBS added (10 times cell incubation volumes) before centrifugation
(2 min, 5000 rpm). The polymersome containing supernatant was then removed and the
wash cycle subsequently repeated twice.
The dissociation constant of the polymersome-cell complex (Kdiss) and the
maximum polymersome-cell binding ([P]max) was determined as best fit parameters of the
dose response equation:
[P] = [P]max[P]0/(Kdiss+[P]0)
where [P] is the amount of cell-bound polymersomes per cell and [P]0 is the
concentration of unbound polymersomes in the incubation medium.
3.3.17.1. Flow Cytometry for Quantification of anti-ErbB2 IP Uptake in HER2 Cells
A BD FACSCalibur flow cytometer (BD Biosciences, Franklin Lakes, NJ) was
employed to determine the extent of fluorescent labeling achieved by NIR emissive
polymersome uptake. Cells were gated using the forward versus side scatter parameters.
All experiments analyzed a minimum of 10 000 cell events. The NIR fluorophores were
excited using an argon ion laser (15 mW, 488 nm) and probed with fluorescence
detection in the FL3 channel (650 nm longpass filter). The uptake of polymersome-antiErbB2 conjugates at different polymersome concentrations (0.22 nM to 3.52 nM) by
BT474 cells and MCF7 cells were analyzed based on the measurement of cellularassociated fluorescence of cells and the mean fluorescence intensity of gated viable cells.
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3.3.17.2. Licor-Odyssey Imaging for Quantification of anti-ErbB2 IP Uptake
The cell detection studies based on the uptake of polymersome-anti-ErbB2
conjugates by BT474 cells and MCF7 cells were performed in a 96-well plate (BD
Falcon, Franklin Lakes, NJ). Labeled cells from 4.3.4 were plated at dilutions of 25000,
5000, 1000, or 200 cells per well. NIR emissive polymersomes were plated in parallel
with 2-fold dilutions ranging from 1.6 to 0.012 fmol of polymersomes per well for
calibration purposes. Images were acquired by excitation using a solid-state diode laser at
785 nm and collected with a dichroic mirror filter above 810nm with an Odyssey Infrared
Imaging System (LI-COR, Lincoln, NE).

3.4. Results and Discussion
3.4.1. Functionalized Block Copolymer Synthesis and Characterization
We developed five different chemistry modification methods to synthesize
functionalized PEO-b-PBD diblock copolymers to provide an amphiphilic polymer with
functional properties suitable for the conjugation of antibody to polymersomes, as shown
in Scheme 3.1. OB18, a member of the PEO-b-PBD family, was used for our
functionalization. The terminal hydroxyl on the PEG end of OB18 was linked to different
moieties. For FNB functionalization, FNB was used to functionalize the hydroxyl end
group of OB18 via an esterification reaction. The functionalization degree for this step
has been measured by NMR to be 88%, and the resulting product was stable at least 30
days at neutral pH and 20 °C. For biotin functionalization, a two-step functionalization
was utilized by adding biocytin to FNB functionalized OB18. In the second step, the
terminal amine in the lysine tail of biocytin nucleophilically displaces an optical absorber
that can be used to monitor the progression of the reaction at 428 nm.70 We measured that
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the success of biotinylation is about 68% of all terminal hydroxyl groups by using the
extinction coefficient of the biotin functionalized OB18 at 428 nm. For amine
functionalization, a two-step reaction was also used by first mesylating the hydroxyl
group of OB18. The functionalization degree for this step was measured by 1H NMR to
be as high as 94%. Hexamethylenediamine was then added to the mesylated OB18 to
form the amine functionalized OB18, the functionalization degree for this step was
measured by NMR to be 54% of the overall polymer. The maleimide functionalization
was carried out by adding PMPI to give a maleimide functionality of OB18. The
functionalization degree was calculated from NMR to be 72%. Finally, the hydrazone
linkage functionalization was using HyNic to functionalize the hydroxyl group of OB18,
and the functionalization degree was measured by NMR to be 63%.
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Figure 3.1 1H NMR of FNB functionalized OB18.
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Figure 3.2 1H NMR of mesylated OB18.
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Figure 3.3 1H NMR of amine functionalized OB18.
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Figure 3.4 1H NMR of HyNic functionalized OB18.
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Figure 3.5 1H NMR of maleimide functionalized OB18.
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3.4.2. Functionalized Polymersome Formation and Characterization
3.4.2.1. Functionalized Polymersome Composition
A polymer mixture of functionalized OB18 and OB2 was used to preform
functionalized polymersomes. The reason we used this polymer mixture is because the
OB18 diblock copolymer has a much longer PEO chain length compared to the OB2
diblock copolymer and will be able to extend its hydrophilic functionalized end group to
a further region on the polymersome outer surface, therefore there is less possibility for
the functionalized end group to bend back towards the bilayer membrane and become
less accessible to the antibody conjugation. Also, the steric hindrance effect on the
polymersomes surface which prevents the antibody conjugation will be minimal because
of the increased PEO chain length. Previous studies on conjugating antibodies to
liposomes prepared from carboxyacyl derivatives of phosphatidylethanolamine with
different chain length showed that with an increasing in PEG chain length from PEG2 to
PEG20, the antibody conjugation efficiency greatly increased from 1% to 63%.79
To make sure the mixture of the two different PEO-b-PBD diblock copolymers
OB18 and OB2 would produce a uniform distribution of the two polymers in
polymersomes, rather than a mixture of separate OB18 polymersomes and OB2
polymersomes, we prepared 11 samples with different OB18 mole percentages ranging
from 0% - 100% in the OB18/OB2 mixture as shown below in Figure 3.6. The
morphology of all these samples was observed by Cryo-TEM, which showed a mixture of
mostly polymersome vesicle structures together with a small amount of worm-like
micelle structures in all the samples. The membrane thickness of the OB18/OB2
polymersomes was also measured by Cryo-TEM. Previous literature results indicate that
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OB2 polymersomes have a membrane thickness of 9.6nm and OB18 polymersomes has a
membrane thickness of 14.8nm.74 The membrane thickness of our OB18/OB2
polymersomes was right within this range of 9.6nm to 14.8nm. In addition, the membrane
thickness increased linearly with the OB18 content in the OB18/OB2 mixture which was
used to prepare OB18/OB2 polymersomes. All these results indicate that the mixtures of
OB18 and OB2 diblock copolymers have a homogenous distribution of the two polymers
in polymersomes, and this polymer mixture system could be used to prepare
functionalized OB18/OB2 polymersomes.
The functionalization end group is very small compare to the OB18 diblock
copolymer, and thus should not change the morphology of the self-assembled OB18/OB2
polymersomes. As expected, Cryo-TEM showed no structure change of 5% FNB
functionalized OB18/OB2 polymersomes compared to the 5% OB18/OB2 polymersomes
(Figure 3.7).

130

Figure 3.6 Polymersome membrane thickness vs. different OB18 content.
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Figure 3.7 Cryo-TEM images of (A) 5% OB18/OB2 polymersomes and (B) 5% FNB
functionalized OB18/OB2 polymersomes.
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3.4.2.2. Peptide Conjugation by Using Functionalized Polymer vs. Preformed
Functionalized Polymersomes
As described in 3.2, there are two different methods to prepare ligand conjugated
polymersomes. The first coupling procedure involves attachment of ligands to
functionalized diblock copolymer to synthesize ligand-conjugated polymers, followed by
using these ligand-conjugated polymers to self-assemble into polymersomes. The other
method is to first form polymersomes from end-functionalized block copolymers, and
then conjugate ligands to the preformed functionalized polymersomes surface. A small
peptide ANHP was chosen to conjugate to FNB functionalized polymer or polymersomes
to compare these two methods. For the first coupling method, we conjugated the ANHP
peptide to the polymersomes via FNB functionalization, as shown in Scheme 3.13. The
ANHP functionalized OB18 was mixed with OB2 at 1%, 3% and 5% to form 100nmsized polymersomes. Cryo-TEM images and DLS data of these three samples were taken
and shown in Figure 3.8. In 1% and 3% ANHP peptide functionalized polymersomes, a
lot of polymersome vesicle structures together with some worm-like micelle structures
were observed by Cryo-TEM.

However, in 5% ANHP peptide functionalized

polymersomes, very few polymersomes structures were observed. DLS data also
confirmed this. In 1% and 3% ANHP peptide functionalized polymersomes, the average
particles size was ~100nm, while in 5% ANHP peptide functionalized polymersomes, the
particles size greatly increased to 1-10 μm, indicated large aggregate formation in
solution. Therefore, by using this method, the maximum functionalization degree to form
polymersomes is ~3% for ANHP peptide functionalized polymers.
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Scheme 3.13 Preparation of ANHP conjugated polymersomes by using (A) preformed
FNB functionalized polymersomes to conjugate ANHP peptide. (B) ANHP peptide
functionalized polymer to self-assemble into polymersomes.
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Figure 3.8 Cryo-TEM images and DLS data of 1%, 3% and 5% ANHP peptide
conjugated polymersomes made from ANHP functionalized polymers.
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For the second method, the ANHP peptide conjugation was performed with the
FNB functionalized polymersomes. 5%, 10% and 30% FNB functionalized
polymersomes were then used for the ANHP conjugation reaction as shown in Scheme
3.13. Cryo-TEM images and DLS data of these three samples were also taken and shown
in Figure 3.9. A lot of polymersome vesicle structures together with some worm-like
micelle structures were observed in ANHP peptide conjugated 5% and 10% FNB
functionalized polymersomes, while in ANHP peptide conjugated 30% FNB
functionalized polymersomes, the main structure were long worm-like micelles with a
small amount of polymersomes. DLS data also showed the same morphology change for
conjugation with increased FNB functionalization. In 5% and 10% FNB functionalized
polymersomes, the average particles size was ~100 nm and didn‟t change much after
ANHP peptide conjugation. However, in 30% FNB functionalized polymersomes, the
particle size changed from average ~100 nm to a very wide size distribution from nmsized to um-sized particles, suggested formation of aggregated structures. Based on these
results, the maximum functionalization degree was determined to be ~10% for ANHP
peptide conjugation to FNB functionalized polymersomes.
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Figure 3.9 Cryo-TEM images and DLS data of ANHP peptide conjugation to preformed
5%, 10% and 30% FNB functionalized polymersomes.
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In summary, both of these methods work well for conjugating small peptides such
as ANHP on the polymersome surface, while the maximum functionalization degree we
can reach by using peptide functionalized polymer is significantly lower (3%) compared
to preformed FNB functionalized polymersomes (10%). For antibody conjugation, the
second method by making antibody conjugated polymersomes from the preformed
functionalized polymersomes is preferred. Preparing antibody polymersomes selfassembled from antibody-conjugated polymers has a few significant drawbacks. First of
all, as predicted from the ANHP peptide conjugation results, the maximum
functionalization degree for antibody conjugation should also be much lower by using the
antibody-conjugated polymer self-assembling method.

In addition, antibodies are

normally very expensive and precious; we would hope to have a high antibody coupling
efficiency to the polymersomes. When using the antibody-conjugated polymer to form
polymersomes, about half of the antibody will be lost in the aqueous inner core of the
polymersomes, resulted in low antibody conjugation efficiency on the polymersomes
outer layer. Besides, considering most antibodies are much larger than small peptides and
ligands, the polymersomes need to be pre-formed before the addition of antibody to
prevent phase separation of antibody-modified and nonmodified block copolymers in the
membrane.80 Therefore, antibody conjugated polymersomes are all prepared from the
preformed functionalized polymersomes.
3.4.3. Coupling Antibodies to Polymersomes: Evaluation and Comparison of the
Different Methods
We have developed a series of different chemical modification methods for
attachment of proteins and antibodies to nanoscale NIR-emissive polymersomes. Using
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these chemical modification procedures, we first functionalized the hydrophilic PEO
terminus of OB18 diblock copolymers with selected activated functional groups. From
these functionalized diblock copolymers, we then constructed polymersomes that vary
with respect to the extent of reactive hydrophilic surface functionality. These surfacemodified vesicles will be subjected to coupling reactions with antibodies.
There are two main approaches to attach antibodies on the surface of NIRemissive polymersomes: non-covalent linkage, such as the avidin-biotin interaction, or
covalent binding. In the biotin-avidin method, avidin, with its four biotin binding sites,
functions to crosslink the biotinylated antibody to biotinylated polymer at the
polymersome surface. In this first approach (Figure 3.10B), the hydroxyl end groups of
OB18 dilock copolymers were functionalized with FNB followed by conjugation to
biocytin. Biotinylated OB18 diblock copolymers were mixed with nonfunctionalzed OB2
and self-assemble into NIR-emissive polymersomes. These polymersomes were then
conjugated to streptavidin and finally, biotinylated antibody was added and conjugated to
these avidin-conjugated, biotinylated NIR-emissive polymersomes.
The second approach involves the direct attachment of antibody to a preformed
polymersome by covalent coupling. The polymersome will contain specifically
functionalized end groups that are predisposed to react with the antibody. Five different
functionalization chemistries have been used in this approach. The first functionalization
method (Figure 3.10 A) involves using FNB functionalization by creating an active
fluoride end group on the polymersome surface which can then be conjugated to amino
bearing antibody. The FNB terminated OB18 diblock copolymers were mixed with
nonfunctionalized OB2 and self-assemble into polymersomes. These FNB functionalized
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polymersomes were then conjugated to antibodies. The second functionalization method
(Figure 3.10C) uses TDIC as a linking group between antiboby and amine functionalized
polymersomes. OB18 diblock copolymers were first functionalized with methanesulfonyl
chloride.

These

mesylated

OB18

diblock

copolymers

then

reacted

with

hexamethylenediamine to form amine terminated OB18 diblock copolymers. Amine
functionalized OB18 diblock copolymers were mixed with nonfunctionalized OB2
diblock copolymers and self-assembled into polymersomes. TDIC was then added to this
polymersome solution followed with antibody conjugation. The third functionalization
method (Figure 3.10D) facilitates a hydrazone bond linkage motif by using the HyNic
functionalized polymersomes to react with SFB modified antibody thus form a hydrazone
bond. Finally, the maleimide (Figure 3.10E) and sulfo-SMCC methods (Figure 3.10F)
involve the formation of a covalent thioether bond between the thiol groups on the
antibody and maleimide groups on the polymersome surface. For the maleimide method,
OB18 diblock copolymers were functionalized with N-(p-maleimidophenyl)isocyanate
(PMPI), and the antibodies were functionalized by Traut‟s reagent. PMPI functionalized
OB18 diblock copolymers were then mixed with unfunctionalized OB2 diblock
copolymers and self-assembled into polymersomes, and conjugated to the thiol-actived
antibody. For the sulfo-SMCC method, Sulfo-SMCC was added to the amine
functionalized polymersome solution followed by thiol-activated antibody conjugation.
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Figure 3.10 Reactions to attach an antibody to the polymersome surface.
(A). Polymersomes are self-assembled from a blend of OB2 and FNB functionalized
OB18. Amino-group-containing antibodies are then attached by the conjugation to the
distant terminus of polymersome surface.
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(B). Attachment of biotinylated antibody to polymersomes by noncovalent biotin-avidin
coupling. Avidin-conjugated, biotinylated OB18 diblock copolymers in self-assembled
polymersomes are used to conjugate biotinlated antibody.
(C). Diblock copolymer OB18 is initially functionalized to feature an amino-group on the
PEO terminus. Attachment of amino-group-containing antibody to amino-groupcontaining polymersomes is carried out by using a bifunctional reagent TDIC.
(D) In a particular case of amino-mediated coupling, SFB-containing antibody can be
attached to HyNic functionalized polymersome with the formation of a hydrazone bond.
(E) Attachment of thio-activated antibody to the maleimide-activated polymersomes. The
sulphydryl group can be introduced into the amino-group-containing antibody by Traut‟s
reagent. The maleimide group is introduced onto the polymersome surface by the
activation of diblock copolymer with N-(p-maleimidophenyl)isocyanate (PMPI). SHcontaining antibody then interacts with maleimide-polymersome.
(F). Attachment of thio-activated antibody to the amine-activated polymersomes via
Sulfo-SMCC linkage. The maleimide group is introduced onto the polymersome surface
by the activation of the amine group with Sulfosuccinimidyl 4-[N-maleimidomethyl]
cyclohexane-1-carboxylate (Sulfo-SMCC), followed by conjugation to SH-containing
antibody.
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The reason we chose these chemistries is based on the following requirements for
a successful antibody to polymersome conjugation: (1) the polymersomal integrity have
to be preserved during the binding procedure; (2) the reaction conditions need to be mild,
in an aqueous solution at a neutral PH range (pH 6-8), to preserve the antibody specificity
and affinity; (3) a sufficient quantity of antibody molecules should be firmly bound to the
polymersome surface; (4) the binding procedure should be simple with a high yield of
antibody binding to the polymersome. The advantages and disadvantages of these six
coupling methods are discussed below.
The avidin-biotin noncovalent strategy has become a very commonly used
method for active targeting. However, it involves multiple conjugation steps, and at a
higher biotin functionalization degree, the polymersomes tend to aggregate,81 so we can
only use a very low functionalization degree. All of these factors lead to a low antibody
conjugation efficiency and polymersome yield.
The FNB method is straightforward and only takes one-step. However, the
reactivity of the FNB group towards antibody is relatively low and requires a very long
reaction time (48 hours) at a relative high temperature (37-40 °C) which might denature
the antibody and make them unreactive. Besides, the ester bond which forms between the
FNB functionalized polymersomes and the antibody tends to hydrolyze over time and
decreases the stability of this bond.
The TDIC method is at a much milder condition and can be performed at room
temperature for only 2 hours. However, as TDIC is sparingly soluble in water, organic
solvent must be used; and TDIC polymerizes during the coupling reaction which
decreases the polymersome recovery yield.
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The hydrazone method requires multistep reaction and involves the use of HyNic
and SFB reagent, both of which are pretty expensive. The main reason for us to choose
this method is that the hydrazone bond formed between the functionalized polymersomes
and antibody is fluorescent, and the conjugation degree could be directly quantified by
measuring the absorbance of this hydrazone bond. However, in our NIR-emissive
polymersomes, the absorbance of the hydrazone bond (λmax = 354 nm) is overlapped with
our porphyrin soret band (250- 450 nm) and this fluorescent hydrazone bond could not be
used for quantification. We expect this method to work well for other fluophore
incorporated polymersomes in which the hydrazone bond absorbance is distinct from the
incorporated fluorophore absorbance spectrum.
The sulfo-SMCC and maleimide method both use a single-step reaction for
polymer functionalization, and the reactivity of the functionalized maleimide group
towards the thiol-actived antibody is very high. Also, the antibody is conjugated to
polymersomes by thioether bond, which is very stable and will not hydrolyze over time.
Therefore, both methods results in rather high antibody conjugation efficiencies.
However, for the sulfo-SMCC method, there are two HPLC separation steps for first
removing the excess Sulfo-SMCC in solution and then removing the unbound antibody.
Both HPLC purification loses some polymersomes and causes a lower polymersome
recovery yield. This is consistent with the experimental results showing 45-50%
polymersome recovery yield with the Sulfo-SMCC method.
Table 3.1 compares the number of streptavidin and rat IgG antibody bound to the
polymersomes for the non-covalent biotin-avidin method, and the five covalent coupling
methods. Functionalized polymers were incorporated into polymersomes at 5 mol%
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except for biotin functionalized polymer which was incorporated at 1 mol%. Using the
biotin-avidin method, there are low levels of antibody attached to the polymersome
surface with low efficiency. For the FNB, TDIC, Hydrazone, and Sulfo-SMCC methods,
a moderate amount of antibody was bound to the polymersome surface. The maleimide
method gave the highest amount of antibody bound to the polymersome surface. The
polymersome recovery yields are also calculated by comparing the mass of the polymer
recovered after antibody conjugation to the mass used to prepare the polymersomes. The
recovery yields of the FNB and maleimide methods are ~30% higher than the noncovalent biotin-avidin method and the hydrozone, TDIC, and sulfo-SMCC method.
Considering both the antibody conjugation efficiency and the polymersome recovery
yield, we conclude that the maleimide method is the best out of these six methods for
antibody conjugation, which is well rationalized by the described advantages and
disadvantages of these methods.
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Table 3.1 Comparison of polymersomes preparation and conjugation procedures.

Method

Polymersomes
composition

# of
streptavidin
per 100nm
polymersome

# of rat IgG
per 100nm
polymersome

Polymersome
Recovery Yield

Biotin

1% OB18-Biotin/
99% OB2

62 ±9

11 ±4

41% - 46%

FNB

5%
OB18-FNB/
95% OB2

92 ±13

37 ±6

72% - 81%

TDIC

5%
OB18-NH2/
95% OB2

78 ±11

23 ±5

45% - 52%

Hydrazone

5% OB18-SANH/
95% OB2

114 ±15

38 ±7

70% - 76%

Sulfo-SMCC

5%
OB18-NH2/
95% OB2

142 ±22

50 ±12

42% - 50%

Maleimide

5%
OB18-PMPI/
95% OB2

162 ±31

64 ±11

75% - 84%

The antibody was coupled to 100 nm polymersomes at an antibody/functionalized
polymer molar ratio of 1:10 for streptavidin or 1:40 for rat-IgG, and a polymersome
concentration of 20 nM. The conversion from antibody concentration to the approximate
number of antibodies per polymersome was based on the following assumptions: the area
per polar head group for PEO-PBD diblock copolymer is 1 nm2 and that there are
approximately 9.6 × 1012 polymersomes per μmol polymer73 and 4 × 1012 antibodies per
μg protein.
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3.4.4. Factors Affecting Antibody Coupling Efficiency
Understanding and controlling the density of reactive antibodies on the
polymersome surface is of great importance for applications such as targeted drug
delivery. In order to investigate the effects of functional group concentration on
polymersome surface modification, we produced different batches of polymersomes
consisting of various molar percentages of the reactive functionalized OB18 diblock
polymer and nonfunctionalized OB2 copolymers. We have investigated, for the FNB and
maleimide coupling procedure, two main factors affecting coupling of antibody to
functionalized diblock copolymer: (1) the concentration of FNB or Maleimide
functionalized OB18 polymer incorporated into the polymersomes (Figure 3.11) , (2) the
antibody concentration (Figure 3.12). For the FNB method, a 20-fold increase in the
amount of incorporated FNB functionalized OB18 diblock copolymer, from 0.05 to 1.0
mol% resulted in a 30-fold increase in the amount of bound streptavidin (Figure 3.11 A);
a 3-fold increase in the amount of incorporated FNB functionalized ob18 diblock
polymer, from 0.1 to 0.3 mol% resulted in a 2-fold increase in the amount of bound ratIgG (Figure 3.11 B). The conjugation of antibody reaches a plateau at 1% FNB
functionalization degree for streptavidin conjugation and at 0.3% FNB functionalization
degree for rat-IgG conjugation. The maximum number of streptavidin that can be
conjugated to polymersomes by FNB coupling method is ~230 per 100 nm polymersome
while the maximum number of rat-IgG that can be conjugated to polymersomes is ~47
per 100 nm polymersome. For maleimide method, a 6-fold increase in the amount of
incorporated maleimide functionalized OB18 diblock copolymer, from 0.5 to 3.0 mol%
resulted in a 4-fold increase in the amount of bound streptavidin (Figure 3.11A); a 5-fold
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increase in the amount of incorporated maleimide functionalized ob18 diblock polymer,
from 0.2 to 1 mol% resulted in a 3-fold increase in the amount of bound rat-IgG (Figure
3.11B). The conjugation of antibody reaches a plateau at 3% maleimide functionalization
degree for streptavidin conjugation and at 1% maleimide functionalization degree for ratIgG conjugation. The maximum number of streptavidin that can be conjugated to
polymersomes by maleimide coupling method is ~447 per 100 nm polymersome while
the maximum number of rat-IgG that can be conjugated to polymersomes is ~158 per 100
nm polymersome. Similarly, as the antibody concentration increased, the total amount of
bound antibody also increased substantially, while the antibody conjugation efficiency
decreased with the increasing antibody concentration (Figure 3.12).
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Figure 3.11 Effect of funtionalized polymer content on coupling of protein streptavidin
(A) and rat IgG (B) to polymersomes by FNB method (black line) and maleimide method
(red line).
Polymersomes were 100 nm in diameter, composed of streptavidin or rat-IgG. (A)
Polymersomes containing 0 to 5 mol% functionalized-polymer were incubated with
streptavidin at an antibody to functionalized polymer molar ratio of 1:2; (B)
Polymersomes containing 0 to 1 mol% functionalized-polymer were incubated with SHrat-IgG at an antibody to functionalized polymer molar ratio of 1:2.
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Figure 3.12 Effect of antibody concentration on coupling of antibody (rat-IgG) to
polymersomes by maleimide method.
5 mol% maleimide-OB18/OB2 polymersomes were incubated with various amounts of
rat-IgG at a constant polymersome concentration of 20 nM.
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The maximum functionalization degree and number of antibody per 100 nm
polymersomes is calculated, assuming the polymersomes surface is 100% cover with the
antibodies are spherical particles. Considering the diameter of streptavidin is ~ 5nm82 and
the diameter of IgG is ~10nm,83 the projected area of each streptavidin on polymersomes
surface is 19.6 nm2 and for rat-IgG is 78.5 nm2. The surface area of 100 nm
polymersomes is 31346 nm2, therefore the maximum number of streptavidin per 100 nm
polymersome is 1600 and the corresponding maximum functionalization degree is 5.3%;
while the maximum number of rat-IgG per 100 nm polymersome is 400 with 1.3%
maximum functionalization degree. Taken into account the steric hindrance effect on the
polymersomes surface, the experimental numbers of antibody per polymersome will be
much smaller than these theoretical calculated numbers. Our measured values correspond
well with the calculated numbers. The rat-IgG antibody, a much larger particle than
streptavidin, has a low conjugation degree on the polymersome surface and the maximum
functionalization degree is much smaller. Also, by comparing the numbers from FNB
coupling method and maleimide coupling method, we could conclude that the maleimide
method has a much stronger reactivity towards antibody conjugation than the FNB
coupling method based on the increasing number of antibodies on the polymersome
surface at the same functionalization degree.
3.4.5. Confocal Microcope Imaging of Antibody Conjugated Polymersomes
Meso-scale biotin functionalized polymersomes were prepared and conjugated to
FITC-streptavidin. The morphology of the formed vesicles is shown in Figure 3.13. The
polymer vesicle structures were very robust and didn‟t change after the antibody
conjugation. The fluorescence from the FITC green chanel indicated uniform binding of
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FITC-streptavidin on the polymersomes surface. However, streptavidin conjugated
polymersomes formed by using this noncovalent method via streptavidin-biotin
interaction were observed to be highly aggregated. This aggregation is due to the crosslinking of streptavidin to biotinylated polymersomes.
Similarly, meso-sized maleimide functionalized polymersomes were prepared and
conjugated to SH-functionalized FITC-rat IgG antibody. The morphology of the formed
antibody conjugated vesicles is shown in Figure 3.14. While the noncovalent biotinavidin conjugation method caused polymersome aggregation, the maleimide coupling
procedures had a minimal aggregation effect and produced well dispersed, nonaggregated antibody conjugated polymersome suspension.
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Figure 3.13 Functionalized polymersomes labeled with FITC-streptavidin by biotin
functionalization show uniform labeling. Green chanel: FITC emission, Red chanel:
porphyrin emission, Orange chanel: overlapped.
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Figure 3.14 Functionalized polymersomes labeled with FITC-rat IgG by maleimide
functionalization show uniform labeling. Green chanel: FITC emission, Red chanel:
porphyrin emission, Orange chanel: overlapped.
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3.4.6. Cryo-TEM of nm-sized AB Conjugated Polymersomes
After the conjugation of 10 nm gold-labeled goat-anti-mouse IgG antibody to
nano-sized polymersomes, the structure of gold- labeled IgG antibody conjugated
polymersomes was examined by multiple TEM techinques (Figure 3.15). The TEM
images revealed that nano-scale antibody conjugated polymersomes were generally round
and of vesicle-like shape, indicating that polymersomes were tough and the conjugation
with the antibody did not rupture the polymersome structure. Conjugation of the antibody
with the polymersome was also confirmed by gold labeled antibody visualized by TEM.
Antibodies have very low scattering contrast and could not be visualized by TEM; by
labeling them with electron-dense gold nanoparticles, the observation of the gold
nanoparticles under TEM will indicate the presence of antibody. In TEM experiments
(Figure 3.15A and B), polymersome samples were air dried, with aqueous solution
trapped in the hydrophilic core, and appeared as black spheres without showing the subtle
bilayer structure, with gold-labeled antibodies as the darker dots surround them. To
confirm the black sphere structures we saw in classic TEM are truly polymersomes other
than possible exist water droplets, negative staining TEM was employed by embedding
the polymersomes in an electron dense material (PTA) providing high contrast, and
polymersomes were seen as white spheres with a black edge which is the bilayer
membrane of the vesicles. Furthermore, to allow the indicative evaluation of the
polymersomal internal structure without discriminating on the fine details, Cryo-TEM
was performed. In Cryo-TEM experiments, polymersome solution was frozen into a thin
water film, thus the vesicle structures were well preserved and the bilayer structure was
clearly revealed.
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Figure 3.15 TEM images of Gold (10nm)-antibody conjugated polymersomes (PO-Gold):
(A) and (B) PO-Gold in PBS buffer. (C) TEM images of PO-Gold negatively stained
with PTA solution. (D) Cryo-TEM images of PO-Gold in PBS buffer.
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3.4.7. ELISA of Antibody Conjugated Polymersomes
Nanoscale polymersomes (100nm diameter) prepared using functionalized OB18
blended with OB2 in 5:95 and polymer with porphyrin trimer (max = 798 nm) in 40:1
were conjugated with rat-IgG and goat-anti-mouse IgG antibody. First, the binding of ratIgG antibody conjugated polymersomes towards goat-anti-rat IgG antibody was studied
by ELISA experiments (Figure 3.16). The rat-IgG antibody conjugated polymersomes
showed positive titers against goat-anti-rat IgG antibody, with enhanced absorbance
intensities by increasing rat-IgG conjugated polymersomes concentration. The very
obvious and quick color change even in dilute rat-IgG polymersome samples (0.37 fmol)
proved the successful antibody conjugation on polymersomes. All of the control samples
showed negative results which indicated that the non-conjugated polymersomes have
minimal non-specific binding to the goat-anti-rat IgG antibody.
Furthermore, the specificity and cross-reactivities of goat-anti-mouse IgG
antibody and rat-IgG antibody conjugated polymersomes were also tested by ELISA
experiments (Figure 3.17). Different IgG antibodies (mouse IgG antibody and rabbit IgG
antibody) were used for ELISA plates coating. ELISA experiments (Figure 3.17) showed
that the goat-anti-mouse IgG antibody conjugated polymersomes were only positive with
plates coated with mouse IgG antibody, and were negative towards rabbit IgG. As
expected, rat-IgG antibody conjugated polymersomes were also negative both to mouseIgG AND rabbit-IgG. This result indicates species-specific reactions. There are no nonspecific or cross-reactivities of antibody conjugated polymersomes. In summary, the
ELISA results show that the conjugation of antibody to polymersomes was successful,
with specific and selective binding towards 96 well plates.
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Figure 3.16 ELISA plate images (left) and polymersomes standard curve (right).
Sample: Rat IgG antibody conjugated 100 nm polymersomes.
Blank1: functionalized, nonconjugated 100 nm polymersomes.
Blank2: nonfunctionalized nonconjugated 100 nm polymersomes.
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Figure 3.17 ELISA plate images for specificity tests.
Polymersomes are dilute in 10 times series in each well (from left to right).
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3.4.8. Licor-Odyssey Imaging of Antibody Conjugated Polymersomes
The binding sensitivity of streptavidin conjugated polymersomes to biotinylated
96 well plates was measured by Licor-Odyssey imaging system as shown in Figure 3.18.
Different amounts (0.9-120 fmol)
polymersomes (λem
polymersomes (λem

max=810
max=723

of PZn3 incorporated streptavidin conjugated

nm), and PZn2 incorporated streptavidin conjugated
nm) were added to the biotinlayted 96 well plate, with

DyLight 680 streptavidin and DyLight 800 streptavidin added at the same concentration
as the polymersomes for comparison. Serial dilutions of the DyLight or polymersome
based NIR emissive probe concentrations in lanes A-D demonstrate that polymersome
enable analyte detection 2-3 orders of magnitude more sensitive than that provided by
commercially available organic fluorophores.
Polymersome particles are much more sensitive than the DyLight streptavidin
particles because each 100 nm polymersome made from 40:1 polymer:porphyrin contains
~ 1,570 copies of porphyrin fluorophores in the bilayer membrane (there are 9.6 ×1012
polymersomes per umol PEO-b-PBD polymer, 73 so each polymersomes are comprised of
62,800 copies of polymer); while each DyLight streptavidin contains only a few copies of
DyLight fluorophores per DyLight streptavidin particle. Therefore, each polymersome
particle is thousands of times brighter than each DyLight streptavidin particle, and will
greatly increases the detection sensitivity.
From the Licor-Odyssey imaging experiments shown below in Figure 3.18, the
minimal detection concentration (average from 3 measurements) is calculated using the
equation:
Minimal detection concentration = 3*SDblank/slope

160

The SDblank is the standard deviation of blank wells. Slope is from the linear
regression fit of a series dilution curve. The minimal detection concentration calculated
for PZn3 incorporated streptavidin conjugated polymersomes (λem max=810 nm) is 0.012
fmol, DyLight 800 streptavidin is 2.37 fmol; for PZn2 incorporated streptavidin
conjugated polymersomes (λem max=723 nm) is 0.69 fmol, DyLight 680 streptavidin is
46.07 fmol. Comparing these numbers, the PZn3 incorporated streptavidin conjugated
polymersomes (λem

max=

810 nm) is 197.5 times more sensitive than DyLight 800

streptavidin, and PZn2 incorporated streptavidin conjugated polymersomes (λem max= 723
nm) is 66.7 times more sensitive than DyLight 680 streptavidin.
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Figure 3.18 Licor Odyssey Imaging experimental results.
Streptavidin, DyLight 800; B. Streptavidin, DyLight 680 conjugated; C. Streptavidin810 nm emissive polymersomes conjugate; D. Streptavidin-723 nm emissive
polymersomes conjugate. All samples are incubated in biotinylated 96 well plates for 1
hour at RT with SEA blocking buffer and then rinsed with PBS three times before
imaging using Licor Odyssey Imaging System. Red chanel: 700 nm emission, green
chanel: 800 nm emission.
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3.4.9. Anti-ErbB2 IPs for Targeting HER2 Cells
We have generated anti-ErbB2 IPs consisting of functionalized polymersomes
linked to anti-ErbB2 monoclonal antibody, to provide targeted delivery to HER2
overexpression cells. Anti-ErbB2 IPs bound efficiently to and internalized in HER2
overexpression cells in vitro as determined by confocal fluorescence microscopy and
quantitative analysis of fluorescent probe delivery.
3.4.9.1. In Vitro Optical Imaging of Labeled Human Breast Cancer Tumor Cells
Anti-ErbB2 antibodys are readily internalized in HER2-overexpression tumor
cells via receptor-mediated endocytosis.84 To assess whether anti-ErbB2 IPs also
internalize within target cells in vitro, a series of studies using confocal fluorescence
microscopy were performed. As seen in Figure 3.19, anti-ErbB2 IPs labeled with 810 nm
emissive porphyrin, were incubated with HCC1569, BT474, SKBR3 fixed breast cancer
cells, which overexpress HER2 (106 molecules/cell), and with MCF-7 fixed breast cancer
cells which have very low or basal levels of HER2 expression (104 receptors/cell).85 The
anti-ErbB2 IPs significantly bind to HCC1569, BT474, SKBR3 cells as evident from
images Figure 3.19A-C, demonstrated intense fluorescence at the cell surface by 30 min,
indicating rapid internalization. In addition, the anti-ErbB2 IPs were localized
intracellular and distributed throughout the cytoplasm as clearly evident in Figure 3.20.
MCF7 cells similarly incubated with anti-ErbB2 IPs showed minimal uptake of antiErbB2 IPs (Figure 3.19D), indicating very weak non-specific binding of anti-ErbB2 IPs
with cells with low HER2 expression.
Furthermore, the specificity of anti-ErbB2 IP uptake was confirmed by incubation
of SKBR3 cells with irrelevant rat-IgG conjugated polymersomes and nonconjugated
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polymersomes in both live and fixed SKBR3 and MCF7 cells lines (Figure 3.21). The
confocal microscope results demonstrated strong specific binding of anti-ErbB2 IPs to
HER2 overexpressed SKBR3 cells, and no detectable interaction of irrelevant rat-IgG
conjugated polymersomes and nonconjugated polymersomes in SKBR3 cells. As
expected, live cells also exhibit similar anti-ErbB2 IP binding properties as fixed cells.
Taken together, these studies demonstrated the ability of anti-ErbB2 IPs to
selectively internalize in target cells, thus the potential for intracellular delivery. This
targeting strategy can provide a critical advantage to the therapeutic action of many
anticancer agents.
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Figure 3.19 Confocal microscopy of fixed cells coincubated at RT 30mins with antiErbB2 emissive IPs (5 mol % Maleimide functionalization, ErbB2 antibody conjugated,
723nm emissive) and Hoechst 33258.
Left column, Hoechst 33258 (blue); central column, emissive polymersomes (red); right
column, overlapped images. (A). HCC1569 cells. (B). BT474 cells. (C). SKBR3 cells.
(D). MCF7 cells. Scale bar: 25 μm.
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Figure 3.20 Detailed confocal microscope images of fixed SKBR3 cells coincubated at
RT 30mins with anti-ErbB2 emissive IPs (5 mol % Maleimide functionalization, ErbB2
antibody conjugated, 723nm emissive) and Hoechst 33258.
A: Hoechst 33258 (blue); (B) emissive polymersomes (red); (C) differential interference
contrast (DIC) image of cells; (D) overlapped images. Scale bar: 10 μm.
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Figure 3.21 Confocal microscopy of cells coincubated at RT 30mins (fixed cells) or 4
hours (live cells) with different polymersomes (red) and Hoechst 33258 (blue).
Left column: anti- ErbB2 IPs; central column: irrelevant IgG conjugated polymersomes;
right column: nonconjugated polymersomes. (A). live SKBR3+ cells. (B). live MCF7cells. (C). fixed SKBR3+ cells. (D). fixed MCF7- cells. Scale bar: 75 um.
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3.4.9.2. Concentration Dependence Anti-ErbB2 IPs Uptake
In order to maximize the intracellular uptake of polymersomes necessary for
optimal cellular labeling, the maximum uptake concentration on HER2 cell uptake were
examined. Flow cytometry was used to measure the intensity of cellular-associated PZn3based fluorescence following cell incubation and washing. The uptake of both anti-ErbB2
IPs and nonconjugated polymersomes controls at various polymersome concentrations
was evaluated in order to distinguish the impact of anti-ErbB2 conjugation on
intracellular delivery. The histograms presented in Figure 3.22 demonstrate clear dosedependent uptake of anti-ErbB2 IPs in HER2 overexpressing BT474 cells, while the
nonconjugated control polymersomes had minimal nonspecific binding in BT474 cells.
The MCF7 cells that lack ErbB2 overexpression showed minimal uptake of both
polymersomes with or without anti-ErbB2 antibody conjugation.
The concentration dependence of anti-ErbB2 IPs uptake is also evident for both
anti-ErbB2 antibody conjugated and nonconjugated (control) polymersomes. The uptake
of anti-ErbB2 NIR emissive polymersomes becomes saturated after incubation with a
concentration of 0.88 nM polymersomes. This saturation is clearly observed in Figure 4B
where the geometric mean fluorescence intensities of the presented histograms are plotted
against the treatment concentration.
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Figure 3.22 Representative histograms for BT474 and MCF7 cells treated at room
temperature 1 hour with either control or anti-ErbB2 NIR emissive polymersomes at the
indicated polymer dose.
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Figure 3.23 Geometric mean fluorescent intensity from flow cytometry analysis with
different polymersome concentration for BT474 cells (black line) and MCF7 cells (red
line) treated with anti-ErbB2-conjugated NIR emissive polymersomes (solid dots) or
control NIR emissive polymersomes (hollow dots).

170

Furthermore, for quantitative studies of anti-ErbB2 IP uptake, internalization and
intracellular delivery, Licor-Odyssey imaging system was used to assay the number of
anti-ErbB2 IPs binding to HER2 cells. HER2 cells that were stained with NIR emissive
polymersomes at different cell concentrations were plated in 96 well plates and the cell
emission from each well were integrated. NIR imaging allows quantitative and repetitive
detection of fluorophore-labeled cells without disturbing cellular function. The
representative images of plated cells are presented in Figure 3.24 and Figure 3.26.
Similar to the flow cytometry results, we observed a clear dose-dependent uptake of antiErbB2 IPs in HER2 overexpression BT474 cells while the nonconjugated control
polymersomes had minimal staining in BT474 cells, while MCF7 cells that lack ErbB2
overexpression showed minimal uptake of both polymersomes with or without antiErbB2 antibody conjugation. For each single Licor-Odyssey imaging measurement, a
standard calibration curve created from the number of NIR fluorophores versus total
photon counts per well (Figure 3.25A and Figure 3.27A) was used for the estimation of
the amount of fluorophore associated with each cell population and ultimately the number
of polymersomes per cell. The number of polymersomes per cell as a function of
polymersome treatment concentration is presented in Figure 3.25B and Figure 3.27B. A
single BT474 cell can be effectively labeled with 86,000 ± 2,500 anti-ErbB2 IPs, and 800
± 50 control polymersomes. However, for MCF7 cells, they can only be labeled with
1,700 ± 130 anti-ErbB2 IPs per cell, or 830 ± 200 control polymersomes per cell. These
results were represented in Figure 3.28 for easy comparison. The binding curve of antiErbB2 IPs to BT474 cells fit very well to the simple Langmuir-type dose response
equation of the equilibrium binding assuming all binding sites equal and independent
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(Figure 3.25C). The maximum number of anti-ErbB2 IPs per cell is calculated to be
88,751 ±5151, and the dissociation constant is 0.84 ±0.37 min-1.
The maximum polymersomes uptake percentage which equals the number of
polymersome uptake up divided by the polymersomes initially added for staining is also
calculated and the results are represented in Figure 3.29. The maximum IP uptake is 37.9
± 1.8% for BT474 cells, and 0.60 ± 0.18% for MCF7 cells. The maximum cellular uptake
for the control polymersomes is 0.19 ± 0.03% for BT474 cells, and 0.19 ± 0.05% for
MCF7 cells.
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Figure 3.24 Representative Licor-Odyssey image of 96-well plate with 5-fold serial
dilutions of BT474 cells with different concentrations of anti-ErbB2-NIR-polymersomes
and control NIR-polymersomes.
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Figure 3.25 (A) Fluorescence calibration with total photon counts versus the number of
NIR-polymersomes (PO) per well (n = 8); linear fit R2 = 0.99. (B) The calculated
number of polymersomes per cell as a function of cellular treatment condition. (C). Fitted
curve for binding of anti-ErbB2 immunoliposomes to BT474 cells.
Black bars represent BT474 cells treated with anti-ErbB2-NIR-polymersomes, and the
red bars represent BT474 cells treated with control NIR-polymersomes. Error bars
represent standard deviation.
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Figure 3.26 Representative Licor-Odyssey image of 96-well plate with 5-fold serial
dilutions of MCF7 cells with different concentrations of anti-ErbB2-NIR-polymersomes
and control NIR-polymersomes.
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Figure 3.27 (A) Fluorescence calibration with total photon counts versus the number of
NIR-polymersomes (PO) per well (n = 8); linear fit R2 = 0.99. (B) The calculated
number of polymersomes per cell as a function of cellular treatment condition.
Black bars represent MCF7 cells treated with anti-ErbB2-NIR-polymersomes, and the red
bars represent MCF7 cells treated with control NIR-polymersomes. Error bars represent
standard deviation.
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Figure 3.28 Number of polymersomes per cell with different polymersome
concentrations for BT474 cells (black line) and MCF7 cells (red line) treated with antiErbB2-conjugated NIR emissive polymersomes (solid dots) or control NIR emissive
polymersomes (hollow dots) measured by Licor-Odyssey experiments.
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Figure 3.29 Relative uptake, percentage of polymersomes added/106 cells (A) BT474
cells and (B) MCF7 cells treated with different polymersome concentration of antiErbB2-conjugated NIR emissive polymersomes (solid dots) or control NIR emissive
polymersomes (hollow dots) measured by Licor-Odyssey experiments.
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Finally, since both Licor-Odyssey imaging and flow cytometry measure the
fluorescence per cell, we compared results from each of these assays by normalizing
individual values with the maximum fluorescence signal intensity observed in each
method. These results are presented in Figure 3.23 and summarized in Table 3.2 which
shows that the independent assays are in close agreement. In both assays, the extent of
labeling is greatest for BT474 cells labeled with anti-ErBb2 NIR emissive IPs. Cellular
labeling levels in the absence of anti-ErbB2 antibody are two orders of magnitude lower
for ErBb2 overexpression BT474 cells and one order of magnitude lower for non-ErbB2
overexpression MCF7 cells. The corroboration of both the NIR imaging and flow
cytometry-based assays shows the reliability of our imaging methods.
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Table 3.2 Comparison of fluorescence per cell value generated from Licor-Odyssey
imaging or flow cytometry analysis.

Normalized fluorescence/cell
BT474 cells
Concentration
(nM)

0.22

0.44

0.88

MCF7 cells
1.76

3.52

0.22

0.44

0.88

1.76

3.52

Flow cytometrya
Anti-ErbB2
IPs

4.67

32.98

55.18

81.39

100

0.70

0.83

1.33

2.03

2.61

Control POs

-

-

0.01

0.21

0.68

0.05

0.09

0.12

0.38

0.89

Licor-odyssey imagingb
Anti-ErbB2
IPs

4.12
(0.18)

31.37
(1.60)

57.84
(2.74)

79.55
(4.31)

100
(5.91)

0.09
(0.09)

0.62
(0.13)

0.67
(0.11)

1.30
(0.07)

2.77
(0.20)

Control POs

-

-

-

0.29
(0.06)

0.98
(0.08)

-

-

-

0.32
(0.10)

1.51
(0.70)

a

Normalized average photon counts per cell (mean ±SD) by Licor-Odyssey image.

b

Normalized geometric mean fluorescence of 10 000 events by flow cytometry analysis.
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3.5. Conclusions
The goal of this work was to design and implement a simple, efficient, and
universal method to covalently attach big biological ligands, such as antibodies, to
polymersomes in order to provide a platform for targeting experiments. Amphiphilic
PEO-b-PBD diblock copolymers comprising FNB, biotin, amine, amide and maleimide
functionalities at their hydrophilic ends were synthesized and characterized. Six different
antibody coupling procedures were developed based on these five different functionalities
on polymersomes surface. All these coupling procedures were evaluated and compared in
terms of antibody conjugation efficiency and polymersome receovery yield. The
maleimide coupling procedure was concluded to be the optimized method for antibody
conjugation, which yields ~162 streptavidin molecules and ~64 rat-IgG antibodies per
100 nm polymersomes at ~80% antibody conjugation efficiency with a high
polymersome yield of 75-84%. The covalent attachment of antibody to polymersomes
can be controlled by varying the molar percentage of functionalized polymer in the
polymersome. The effect of antibody concentration on conjugation efficiency was also
studied. Characterization of the antibody conjugated polymersomes by confocal
microscope and Cryo-TEM experiments showed successful conjugation of antibody to
the surface of polymersomes. The reactivity and specifity of the antibody after
conjugation to polymersomes was also studied by ELISA. The results demonstrated that
antibody conjugated polymersomes showed speficic and selective binding in
immunoassays. Furthermore, the sensitivity of antibody polymersomes conjugates for
optical based NIR imaging was studied by Licor-Odyssey imaging. The antibody
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conjugated polymersomes appear to be 1-2 orders more sensitive than the commercially
available fluorescent-tagged antibodies.
Finally, anti-ErbB2 NIR emissive IPs were developed based on these established
functionalization chemistries to combine the tumor-targeting propertied of anti-ErbB2
monoclonal antibodies with the pharmacokinetic and delivery properties of long
circulating polymersomes. Anti-ErbB2 IPs bound efficiently to and internalized in HER2
overexpressing cells, resuling in intracellular delivery in vitro, as determined by
fluorescence confocal microscopy and quantitative analysis of fluorescent probe delivery.
HER2 overexpression tumor cells uptake of the probes was saturated at high
concentrations. Optimized cellular uptake of NIR emissive polymersomes was achieved
in BT474 cells incubated with anti-ErbB2 IPs at 0.88 nM concentration in 1 h, with
uptake efficiency as high as 37.3%. This high efficiency uptake of IPs in BT474 cells
corresponds to 86,000 ± 2,500 polymersomes per cell. This number is much higher than
the anti-HER2 immunoliposomes uptake which is only 8,000-23,000 IPs per cell.86
Although this maximum number of polymersomes per cell is similar to other peptide
conjugated polymersomes, for example, the uptake of Tat-polymersomes into dentric
cells resulted in ~ 70,000 polymersomes per cell,39 the uptake of our antibody conjugated
IPs is much more rapid (within 1 hour incubation) compared to the small peptide
conjugated polymersomes (over 10 hours incubation), suggests a much stronger
interaction of IPs with the cells than peptide conjugated polymersomes. In summary, we
developed a new antibody-polymersome platform, based on a series of different
conjugation chemistries that allows multifaceted and stable attachment of targeting
antibodies. This targeting strategy can provide a critical advantage to the therapeutic
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action of many anticancer agents and presents new opportunities to make highly sensitive
and effective immunoassays for in vivo imaging and biomedical applications.
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CHAPTER 4. Synthesis,
Preparation,

Characterization,

Morphology

Polymersome

Assessment

and

Functionalization of Biodegradable Diblock Copolymers

4.1. Summary
Polymersomes have been shown to possess a number of attractive biomaterial
properties including prolonged circulation times, increased mechanical stability, and the
unique

ability

to

non-covalently

incorporate

numerous

high-molecular-weight

hydrophobic molecules within their thick lamellar membranes.

A long-standing

challenge in materials chemistry, however, has been the development of polymersomes
comprised entirely of biodegradable, non-toxic synthetic amphiphiles that would make
these vesicles truly competitive with liposomes for in vivo applications. In this chapter,
we described the formation of polymersomes through self-assembly of an amphiphilic
bioresorbable polymer consisting of three previously FDA-approved building blocks:
poly(ethyleneoxide) (PEO) , poly(ε-caprolactone) (PCL) and poly(1,3-trimethylene
carbonate) (PTMC). Unlike other published reports of degradable peptide, polyester, or
polyanhydride-based

polymersomes,

these

biodegradable

vesicles

are

formed

spontaneously through self-assembly without the addition of co-solvent or blending with
other non-degradable vesicle-forming polymers, enabling facile, large-scale synthesis and
thus obviating the need for post-assembly processing. We found the PEO-b-PCL diblock
copolymer compositions that form none or very little meso-scale polymersomes could
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form ~100% nano-scale polymersomes, implicates various in vivo applications for this
diblock copolymers as nano-sized drug delivery vesicles.
Furthermore, by copolymerizing TMC, soft, bioresorbable vesicles with reduced
membrane crystallinity were prepared. Notely, the vesicles prepared from these TMC
containing materials have much smaller sizes compare to classic polymer vesicles,
suggests prolonged in vivo circulation time and thus delayed clearance by the
reticuloendothelial system (RES), a highly desired property for in vivo applications. In
addition, these PEO-b-PTMC and PEO-b-P(CL-co-TMC) can also self-assemble into
uniform distributed large spherical micelles at very high yields, enable the arising of new
promising nanomaterials for various biomedical applications.
Finally, we synthesized vinyl sulfone functionalized PEO-b-PCl diblock
copolymers which can be readily used for peptide conjugation and tumor targeting. As
such, these bioresorbable polymersomes hold promise as nanomaterials for future
imaging, targeting and drug delivery applications.

4.2. Introduction
Polymersomes (50 nm - 50 μm diameter polymer vesicles)

formed from

amphiphilic block copolymers have attracted much attention due to their superior
mechanical stabilities and unique chemical properties relative to those of conventional
lipid-based vesicles (liposomes) and micelles.1-5 Polymer vesicles have not only proven
capable of entrapping water-soluble hydrophilic compounds (drugs, vitamins,
fluorophores, etc.) inside of their aqueous cavities, but have been shown to disperse
hydrophobic molecules5 within their thick lamellar membranes. Moreover, the size,
membrane thickness, and stability of these synthetic vesicles can be rationally tuned via
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various preparation methods1,

4

through modulation of block copolymer chemical

structure, number-average molecular weight, and hydrophilic to hydrophobic volume
fraction: polymersomes thus have adjustable characteristics that lend to their potential
function in medical imaging, drug delivery, and cosmetic applications.1, 5, 6
To date, polymersomes have been formed predominantly from amphiphilic
diblock copolymers that include poly(ethylene oxide)-b-polybutadiene (PEO-b-PBD),1, 5,
7

poly(ethylene oxide)-b-polyethylethylene (PEO-b-PEE),7 polystyrene-b-poly(ethylene

oxide) (PS-b-PEO),8-10 polystyrene-b-poly(acrylic acid) (PS-b-PAA),1, 9, 11 poly(ethylene
oxide)-b-poly(propylenesulfide)

(PEO-PPS),12

13,

14

poly(2-(methacryloyloxy)

ethylphosphorylcholine)-b-poly(2-(diisopropylamino)ethylmethacrylate)
PDPA)15,

16

(PMPC-

and polystyrene-b-polyisocyanoalanine(2-thiophene-3-yl-ethyl)amide (PS-

PIAT)17-20. None of these well-established polymersome formulations, however, yields
self-assembled fully-biodegradable polymer-based vesicles useful for in vivo applications.
A few biodegradable polymersomes prepared from amphiphilic biodegradable diblock
copolymers of PEO and aliphatic polyesters/polycarbonates using an organic cosolvent/water injection/extraction system have been reported;21-23 in contrast with other
polymersome preparation procedures based on self-assembly (i.e. film hydration, bulk
hydration, or electroformation), a drawback of the co-solvent method is that the organic
co-solvent must be completely removed from the aqueous polymersome suspension postassembly; in addition to this required processing, the presence of any residual organic
solvent in such vesicles constitutes an additional concern in the transition of these
polymersomes for in vivo application. The other drawback of the co-solvent method is
that the self-assembling process of diblock copolymer are affected by many different
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factors, such as the diblock copolymer concentration, the water content, temperature, the
mixing time and order of aqueous phase and organic phase.22,

24-26

Therefore the

cosolvent method is relatively hard to control and repeat, whereas the thin-film hydration
method is not affected by these factors and is much more facile.
We have previously reported the generation of self-assembled polymersomes
comprised entirely of an amphiphilic diblock copolymer PEO(2K)-b-PCL(12K) by thin
film hydration featuring two previously FDA-approved polymers, poly(ethylene oxide)
(PEO) and polycaprolactone (PCL).27 Unlike degradable polymersomes formed from
blending "bio-inert" and hydrolysable components,28, 29 these PEO-b-PCL-based vesicles
promise to be fully bioresorbable,30 leaving no potentially toxic byproducts upon their
degradation.

Besides, unlike published reports of other degradable (polypeptide-,

polyester-, or polyanhydride-based) polymersomes,21, 22, 31-33 these bioresorbable vesicles
are formed through spontaneous self-assembly of their pure amphiphile component,
offering manufacturing advantages in terms of cost, tune, and safety. Moreover, these
self-assembled vesicular architectures allow for the economic generation of mesoscopic
colloidal devices, enabling large-scale production while eliminating the need for costly
removal of organic cosolvents post assembly. These polymersomes are also found to
possess slow in vivo drug release kinetics which makes them appropriate for potential
intravascular drug delivery applications. However, it is well known that the size of
particles has a big influence on blood circulation times, RES recognition, biodistribution
and the mechanism of cell uptake.34-36 The in vivo uptake of particles and the extent of
drug absorption increase with decreasing particle size and increasing specific surface area;
the optimum size for circulation in the blood stream is around 80-150 nm, and the uptake
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of particles larger than 1 μm in diameter is minimal.37-39 Therefore, it is very important to
make nano-sized vesicles for in vivo applications using the vesicle morphology for
encapsulation and drug delivery, which implicates an urgent need to screen for PEO-bPCL diblock copolymer compositions that can self-assemble into nano-scale
polymersomes by examining the effect of hydrophilic fraction and PEO chain length on
the formation of nano-sized vesicles. Butler et al.22 have looked into the formation of
nano-sized vesicles from a number of PEO-b-PCL block copolymers. However, they
were using co-solvent method for the vesicle preparation, and only checked on a very
narrow range of commercial available PEO-b-PCL polymers at small PEO chain length
and low copolymer molecular weights. Besides, they only checked on the effect of
hydrophilic fraction on the formation of vesicles. In this work, we report the synthesis,
characterization, and morphologies formed via aqueous self-assembly, of a very wide
range of amphiphilic PEO-b-PCL compositions varying both the hydrophilic fraction and
the PEO chain length.
These biodegradable PEO-b-PCL diblock copolymers were fabricated by: (i) ringopening polymerization of ε-caprolactone monomer (ε-CL) followed by coupling to
commercially available monomethoxyl PEO (MePEO); and (ii) sequential anionic living
polymerization of ethylene oxide and caprolactone monomers. The number-average
molecular weight and molecular weight distribution were characterized for each
copolymer formulation by nuclear magnetic resonance (NMR) spectroscopy and gel
permeation chromatography (GPC). These PEO-b-PCL diblock copolymers possessed
number-average molecular weights spanning 3.6-57K, PEO block weight fractions
ranging from 0.08-0.33 and polydiserpsity index (PDI) ranging between 1.14 and 1.37.
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The thin film hydration method and organic co-solvent water injection/extraction method
were employed to self-assemble diblock copolymers into various aqueous morphologies.
The resultant structures were visualized by confocal, optical, and cryogenic transmission
electron microscopic imaging.
PEO was chosen as the hydrophilic block for increasing of vesicles surfaces
biocompatibility and prolonged blood circulation times.40-42

PCL constitutes the

hydrophobic membrane portion of the vesicles. PCL is degraded by hydrolysis of its
ester linkages in physiological conditions and has therefore received lots of attention for
use as an implantable biomaterial in drug delivery devices, bioresorbable structures,
adhesion barriers, and as scaffolds for injury repair via tissue engineering.43-46 PCL has
several advantageous properties compared to other biodegradable aliphatic polyesters: (1)
high permeability to small drug molecules; (2) maintenance of neutral pH upon
degradation; (3) facility in forming blends with other polymers; and (4) suitability for
long-term delivery afforded by slow erosion kinetics as compared to polyglycolide
(PGA), polylactide (PLA), and polylactic-co-glycolic acid (PLGA).44 Therefore, the
utilization of PCL as the hydrophobic block promises that the resultant polymersomes
should have safe and complete in vivo degradation. However, different from the PEO-bPBD polymersomes that are “stealth” like, the biodegradable PEO-b-PCL polymersomes
are found to be highly crystallized as determined by differential scanning calorimetry
(DSC).27 It is known that membrane rheology can significantly influence how
polymersomes interact with their surroundings.47 Soft membranes have several
advantages over rigid membranes, the contact area between a soft vesicle and substrate is
increased as the soft vesicle can deform and flatten on a surface, while no conformational
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change can occur to improve the contact area for rigid vesicles. Consequently, the
binding between soft vesicles and a substrate (i.e. a tissue) would be enhanced compared
to a rigid vesicle‟s binding.48 Another advantage of soft membrane vesicles is their ability
to successfully passivate tumor tissue in vivo by deform-to elongate-to fit through the
endothelial pore,49 since the leaky junction pathway of tumor vasculatures is only 40-80
nm, which is smaller than the typical polymersome diameter.50 In addition, crystallized
polymers easily form multi-molecular aggregates which could accumulate undesirably in
cells and kidneys as crystalline aggregates.
To decrease the crystallization of PCL blocks in PEO-b-PCL polymersomes and
make soft polymersomes which can easily go through flesh and skin cells, poly(1,3trimethylene carbonate) (PTMC), a rubbery and amorphous polymer with low glass
transition temperatures, was taken as a starting point in the design of alternative synthetic
materials with suitable mechanical properties. Poly(trimethylene carbonate) (PTMC) is a
valuable candidate for biomedical applications in light of its biodegradability,
biocompatibility and low toxicity.51 Due to its excellent flexibility and poor mechanical
strength, PTMC have been evaluated as flexible synthetic materials for the preparation of
tissue engineering scaffolds or as depots for controlled release systems,52-61 as well as in
the design of implants, such as anti-adhesion membranes or vascular prostheses.62 In vivo,
PTMC degrades relatively rapid without the release of acidic degradation products. 51, 63,51,
64

Unlike the PCL, PMTC undergo surface degradation, the degradation and erosion are

only limited to the polymer surface and the mass loss is linear. Therefore, the molecular
weight of the polymer should be constant and the mechanical strength of the polymer
should slowly decrease during the degradation process.
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Seeing the promise in this material, biodegradable amphiphilic Poly(ethylene
oxide)-b-Poly(trimethylene

carbonate)

(PEO-b-PTMC)

diblock

copolymers

and

Poly(ethylene oxide)-b-Poly(-caprolactone-co- trimethylene carbonate) (PEO-b-P(CLco-TMC) diblock tripolymers varying in a number average molecular weight (Mn: 5.735.6k) and PEO weight fraction (fPEO: 0.10-0.25) and TMC molar fraction of the
hydrophobic block (30%, 50%, 100 %) were synthesized. The number-average molecular
weight and molecular weight distribution were characterized for each copolymer
formulation by nuclear magnetic resonance (NMR) spectroscopy and gel permeation
chromatography (GPC). The chemical and thermal properties of these polymers in bulk
were characterized by differential scanning calorimetry (DSC). The polymers were also
subsequently screened for their ability to self-assemble into meso-scale and nano-scale
polymersomes in dilute aqueous solution. All copolymers robustly assembled into both
micron-sized and nano-sized vesicles. These vesicles were characterized for their
mechanical rigidity, and stability properties.
Finally, as described in Chapter 3, actively targeted carriers have proven to be
particularly promising for enhancing the specificity of drug delivery systems. 65 However,
very little study has done on the functionalization of biodegradable PEO-b-PCL
polymersomes. Jiang etc. reported functionalized vesicles formed from maleimide
functionalized PEO-b-PCL;

66-68

the maleimide functionalized PEO-b-PCL diblock

copolymer synthesis is based upon custom-synthesized hydroxy-polyethyleneglycolmaleimide, which is costly and have very few options of PEO molecular weight. Herein
we report the synthesis of vinyl sulfone functionalized PEO-b-PCL diblock copolymer
with a wide molecular weight distribution and capable of reacting with targeting ligands
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under mild conditions via conjugate addition following vesicle formation. Following a
related procedure by Bae et al., the functionalized diblock copolymers were synthesized
by preferentially modifying one end of PEO diol with divinyl sulfone (VS).69 To allow
thiol-reactivity of the copolymer, heterobifunctional PEG with a VS group at one
terminus was prepared by a multi-step synthetic procedure and PCL was then introduced
to the remaining terminal hydroxyl group of PEG using ring opening polymerization.
Compared to maleimide-PEG, which has been widely used to make targeted and longcirculating nanocarriers,70-72 VS-PEO are reported to have several advantages: (1)The
reaction rate of VS-PEO towards peptides and proteins is relative faster than maleimidePEG; (2) The specificity is slightly better at pH below 8 and the thioether linkage formed
with thiol compounds is much more stable than the linkage formed with maleimides;73 (3)
The VS group is quite stable in aqueous solution74, 75 while maleimide group is easy to
hydrolysis. This VS functionalized block copolymer self-assembles in water to form
polymersomes containing the VS functionality at the hydrophilic PEO corona terminus,
which can undergo an efficient, site-selective attachment to thiol-containing peptides
under mild conditions and did not react with targeting peptides lacking a thiol. Properties
of these obtained VS functionalized block copolymer were fully characterized, and the
reactivity of the VS functionalized vesicles toward thiols was investigated using peptidebased cancer targeting molecules. Overall, this work develops a versatile platform for the
targeted delivery of therapeutics and offers the possibility to greatly improve treatment
outcomes for diseases by enhancing specificity, thus minimizing detrimental side effects.

199

4.3. Experimental Methods
4.3.1. Synthesis, Characterization, Polymersome Preparation and Morphology
Assessment of Biodegrable PEO-b-PCl, PEO-b-PTMC and PEO-b-P(CL-coTMC) Polymers
4.3.1.1. Materials
-caprolactone (-CL, Aldrich) was dried over calcium hydride (CaH2) at room
temperature for 48 h, and distilled under reduced pressure. Monomethoxyl poly(ethylene
oxide) (MePEO) homopolymers featuring a terminal -OH group and molecular weights
of 5000, 2000, 1100 and 750, were purchased from Fluka. Higher molecular weight
MePEO homopolymers (Mn = 1100, 2000 and 5000) were purified by dissolution in
tetrahydrofuran (THF), followed by precipitation into ether, and subsequent drying at 40
ºC under reduced pressure (10 mm Hg) for 24 h. Polymer grade 1, 3-trimethylene
carbonate (TMC) (Boehringer Ingelheim, Germany) were used without further
purification. Stannous octoate (SnOct2) (stannous 2-ethylhexanoate) (Sigma, USA) and
1,6-hexanediol (Aldrich, Germany) were used as received. Stannous (II) octonate (SnOct2,
Sigma) was used as received. Ethylene oxide (EO, Aldrich) was purified by passage
through potassium hydroxide, condensed onto CaH2, stirred for 2h, and distilled.
Naphthalene was recrystallized from ether. THF was distilled over Na mirror under
nitrogen. Other chemicals were commercially available and used as received.
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4.3.1.2. General Polymerization Reaction Conditions

Scheme 4.1 Synthesis of PEO-b-P(CL-co-TMC) diblock copolymers by ring-opening
polymerization.
Ring-opening polymerization: Monomethoxyl poly(ethylene oxide) (MePEO) was
delivered to a flamed-dried flask under argon. A known mass of -caprolactone (CL)
monomer and 1, 3-trimethylene carbonate (TMC) monomer were then injected into the
flask via syringe, was then injected into the flask via syringe, following which two drops
of SnOct2 were added to the reaction mixture. The flask was connected to a vacuum line,
evacuated, and immersed in an oil bath at 130 ºC. A progressive increase in viscosity of
the homogeneous mixture was evident as the polymerization reaction progressed. After
24 h, the volatiles were removed; the recovered solid residue was dissolved in methylene
chloride, precipitated with cold methanol/hexane (4°C), and dried under vacuum.
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Scheme 4.2 Synthesis of PEO-b-P(CL-co-TMC) diblock copolymers by anionic living
polymerization.
Anionic living polymerization: A flame-dried flask was purged with Ar and charged
with 30 mL of anhydrous THF, acetonitrile (0.55 mL, 10 mmol), and potassium
naphthalenide (5 ml of a 1 M THF solution). After vigorous stirring at 20 ºC for 70 min,
the mixture was cooled in an ice-water bath, following which distilled EO was added via
syringe. The polymerization reaction was carried out at ambient temperature; a sample of
reaction product (~5 mL CN-PEO) was removed, treated with an acetone solution
containing acetic acid, precipitated with excess diethyl ether, and dried under vacuum at
room temperature to check the molecular weight of PEO block by NMR and GPC.
Subsequently, -caprolactone and 1, 3-trimethylene carbonate dissolved in THF at a
calculated mole ratio of -CL and TMC to EO, were added to the remaining reaction
mixture of CN-PEO. After 10 min at 0 ºC, the polymerization was quenched by adding a
small amount of acetic acid and then poured into acetone to precipitate. The reaction
product was further purified by precipitation in diethyl ether and dried under vacuum at
40 ºC for two days.
4.3.1.3. Copolymer Characterization
PEO polymers and copolymers were characterized by 1H-NMR spectroscopy.
Weight-average molecular weight (Mw) and polydispersity index (Mw/Mn) values for
each copolymer formulation were determined using a GPC system that featured two
columns (PLgel 5m mixed, 300 × 7.5mm) connected in series, and dynamic laser
scattering and refractive index detectors (Enterprise System, Precision Technologies).
THF was utilized as the eluting solvent.

PEO standards were used to calibrate
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copolymers molecular weights determined from refractive index data. And differential
scanning calorimetry (DSC; TA Instruments Q100, New Castle, DE) was utilized to
elucidate the thermal transitions of the polymers in bulk and within aqueous vesicle
solutions. The thermal properties of the purified polymers were evaluated by differential
scanning calorimetry (DSC). Samples (5-10 mg) were analyzed at a heating rate of
10 °C/min. Samples of amorphous polymers were heated from −100 °C to 100 °C, while
semi-crystalline specimens were heated from −100 °C to 20 °C above their peak melting
temperature. After the first heating scan, the samples were quenched rapidly (300 °C/min)
to −100 °C, after 5 min at that temperature a second scan was recorded. Cyclohexane,
indium, gallium and tin were used as standards for temperature calibration.
4.3.1.4. Preparation of Polymersomes
Two vesicle preparative methods, thin-film hydration and organic cosolvent/aqueous extraction, were employed to assemble the PEO-b-PCL copolymers into
their equilibrium aqueous morphologies. For PEO-b-PTMC and PEO-b-P(CL-co-TMC)
polymersomes, only thin-film hydration method was used. Thin film hydration has been
extensively utilized for preparing non-biodegradable polymersomes comprised of PEO-bPBD diblock copolymers; an analogous protocol was employed in experiments involving
PEO-b-PCL copolymers.

The biodegradable polymer (200 μL of 7 mg/mL CHCl3

solution) was uniformly coated on the surface of a roughened Teflon plate, following
which the sample was placed under vacuum for > 12 h. Addition of an aqueous solution
(e.g. 250-300 milliosmolar sucrose or PBS) and heating at 60°C for 48 h led to
spontaneous budding of giant (5-20 μm) biodegradable polymersomes into solution. In
the preparation of samples that contained 1 mol % Nile red, the dye was incorporated into
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the polymersome hydrophobic bilayer during the self-assembly process noted above,
which enabled facile visualization of resultant copolymer aqueous morphology via
confocal fluorescence microscopy.
Small (< 300 nm diameter) unilamellar polymersomes that possess appropriately
narrow size distributions were prepared via procedures analogous to those used to
formulate small lipid vesicles (sonication, freeze-thaw extraction, and extrusion). The
sonication procedure involved placing a sample vial containing the aqueous-based
solution and a dried thin-film formulation (of polymer uniformly deposited on Teflon)
into a bath sonicator (Fischer Scientific; Model FS20) with constant agitation for 30 min.
Several cycles of freeze-thaw extraction were carried out by placing the sample vials
(containing solutions of 300-500 nm diameter polymersomes) in liquid N2. The vials
were then transferred to a 60 °C water bath, and extruded to give a mono-dispersed
suspension of small (100 nm diameter) vesicles; this was accomplished through the
introduction of a polymersome solution into a thermally controlled stainless steel cylinder
connected to pressurized nitrogen gas. The size distributions of the PEO-b-PCL
suspensions were determined in each case by dynamic light scattering.
For the co-solvent/water extraction method, the PEO-b-PCl diblock copolymers
were dissolved in chloroform or THF (at 10 mg/mL) and introduced at 1:100 vol% into
aqueous solution (sucrose, PBS or benzene/alcohol aqueous solution) via organic cosolvent injection. The various structures formed from these diblock copolymers were
extracted from the solvent mixture by aqueous dialysis (for organic co-solvent removal)
at room temperature for 24 h.
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4.3.1.5. Characterization of Sample Morphology in Dilute Aqueous Solution
Confocal laser scanning microscopy (BioRad Radiance 2000) and epifluorescent
optical microscopy (Zeiss Axiovert 200) were employed to characterize the selfassembled aqueous morphologies of the biodegradable polymer compositions that
featured dispersed Nile Red (1:99 dye:polymer). The instruments were equipped with
appropriate excitation and emission filters for these experiments.
Nanometric functionalized polymersomes were formulated as described above.
Vitreous samples were prepared within a controlled environment vitrification system
(Vitrobot). A droplet of solution (10 ul) was deposited on a copper TEM grid coated with
a porous polymer film. A thin film (< 300 nm) was obtained by blotting with filter paper.
After allowing the sample sufficient time to relax from any residual stresses imparted
during blotting (30 s), the grid was plunge cooled in liquid ethane at its freezing point (180 °C), resulting in vitrification of the aqueous film. Sample grids were examined in a
FEI Tecnai G²Twin transmission electron microscope operating at 200 kV, and images
were recorded with a Gatan 724 multiscan digital camera.
4.3.2. Vinyl Sulfone Functionalization of PEO-b-PCl Diblock Copolymers
The PEO tosylation, displacement of tosylated PEO with thioacetate and
deprotection to thiol, and the final divinyl sulfone attachment to PEO polymer is
following the procedures previously described.76
4.3.2.1. Tosylation of PEO

Scheme 4.3 Synthesis of monotosylated PEO.
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Dihydroxy terminated PEO with molecular weight 2 kg/mol (10 g, 5 mmol) was
dissolved in 200 mL dry CH2Cl2 and chilled to 0 °C. Ag2O (1.75 g, 7.5 mmol)
synthesized from aqueous NaOH and AgNO3 was added to the chilled PEO under
vigorous stirring followed by addition of KI (0.6 g, 3.6mmol) and p-toluenesulfonyl
chloride (1.5 g, 7.8 mmol). The reaction mixture was stirred rapidly for 2 h at 0 °C,
filtered over Celite, and reduced under vacuum to a white solid. The solid was then
dissolved in 75 mL H2O, filtered, extracted into 50 mL CH2Cl2 three times, dried over
MgSO4, and precipitated into ice-cold diethyl ether. Residual solvent was removed from
the resulting white solid under vacuum. The yield is 95% and the tosylation degree
determined by 1H NMR is 90%.
4.3.2.2. Displacement with Thioacetate and Deprotection to Thiol

Scheme 4.4 Synthesis of monothiol-PEO.
Potassium thioacetate (5.1 g, 50 mmol) was dissolved in 125 mL dry N,Ndimethylformamide (DMF) and the mixture was added to tosylated PEO from the
previous reaction (9.5 g, 4.75 mmol) and stirred until no solid was visible. The mixture
was degassed by three freeze-pump-thaw cycles, backfilled with nitrogen, and allowed to
react under stirring for three days at 35 °C. DMF was removed by vacuum distillation,
the residue was dissolved in 200 mL H2O, filtered, extracted three times with 60 mL
CH2Cl2 and dried over MgSO4. Volume was then reduced under vacuum and polymer
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precipitated into ice-cold diethyl ether followed by solvent removal under reduced
pressure. The PEO thioacetate (8.5 g, 4.25 mmol) was dissolved in 150 mL methanol
containing 150mM potassium methoxide and stirred at room temperature for 1.5 h. The
mixture was subsequently acidified with HCl, filtered, and solvent removed under
vacuum. To reduce disulfide bonds the residue was dissolved in 300 mL of 0.1 M
aqueous sodium bicarbonate to which was then slowly added sodium borohydride to 0.1
M (1.13 g, 29 mmol) followed by stirring under a nitrogen atmosphere. The solution was
then acidified to pH 3 by dropwise addition of HCl, extracted three times into 50 mL
CH2Cl2, dried over MgSO4, volume reduced under vacuum, and precipitated into icecold diethyl ether. The reduction–precipitation step was performed twice to yield a lightyellow solid. The yield is 75%, and the thiol modification degree is ~100% determined
by 1H NMR.

4.3.2.3. Divinyl Sulfone Attachment

Scheme 4.5 Synthesis of vinyl sulfone terminated PEO.
Thiol-terminated PEO (2.0 g, 1 mmol) was dissolved in 50 mL tetrahydrofuran
(THF) containing triethylamine (700 mL, 5 mmol) and degassed by three freeze-pumpthaw cycles. A small amount of dithiothreitol (DTT) (38 mg, 0.25 mmol) was added
under nitrogen atmosphere to reduce any residual disulfide bonds and the reaction was
allowed to stir for 1 h. Divinyl sulfone (DVS) (5 mL, 50 mmol) was then added rapidly
under vigorous stirring. The reaction vessel was capped and allowed to react for 18 h at
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room temperature. The solution was then reduced in volume under vacuum, precipitated
three times into ice-cold diethyl ether and solvent removed under vacuum. The yield is
86%, and the thiol modification degree is 81% determined by 1H NMR.
4.3.2.4. Polymerization of CL

Scheme 4.6 Synthesis of vinyl sulfone terminated PEO-PCl diblock copolymer.
To a solution of VS-PEO (1.5 g, 0.75 mmol) in 50 mL of dichloromethane under
nitrogen, AlEt3 (1.9 M solution, 750 μL, 1.4 mmol) and pyridine (100 μL, 1.2 mmol)
were added. The reaction mixture was stirred vigorously at room temperature for 3 h.
Next, different amount of caprolactone was added into the reaction mixture, and the
solution was allowed to react at room temperature for 42 h. The polymerization was
quenched by adding 2 equivalent of HCl (1M solution) and the solution was poured in
excess of methanol. Finally, the functionalized diblock copolymer (3.4 g) was isolated by
precipitation three times over methanol. 1H NMR showed the final VS functional degree
is 60-68%.

4.4. Results and Discussion
4.4.1. Synthesis and Characterization of Biodegradable PEO-b-PCL Diblock
Copolymers
A series of PEO-b-PCL diblock copolymers were synthesized via ring-opening
polymerization (Scheme 4.1) of ε-caprolactone and commercially available MePEO (Mn
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= 750, 1100, 2000 and 5000). MePEO homopolymers bearing one hydroxyl end group
were used as the macroinitiator to activate polymerization (130 C, 24 h) of εcaprolactone monomer (ε-CL) in the presence of catalyst (stannous (II) octoate, SnOct2).
Such PEO-b-PCL diblock copolymers have been previously synthesized under a variety
of catalyzed21

77-79

and non-catalyzed conditons.80,

81

Of the previously established

catalysts, SnOct2 is the most widely used for the production of biodegradable polyesters,
as it is commercially available, easy to handle, soluble in common organic solvents and
neat liquids (e.g., cyclic ester monomers), and is a permitted food additive in numerous
countries.82 For these reasons, coupled with the fact that non-catalyzed ring-opening
polymerization of -CL must be carried out at high temperature (180C) over long time
periods (days), SnOct2 was employed as the catalyst in the synthesis of these PEO-b-PCL
copolymers (Table 4.1).
Although the synthesis of PEO-b-PCL copolymers from MePEO via ring-opening
polymerization of -caprolactone is facile, the availability of MePEO homopolymers is
limited. As such, we utilized anionic living polymerization of ethylene oxide monomers
to produce PEOs of varying Mw; subsequent caprolactone polymerization yields PEO-bPCL copolymers having a diverse range of number-average molecular weights (Mn: 3.6 57K) and PEO weight fractions (fPEO: 0.08-0.33).

An additional advantage of this

approach is the fact that the copolymers‟ terminal PEO end group can be easily varied
(Scheme 4.2). Ethylene oxide polymerization reactions utilized cyanomethyl potassium
as the protected initiator, which was prepared by metalation of acetonitrile with
potassium naphthalenide in THF.69, 83-85 While anionic living polymerization had been
utilized previously in the syntheses of low molecular weight, high PEO weight fraction
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PEO-b-PCL copolymers [e.g., PEO(2.2K)-b-PCL(1.2K)],85 this strategy provides PEO-bPCL copolymers that possess a diverse range of PEO block molecular weights (1500,
2600, 3000, 3800, and 5800), low PEO weight fractions (fPEO: 0.10-0.23), and a wide
range of diblock Mn (7.8-47K).
1

H NMR spectroscopy was utilized to characterize the number-average molecular

weight of the PEO homopolymers and the corresponding PEO-b-PCL diblock
copolymers.21, 77-81, 84 A typical 1H NMR spectrum for MePEO-b-PCL is shown in Figure
4.1. The appearance of a resonance at ~4.20 ppm (b‟), consistent with the terminal
methylene end group of the PEO block in the 1H NMR spectrum, indicates that the final
reaction products were limited to only diblock copolymers of PEO and PCL. The sharp
weak resonance at 3.38 ppm and the intense peak at 3.65 ppm correspond to methyl (a,
CH3O- terminated PEO) and methylene groups (b, repeat unit of MePEO), respectively.
Resonances at 2.23 ppm, 1.63 ppm, 1.38 ppm and 4.06 ppm were assigned to protons in
PCL repeat units (c, d, e, and f methylene). The peak at 3.65 ppm (the methylene proton
signal for the PEO block) and the triplet at 2.23 ppm, (the methylene proton signal of the
caprolactone repeating units, b, COCH2CH2CH2CH2CH2O), were used to establish the
degree of PCL block polymerization and Mn. 1H NMR spectroscopy was further utilized
to characterize the number-average molecular weight of PEO from the calculated
ethylene oxide repeat unit number, by comparison of the integrated intensities of the
resonances that corresponded to of the end groups (i.e. CH3O- or CNCH2CH2-). The key
difference between the 1H NMR spectra of CN-PEO-b-PCL and MePEO-b-PCL diblock
copolymers evident is highlighted by the two weak signals around 2.50 ppm which
correspond respectively to α- and β-CH2 groups at the diblock copolymer CN terminus.
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Number-average molecular weight values of CN-PEO-b-PCL diblock copolymers were
also calculated from the NMR spectra.
GPC was employed to characterize the molecular weight (M w) and molecular
weight distribution (Mw/Mn) (PDI) of each PEO-b-PCL diblock copolymer formulation.
Two types of weight-average molecular masses were calculated from refractive index
data using PEO standard samples and dynamic light scattering data (Table 4.2). Some
copolymers, such as PEO(5.8K)-b-PCL(24K), PEO(5K)-b-PCL(22K), PEO(2K)-bPCL(12K), and PEO(2K)-b-PCL(15K), exhibited similar GPC and 1H NMR determined
molecular weight values; in contrast, PEO(5.8K)-b-PCL(33.6K) and PEO(2K)-bPCL(9.5K), the largest and smallest Mw copolymers synthesized, respectively, showed
significant differences between 1H NMR and GPC based Mw determinations. As PEO-bPCL diblock copolymer standard samples are not commercially available for the
calibration of RI data (GPC), the dn/dc values of the copolymers were calculated from
internal instrument parameters calibrated from a PS standard sample; these values were
then used to calculate Mw values from the DLS data. The use of polystyrene-based Mw
standards likely accounts for the differences in determined GPC and 1H NMR Mw at the
extremes of the copolymer Mw range.
GPC data indicate that PEO-b-PCL diblock copolymers synthesized by anionic
living polymerization having PEO molecular weights of 2600, 3000, 3800 and 5800,
exhibited the narrowest molecular weight distributions (PDI: 1.2-1.27). PEO-b-PCL
diblock copolymers synthesized from PEO(2K) via ring-opening polymerization showed
narrow molecular weight distributions (PDI: 1.1-1.2) while copolymers derived from
PEO(5K) displayed slightly wider distributions (PDI: 1.32-1.37).

Anionic living
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polymerization therefore provides the best route for synthesizing of PEO-b-PCL diblock
copolymers with controlled PEO chain lengths, modulating PEO/PCL block ratios, and
isolating block copolymers with narrow molecular weight distributions.
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Figure 4.1 Representative 1H NMR spectrum of PEO-b-PCL diblock copolymer.
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Table 4.1 Self-Assembled Morphologies Asessed via Microsopic Studies of PEO-b-PCL
Diblock Copolymers (PEO: 0.75-5.8K) in Aqueous Media Prepared via Film Hydration.

PEO-b-PCL Copolymersa

fPEOb

Morphologiesc

PEO(5.8k)-b-PCL(22k)
PEO(5.8k)-b-PCL(23.8k)
PEO(5.8k)-b-PCL(24k)
PEO(5.8k)-b-PCL(30.2k)
PEO(5.8k)-b-PCL(33.6k)
PEO(5.8k)-b-PCL(37.7k)
PEO(5.8k)-b-PCL(41.2k)
PEO(5k)-b-PCL(10k)
PEO(5k)-b-PCL(16k)
PEO(5k)-b-PCL(22k)
PEO(5k)-b-PCL(26k)
PEO(5k)-b-PCL(32k)
PEO(5k)-b-PCL(52k)
PEO(3.8k)-b-PCL(17k)
PEO(3.8k)-b-PCL(17.7k)
PEO(3.8k)-b-PCL(20k)
PEO(3.8k)-b-PCL(22.2k)
PEO(3k)-b-PCL(16.5k)
PEO(3k)-b-PCL(19k)
PEO(3k)-b-PCL(20.5k)
PEO(3k)-b-PCL(24.7k)
PEO(3k)-b-PCL(25.8k)
PEO(2.6k)-b-PCL(11.2k)
PEO(2.6k)-b-PCL(12.3k)
PEO(2.6k)-b-PCL(13.9k)
PEO(2.6k)-b-PCL(15.5k)
PEO(2k)-b-PCL(7.4k)
PEO(2k)-b-PCL(9.5k)
PEO(2k)-b-PCL(12k)
PEO(2k)-b-PCL(15k)
PEO(2k)-b-PCL(22k)
PEO(1.5k)-b-PCL(6.3k)
PEO(1.5k)-b-PCL(10.4k)
PEO(1.5k)-b-PCL(12.4k)
PEO(1.5k)-b-PCL(13.7k)
PEO(1.1k)-b-PCL(2.9k)
PEO(1.1k)-b-PCL(3.7k)
PEO(1.1k)-b-PCL(6.3k)

0.21
0.20
0.19
0.16
0.15
0.13
0.12
0.33
0.24
0.18
0.16
0.14
0.09
0.18
0.17
0.16
0.15
0.15
0.14
0.13
0.11
0.10
0.19
0.17
0.16
0.14
0.27
0.17
0.14
0.12
0.08
0.19
0.13
0.11
0.10
0.27
0.23
0.15

Irregular particles
Microspheres, irregular particles
Microspheres, irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Irregular particles
Irregular particles
Irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Polymersomes, irregular particles
Irregular particles
Polymersomes, irregular particles
Polymersomes
Polymersomes, irregular particles
Irregular Particles
Microspheres, irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Microspheres, irregular particles
Microspheres, irregular particles

Vesicle
Yieldd
0
0
0
0
0
0
0
0
0
0
0
0
0
30-50%
10-20%
10-20%
<5%
10-20%
<5%
0
0
0
60-80%
30-50%
10-20%
10-20%
10-20%
60-80%
~100%
30-50%
0
0
0
0
0
0
0
0
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PEO(1.1k)-b-PCL(7.0k)
PEO(1.1k)-b-PCL(7.7k)
PEO(1.1k)-b-PCL(9.5k)
PEO(1.1k)-b-PCL(13.0k)
PEO(0.75)-b-PCL(2850)
PEO(0.75)-b-PCL(5790)
PEO(0.75)-b-PCL(9k)

0.14
0.12
0.10
0.08
0.21
0.11
0.07

Microspheres, irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Irregular particles

0
0
0
0
0
0
0

a

Number-average molecular weight of PEO-b-PCL diblock copolymers as determined
by H NMR spectroscopy. b Weight fraction of the PEO block as determined by 1H NMR
data. c Determined qualitatively from fluorescence confocal and laser optical microsopic
studies of the self-assembled structures formed from thin film rehydration of 50:1
copolymer: Red Nile films. Observed polymersome and irregularly shaped particle
diameters ranged from less than 1 μm to greater than 30 μm; microsphere diameters
ranged from ~5-30 μm. d Approximate yield of polymer vesicles visually estimated from
fluorescence confocal and laser optical microsopic studies qualitatively by comparison of
the morphological fraction corresponding to polymersomes in aqueous solution.
1
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Table 4.2 GPC and 1H NMR Characterization Data for PEO-b-PCL Diblock Copolymers.

PEO-b-PCL Copolymersa

fPEOb

Mn b

Mwc

PDIc

Mwd

PEO(5.8k)-b-PCL(24k)
PEO(5.8k)-b-PCL(33.6k)
PEO(5k)-b-PCL(22k)
PEO(5k)-b-PCL(26k)
PEO(3.8k)-b-PCL(17k)
PEO(3.8k)-b-PCL(20k)
PEO(3.8k)-b-PCL(22.2k)
PEO(3k)-b-PCL(16.5k)
PEO(3k)-b-PCL(19k)
PEO(2.6k)-b-PCL(11.2k)
PEO(2.6k)-b-PCL(12.3k)
PEO(2.6k)-b-PCL(15.5k)
PEO(2k)-b-PCL(9.5k)
PEO(2k)-b-PCL(12k)
PEO(2k)-b-PCL(15k)

0.20
0.15
0.18
0.16
0.18
0.16
0.15
0.15
0.14
0.19
0.17
0.14
0.17
0.14
0.12

29800
39400
27000
31000
20800
23800
26000
19000
22000
13800
14900
18100
11500
14000
17000

27800
28500
25300
31400
15100
17600
19200
16700
19400
16200
17300
19600
12500
13700
16100

1.24
1.20
1.37
1.32
1.20
1.25
1.26
1.23
1.24
1.27
1.25
1.25
1.14
1.21
1.21

28100
31100
24000
36200
18900
19100
22100
17300
19400
19000
20600
24100
16300
15400
18300

a

Number-average molecular weight of PEO-b-PCL diblock copolymers as determined
by 1H NMR spectroscopy. b Weight fraction of the PEO block as determined by 1H NMR
data. c Polydispersity index and weight-average molecular weight of PEO-b-PCL diblock
copolymers as determined from dynamic light scattering (DLS) data of samples analyzed
by gel permeation chromatography (GPC). d Weight-average molecular weight of PEO-bPCL diblock copolymers calculated from refractive index (RI) data of samples analyzed
by gel permeation chromatography using PEO standard samples as calibrants.
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4.4.2. Aqueous Assembly of Meso-scale PEO-b-PCL Diblock Copolymers
Two

preparation

methods,

film

hydration

and

organic

co-solvent

injection/extraction, were chosen to assemble meso-scale amphiphilic PEO-b-PCL
diblock copolymers into their equilibrium aqueous morphologies. While both methods
produced similar results, as film hydration promotes aqueous self-assembly of the
copolymers, is amenable to large-scale preparation while obviating the need for postassembly processing, this technique was used to generate the data summarized in Table
4.1, which describe the observed aqueous morphologies for the comprehensive set of
PEO-b-PCL diblock copolymers that were fabricated. The equilibrium aqueous
morphologies for each PEO-b-PCL diblock copolymer were determined using
fluorescence confocal and optical microscopies under conditions where 1 mol% Nile red
was incorporated into the resultant structures.
Meso-scale polymersomes were obtained uniquely, in near quantitative yield from
aqueous hydration and self-assembly of the PEO(2K)-b-PCL(12K) diblock copolymer
(fPEO = 0.14), as shown in Figure 4.2. These polymersomes possessed both multilamellar
(Figure 4.2c) and unilamellar (Figure 4.2d) bilayer structures. In constrast,
polymersomes were found to coexist with irregular particles in aqueous preparations of
PEO(2-3.8K)-b-PCL diblock copolymers with fPEO ranging between 0.12 and 0.19. In
aqueous suspensions of PEO-b-PCL diblock copolymers derived from higher (5-5.8K) or
lower (0.75-1.5K) molecular weight PEO blocks, no polymersomes were observed
regardless of the PEO/PCL ratio. Note that Disher et al. have also studied the meso-scale
morphologies of a series of PEO-b-PCL diblock copolymers by using solvent evaporation
method.86 And our results by using thin-film hydration preparation method correspond
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well with their observations on the trend of the ability of diblock copolymer compositions
to self-assemble into vesicle structures.
In order to elucidate the effects of diblock copolymer molecular weight
distribution on vesicle formation, PEO-b-PCL diblock copolymers with varying PEO
block size (2600, 3000 or 3800) and narrow molecular distributions (PDI = 1.1) were
separated by GPC and used to generate polymersomes. No further improvement in the
yield of vesicles from these samples was observed relative to the samples with the same
molecular weight but broader molecular distributions (PDI: 1.2-1.4). Furthermore, the
ability of PEO-b-PCL diblock copolymers mixtures which have much wider molecular
weight distributions to self-assemble into polymersomes is also assessed by scanning
laser confocal microscopy. As shown in Figure 4.3, polymersomes can be obtained at a
very high yield from these copolymer mixtures, indicates the molecular weight
distribution had little influence on biodegradable polymersomes formation from
involving PEO(2K)-b-PCL(12K) diblock copolymers.
As PEO-b-PCL diblock copolymers with low PEO weight fractions (<0.12) were
found to be strongly adherent to the Teflon film (following aqueous hydration), an
organic co-solvent water injection/extraction method was employed in an attempt to
prepare polymersomes from a small subset of these copolymers. While no polymersomes
were obtained by this extraction method, porous spherical particles were seen upon
organic co-solvent removal via dialysis; the typical morphology of these particles is
depicted in the fluorescent micrograph (Figure 4.4). These Nile Red encapsulated
spherical particles possess porous surfaces as directly visualized by scanning laser
confocal microscopy (Figure 4.4b), with the bright regions corresponding to the
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emission of encapsulated Nile Red fluorophores in the polymersomes bilayer membrane
alternate with dark regions of the porous surface without Nile Red encapsulation. Note
that, while PEO(5.8K)-b-PCL(24K) has been previously shown to form meso-scale
vesicles via a solvent injection technique,21 no polymersomes were observed in aqueous
suspensions

of

this

diblock

(PDI =

1.2)

formed

via

thin-film

hydration.
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Table 4.3 Comparative Self-Assembled Meso-Scale Morphologies of PEO-b-PCL
Diblock Copolymers in Aqueous Suspensions Obtained via Film Hydration and Organic
Co-Solvent Injection/Extraction Methods.

PEO-b-PCL Copolymers

a

fPEO

b

PEO(5k)-b-PCL(10k)
PEO(5k)-b-PCL(16k)
PEO(5k)-b-PCL(22k)
PEO(5k)-b-PCL(52k)

0.33
0.24
0.18
0.09

PEO(2k)-b-PCL(15k)

0.12

PEO(2k)-b-PCL(22k)

0.08

Morphologies
Observed from
Film Hydrationc
Irregular particles
Irregular particles
Irregular particles
Irregular particles
Polymersomes,d
irregular particles
Irregular particles

Morphologies
Observed
from
Organic Co-Solvent
Injectiona/Extractionc
Small particles
Small particles
Microspherese
Microspherese
Microspherese
Microspherese

a

Number-average molecular weight of PEO-b-PCL diblock copolymers as determined
by H NMR spectroscopy. b Weight fraction of the PEO block as determined by 1H NMR
data. c Determined qualitatively from fluorescence confocal and laser optical microsopic
studies of the self-assembled structures formed from thin film rehydration of 50:1
copolymer: Red Nile films. Observed polymersome and irregularly shaped particle
diameters ranged from less than 1 m to greater than 30 m; microsphere diameters
ranged from ~5-30 m. d Less than 5% of the observed morphologies corresponded to
polymersomes. e Formed quantitatively.
1
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Figure 4.2 Scanning fluorescence confocal micrographs (λex = 488 nm) of PEO(2K)-bPCL(12K)-based vesicles, containing membrane-encapsulated Nile Red (peak emission =
603 nm) in DI water at 25 °C, that display continuous spherical morphology but jagged
edges supportive of solid vesicle membranes. Scale bar = 5 μm.
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Figure 4.3 Scanning fluorescence confocal micrograph (λex = 488 nm) of polymersomes
comprised of a 1:1:1 mixture of PEO(2k)-b-(9.5k), PEO(2k)-b-(12k), and PEO(2k)-bPCL(15k), containing membrane-encapsulated Nile Red (peak emission = 603 nm) in DI
water at 25 °C.
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Figure 4.4 Microspheres imaged using (a) optical microscopy and (b) confocal
fluorescence micrograph (λex = 488 nm) derived from organic co-solvent extraction of
PEO(5k)-b-PCL(52k) containing membrane-encapsulated Nile Red (peak emission = 603
nm) in DI water at 25 ºC.
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4.4.3. Aqueous Assembly of Nano-scale PEO-b-PCL Diblock Copolymers
Small, nano-scale polymersomes can be made by aqueous sonication of a dry
thin-film formulation of PEO-b-PCL on Teflon followed by several cycles of freeze/thaw
extraction. A number of diblock copolymers (Figure 4.5 and Figure 4.6) were selected
to prepare nano-sized self-assembles to check the effect of both hydrophilic fraction and
PEO chain on the formation of vesicles. OL 1-6 are PEO-b-PCL diblock copolymers with
the same PEO chain length (2K) but different hydrophilic PEO weight fraction, while OL
A-E are PEO-b-PCL diblock copolymer with the same PEO weight fraction but different
PEO chain length. Solution morphologies were characterized with Cryo-TEM which
allows for direct visualization of the aggregate nano-sized structures formed in aqueous
solution.
Very different from the meso-scale diblock copolymer particle morphologies,
polymersomes constitute the dominant self-assembled nano-scale morphology. As seen in
Figure 4.5, an increase in the molecular weight of the PCL core block, and subsequent
decrease in the diblock PEO weight fraction to 0.08, results in the shape transition from
bilayer vesicle structures to micellar aggregates. Through the increasing length of PCL
block, the hydrophobic content of the amphiphile is increased and the interfacial
curvature is decreased, which leads to the development of micelles morphologies. Figure
4.5 shows a set of fairly uniform spherical vesicle structures formed from PEO(2K)-bPCL diblock copolymers with fPEO ranging from 0.14 to 0.21. The coexistence of micelles
appears when the fPEO is below 0.14. And for PEO-b-PCL diblock copolymers with a
fixed fPEO (~15%), a change in PEO chain length reveals diblock self-assembly into
micellar and large particle aggregates. In Figure 4.6, micelles formed with the PEO
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molecular weight lower than PEO(1.1K) or higher than PEO(3K) are clearly visible. The
reduced PEO weight fractions of these polymersome-forming PEO-b-PCL compositions
(fPEO: 0.14-0.21) contrast sharply to the PEO-polybutadiene diblock formulations (fPEO:
0.28-0.39),87 and suggest the low PEO weight fraction to be a common theme for
polymersomes generated from diblock copolymers that exploit PCL as a biodegradable
hydrophobic block. This is because the strength of segregation of polybutadiene with
considerably exceeds that of polycaprolactone.86
It is well known that the morphology of diblock copolymer assemblies is
determined by the interfacial curvature,86, 88-90 and previous work reveals that the surface
elasticity of vesicle bilayer membranes is scale independent and only depends on the
interface.4, 87 Therefore, people would expect by examining the meso-scale morphology
of diblock copolymers self-assemblies, it will lead to predictive insights of the nano-scale
morphology. However, our nano-scale experiment results show a very distinctive trend
from expectation that the diblock polymers that could not form meso-scale vesicles may
be able to self-assemble into high yield of nano-scale vesicles. This evolution of
structures change formed from the self-assembly of meso-scale or nano-scale PEO-bPCL diblock copolymers in aqueous solution is very interesting. And this paper is the
first example looking at this morphology transition. The reason for this morphology
transition might be due to the decreased nano-scale polymersomes particle size which
results in increased total surface area and decreased surface tension, core-chain stretching
and the corona chain repulsion as compared to the meso-scale polymer vesicles and thus
cause the change of interface curvature required for vesicle structure formation
accordingly.
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The effect of PEO molecular weight and PEO weight fraction on membrane
thickness has also been measured for these PEO-b-PCl diblock copolymers in Figure 4.5
and Figure 4.6. As we expected, for OL A-E which are PEO-PCL diblock copolymer
with the same PEO weight fraction but different PEO molecular weight, a linear
increasing of the membrane thickness is observed with the increasing of the polymer
molecular weight. However, surprisingly, for OL 1-6 which are PEO-PCL diblock
copolymers with the same PEO molecular weight (2K) but different PEO weight fraction,
varying in the hydrophobic PCL block molecular weight doesn‟t result in the change of
membrane thickness. Therefore, for a fixed hydrophilic PEO block length, the membrane
thickness is not dependent on the hydrophobic PCL block density. We have not observed
such phenomenon in any other amphiphilic diblock copolymer systems. More
experiments are now undergoing to try to explain this membrane thickness independence
on PCL block weight fraction.
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A

B
OL-1
OL-2
OL-3
OL-4
OL-5
OL-6

PEO-b-PCL
Copolymers

fPEO

Vesicle yield Vesicle yield
(μm-sized)
(nm-sized)

PEO(2k)-b-PCL(7.4k)
PEO(2k)-b-PCL(9.5k)
PEO(2k)-b-PCL(12k)
PEO(2k)-b-PCL(15k)
PEO(2k)-b-PCL(18k)
PEO(2k)-b-PCL(22k)

0.21
0.17
0.14
0.12
0.10
0.08

0
60-80%
~100%
<5%
0
0

~100%
~100%
~100%
30-50%
<5%
0

Figure 4.5 (A) Cryo-TEM images of nano-scale PEO-b-PCL diblock copolymers OL 1-6
particles in aqueous suspensions obtained via film hydration and subsequent selfassembly; (B) Morphology of self-assembled meso- and nano-scale structures derived
from PEO-b-PCL diblock copolymers OL 1-6.
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A

B
OL-A
OL-B
OL-C
OL-D
OL-E
OL-F

PEO-b-PCL Copolymers

fPEO

PEO(1.1k)-b-PCL(6.3k)
PEO(2k)-b-PCL(12k)
PEO(2.6k)-b-PCL(15.5k)
PEO(3k)-b-PCL(16.5k)
PEO(3.8k)-b-PCL(22.2k)
PEO(5k)-b-PCL(27k)

0.15
0.14
0.14
0.15
0.15
0.15

Vesicle yield
(μm-sized)
0
~100%
10-20%
10-20%
<5%
0

Vesicle yield
(nm-sized)
60-80%
~100%
~100%
40-50%
10-20%
0

Figure 4.6 (A) Cryo-TEM images of nano-scale PEO-b-PCL diblock copolymers OL AF particles in aqueous suspensions obtained via film hydration and subsequent selfassembly; (B) Morphology of self-assembled meso- and nano-scale structures derived
from PEO-b-PCL diblock copolymers OL A-F.
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Figure 4.7 Membrane thickness of vesicles prepared from OL 1-5.

Figure 4.8 Membrane thickness of vesicles prepared from OL A-E.
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4.4.4. Synthesis, Characterization and Aqueous Assembly of PEO-b-PTMC and
PEO-b-P(CL-co-TMC) Polymers
The ideal candidates for in vivo imaging and drug releasing require soft
biodegradable membranes. However, differential scanning calorimetry (DSC) strongly
suggested that PEO(2K)-b-PCL(12K)-based vesicles are highly crystalline structures with
glass transition temperature over 60 °C.
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To form functional soft resorbable, flexible

and elastic materials, TMC (a highly flexible rubbery polymer) were used to
copolymerize with PEO. An extensive family of FDA proved biodegradable amphilic
PEO-b-PTMC and PEO-b-P(CL-co-TMC) polymers varying in a number average
molecular weight (Mn: 5.7-35.6k) and PEO weight fraction (fPEO: 0.10- 0.25) and TMC
molar fraction of the hydrophobic block (30%, 50%, 100 %) were synthesized,
characterized and examined.
These TMC containing polymers were synthesized either by ring-opening
copolymerization of -caprolactone monomer and trimethylene carbonate monomer using
commercially available monomethoxyl PEO (MePEO2K, MePEO5K) as macro-initiator
in the presence of stannous(II) octoate (SnOct), or by anionic living polymerization of
ethylene oxide monomers to produce PEOs of varying Mn (1.1K, 3.8K). The numberaverage molecular weight was characterized for each copolymer formulation by 1H NMR
spectroscopy (Figure 4.9 and Figure 4.10). The polymers were subsequently screened
for their ability to self-assemble into meso-scale polymersomes in dilute aqueous solution,
the results were summarized in Table 4.4, Table 4.5 and Table 4.6. While many PEO-bPTMC and PEO-b-P(CL-co-TMC) polymers were observed to form meso-scale
polymersomes, none of them produced meso-scale polymersomes quantitatively under
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the thin-film rehydration conditions employed. Therefore, we sought to use blends of the
PEO (2K)-b-PCL(12K) diblock copolymer and PEO(2K)-b-P(CL-co-TMC)(~12K)
diblock tripolymer with different molar fractions of TMC (29% and 49%) to test their
ability to self-assemble into polymersomes. PEO (2K)-b-PCL(12K) diblock copolymer
and PEO(2K)-b-P(Cl-co-TMC) diblock tripolymer were mixed at different ratios: 95:5,
90:10, 80:20, 70:30, 50:50, 30:70 and followed with aqueous hydration of a dry thin-film
of the blend polymers on Teflon film. Scanning confocal microscope images showed that
all these blends form polymersomes, as shown in Figure 4.11 and 4.12, and the blend of
PEO(2K)-b-P(CL-co-49mol%TMC)(11.9K) with PEO(2K)-b-PCL(12K) in 50:50 was
producing polymersomes quantitatively under the thin-film rehydration conditions
employed.
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Figure 4.9 Representative 1H-NMR spectrum of PEO-b-PTMC diblock copolymer.

Figure 4.10 Representative

1

H-NMR spectrum of PEO-b-P(CL-co-TMC) diblock

tripolymer.
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Table 4.4 Self-assembly of PEO-b-PTMC copolymers.

PEO-b-PTMCa

Mnb

fPEOc

% Yield of
polymersomesd

PEO(1.1K)-b-PTMC(4.6K)

5.7K

19.3%

0

PEO(1.1K)-b-PTMC(5.1K)

6.2K

17.7%

0

PEO(1.1K)-b-PTMC(6.2K)

7.3K

15.1%

0

PEO(2K)-b-PTMC(6.8K)

8.8K

22.7%

0

PEO(2K)-b-PTMC(9.4K)

11.4K

17.5%

5-10%

PEO(2K)-b-PTMC(11.2K)

13.2K

15.2%

5-10%

PEO(2K)-b-PTMC(13.0K)

15.0K

13.3%

5-10%

PEO(2K)-b-PTMC(13.8K)

15.8K

12.7%

5-10%

PEO(2K)-b-PTMC(15.3K)

17.3K

11.6%

0

PEO(2K)-b-PTMC(18.2K)

20.2K

9.9%

0

PEO(3.8K)-b-PTMC(17.7K)

21.5K

17.7%

0

PEO(3.8K)-b-PTMC(19.8K)

23.6K

16.1%

0

PEO(3.8K)-b-PTMC(25.8K)

29.6K

12.8%

5-10%

PEO(5K)-b-PTMC(18.0K)

23.0K

21.7%

< 5%

PEO(5K)-b-PTMC(23.0K)

28.0K

17.9%

< 5%

PEO(5K)-b-PTMC(25.9K)

30.9K

16.2%

< 5%

PEO(5K)-b-PTMC(27.5K)

32.5K

15.4%

< 5%

PEO(5K)-b-PTMC(30.6K)

35.6K

14.0%

< 5%

μm-sized

a,b

Number-average molecular weight of PEO-b-PCL diblock copolymers as
determined by 1H NMR spectroscopy. c Weight fraction of the PEO block as determined
by 1H NMR data. d Approximate yield of polymer vesicles visually estimated from
fluorescence confocal and laser optical microsopic studies qualitatively by comparison of
the morphological fraction corresponding to polymersomes in aqueous solution.
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Table 4.5 Self-assembly of PEO-b-P(CL-co-TMC) tripolymers with ~30% TMC molar
fraction in the P(CL-co-TMC) block.
PEO-b-P(CL-co-TMC) tripolymersa

Mn b

fTMCc

fPEOd

μm-sized
Vesicle Yielde

PEO(2K)-b-P(CL-co-TMC)(11.0K)

13.0K

29%

15.4%

0

PEO(2K)-b-P(CL-co-TMC)(11.2K)

13.2K

27%

15.2%

<5%

PEO(2K)-b-P(CL-co-TMC)(12.4K)

14.4K

29%

13.9%

5-10%

PEO(2K)-b-P(CL-co-TMC)(13.1K)

15.1K

29%

13.2%

5-10%

PEO(2K)-b-P(CL-co-TMC)(14.9K)

16.9K

29%

11.8%

0

PEO(3.8K)-b-P(CL-co-TMC)(16.4K)

20.2K

30%

18.8%

5-10%

PEO(3.8K)-b-P(CL-co-TMC)(19.2K)

23.0K

32%

16.5%

5-10%

PEO(3.8K)-b-P(CL-co-TMC)(20.0K)

23.8K

33%

16.0%

<5%

PEO(5K)-b-P(CL-co-TMC)(18.5K)

23.5K

29%

21.3%

0

PEO(5K)-b-P(CL-co-TMC)(25.6K)

30.6K

29%

16.3%

10-20%

PEO(5K)-b-P(CL-co-TMC)(27.5K)

32.5K

28%

15.4%

5-10%

a,b

Number-average molecular weight of PEO-b-PCL diblock copolymers as
determined by 1H NMR spectroscopy. c Molar fraction of the TMC in the P(CL-co-TMC)
block as determined by 1H NMR data. d Weight fraction of the PEO block as determined
by 1H NMR data. e Approximate yield of polymer vesicles visually estimated from
fluorescence confocal and laser optical microsopic studies qualitatively by comparison of
the morphological fraction corresponding to polymersomes in aqueous solution.
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Table 4.6 Self-assembly of PEO-b-P(CL-co-TMC) tripolymers with ~50% TMC weight
fraction in the P(CL-co-TMC) block.
PEO-b-P(CL-co-TMC) tripolymersa

Mn b

fTMCc

fPEOd

PEO(2K)-b-P(CL-co-TMC)(5.9K)

7.9K

49%

25.3%

0

PEO(2K)-b-P(CL-co-TMC)(7.0K)

9.0K

49%

22.2%

0

PEO(2K)-b-P(CL-co-TMC)(8.2K)

10.2K

49%

19.6%

0

PEO(2K)-b-P(CL-co-TMC)(9.3K)

11.4K

49%

17.7%

0

PEO(2K)-b-P(CL-co-TMC)(9.5K)

11.5K

50%

17.4%

0

PEO(2K)-b-P(CL-co-TMC)(11.9K)

13.9K

49%

14.4%

5-10%

PEO(2K)-b-P(CL-co-TMC)(14.3K)

16.3K

48%

12.3%

5-10%

PEO(2K)-b-P(CL-co-TMC)(18.4K)

20.4K

50%

9.8%

<5%

PEO(3.8K)-b-P(CL-co-TMC)(15.5K)

19.3K

51%

19.7%

<5%

PEO(3.8K)-b-P(CL-co-TMC)(19.2K)

23.0K

50%

16.5%

5-10%

PEO(3.8K)-b-P(CL-co-TMC)(22.0K)

25.8K

50%

14.7%

<5%

PEO(5K)-b-P(CL-co-TMC)(18.9K)

23.9K

49%

20.9%

0

PEO(5K)-b-P(CL-co-TMC)(25.3K)

30.3K

48%

16.5%

10-20%

PEO(5K)-b-P(CL-co-TMC)(28.4K)

33.4K

51%

15.0%

5-10%

μm-sized
Vesicle Yielde

a,b

Number-average molecular weight of PEO-b-PCL diblock copolymers as
determined by 1H NMR spectroscopy. c Molar fraction of the TMC in the P(CL-co-TMC)
block as determined by 1H NMR data. d Weight fraction of the PEO block as determined
by 1H NMR data. e Approximate yield of polymer vesicles visually estimated from
fluorescence confocal and laser optical microsopic studies qualitatively by comparison of
the morphological fraction corresponding to polymersomes in aqueous solution.
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Table 4.7 Self-assembly of tripolymer with 29% TMC content in the P(CL-co-TMC)
block and PEO-b-PCL copolymer blends.
PEO(2.0K)-b-P(CL-co-29mol%TMC)(12.4K)
/PEO(2K)-b-PCL(12K)

Yield of μm-sized
polymersomes

a

70/30

<5%

b

50/50

40-60%

c

30/70

10-20%

d

20/80

10-20%

Figure 4.11 Confocal laser fluorescence micrographs of PEO(2K)-b-(PCL-co-49%TMC)
(12.4K) / PEO(2K)-b-PCL(12K) blends. Scale bar = 50 μm.
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Table 4.8 Self-assembly of tripolymer with 49% TMC content in the P(CL-co-TMC)
block and PEO-b-PCL copolymer blends.
PEO(2.0k)-b-P(CL-co-49mol%
/PEO(2k)-b-PCL(12k)

TMC)(12.4k)

Yield of μm-sized
polymersomes

a

70/30

<5%

b

50/50

~100%

c

30/70

40-60%

d

20/80

10-20%

e

10/90

10-20%

f

5/95

10-20%

Figure 4.12 Confocal laser fluorescence micrographs of PEO(2K)-b-(PCL-co-49%TMC)
(12.4K) / PEO(2K)-b-PCL(12K) blends.
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Furthermore, the ability of these TMC containing PEO-b-PTMC and PEO-bP(CL-co-TMC) polymers to self-assemble into nano-scale morphologies were examined
by Cryo-TEM. The results are summerized in Table 4.9. As shown in Figure 4.13,
PEO(1.1K)-b-PTMC(4.6-6.2K) that could not form meso-scale polymersomes selfassembled into ~100% nano-scale polymersomes, follows a similar trend with the
previously reported PEO-b-PCL diblock copolymers that the ability to self-assemble into
meso-scale and nano-scale polymersomes is different. Note that, the sizes of these
PEO(1.1K)-b-PTMC polymersomes are much smaller compare to classic polymer
vesicles. As observed from Cryo-TEM images, most polymersomes are 20-50 nm in
diameter without extrusion, their small sizes will enable them to have prolonged in vivo
circulation time and thus make them great candidate for biomedical applications.
Very interestingly, the PEO(2K, 3.8K, 5K)-b-PTMC with PEO molecular weight
~17% all form novel micelles with very large hydrophobic cores in a quantitative yield
(Figure 4.14). The sizes of these micelles are very narrowly distributed as determined by
both Cryo-TEM and dynamic light scattering (DLS) measurements. In addition, the sizes
can be readily tuned from ~40nm (PEO(2K)-b-PTMC(9.4K)) to ~120nm (PEO(5k)-bPTMC(25.9k)) by simply varying the diblock copolymer molecular weight. Therefore,
these polymeric micelles can be served as highly effective delivery vehicles for poorly
water-soluble drugs with well-defined hydrophobic volume. Moreover, the unusual large
sizes of these micelles suggest enhanced mechanical stability over conventional micelles
in vitro and in vivo.
Similar with PEO-b-PTMC, PEO-b-P(CL-co-TMC) diblock tripolymers also
displayed similar properties of forming quantitative amount of small sized (20-50 nm)
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vesicles or large sized (50-100 nm) micelles (Figure 4.15). So far, only a small portion of
PEO-b-PTMC and PEO-b-P(CL-co-TMC) polymer self-assemblies have been observed
by Cryo-TEM. More PEO-b-PTMC and PEO-b-P(CL-co-TMC) polymers will be
examined soon. In addition, the self-assembling morphology of the PEO-b-PCL and
PEO-b-PTMC or PEO-b-P(CL-co-TMC) polymer blends will also be studied for fully
characterization and understanding of these TMC containing polymers.
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Table 4.9 Morphology of self-assembled meso- and nano-scale structures derived from
PEO-b-PTMC and PEO-b-P(CL-co-TMC) diblock copolymers.

Diblock copolymera

fTMCb

fPEOc

Vesicle
yieldd

Nano-scale
morphologiese

PEO(1.1K)-b-PTMC(4.6K)

100%

19.3%

0

~100% vesicles

PEO(1.1K)-b-PTMC(5.1K)

100%

17.7%

0

~100% vesicles

PEO(1.1K)-b-PTMC(6.2K)

100%

15.1%

0

~100% vesicles

PEO(5K)-b-PTMC(25.9K)

100%

16.2%

< 5%

~100% micelles

PEO(5K)-b-PTMC(25.9K)

100%

16.2%

< 5%

~100% micelles

PEO(2K)-b-P(CL-co-TMC)(11.9K)

49%

14.4%

5-10%

~100% micelles

PEO(3.8K)-b-P(CL-co-TMC)(19.2K)

50%

17.3%

5-10%

~100% micelles

PEO(5K)-b-P(CL-co-TMC)(25.3K)

48%

16.5%

10-20%

~100% micelles

PEO(2K)-b-P(CL-co-TMC)(12.4K)

29%

13.9%

5-10%

~100% vesicles

PEO(3.8K)-b-P(CL-co-TMC)(19.2K)

32%

16.5%

5-10%

~100% micelles

PEO(5K)-b-P(CL-co-TMC)(25.6K)

29%

16.3%

10-20%

~100% micelles

a

Number-average molecular weight of PEO-b-PCL diblock copolymers as determined
by H NMR spectroscopy. b Molar fraction of the TMC in the P(CL-co-TMC) block as
determined by 1H NMR data. c Weight fraction of the TMC and PEO block as determined
by 1H NMR data. e Approximate yield of polymer vesicles visually estimated from
fluorescence confocal and laser optical microsopic studies qualitatively by comparison of
the morphological fraction corresponding to polymersomes in aqueous solution. f
Determined qualitatively from cryo-TEM studies of the self-assembled structures formed
from thin film rehydration followed by sonication.
1
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Figure 4.13 Cryo-TEM images of nano-scale PEO(1.1k)-b-PTMC(5.1k) diblock
copolymers particles forming ~100% polymersomes in aqueous suspensions obtained via
film hydration and subsequent self-assembly. Scale bar = 500 nm.
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Figure 4.14 Cryo-TEM images of nano-scale PEO-b-PTMC diblock copolymers
particles forming ~100% micelles in aqueous suspensions obtained via film hydration
and subsequent self-assembly.
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Figure 4.15 Cryo-TEM images of nano-scale PEO-b-P(CL-co-TMC) diblock tripolymers
particles in aqueous suspensions obtained via film hydration and subsequent selfassembly.

243

Differential scanning calorimetry was also utilized to elucidate the thermal
transitions properties of these TMC containing polymers synthesized. Figure 4.16
compares the glass transition temperature of the five single polymers: PEO (2K),
PCL(12K)-b-PEO(2K),

P(CL-co-TMC(29

mol%))

(12.4K)-b-PEO(2K),

P(CL-co-

TMC(49 mol%)) (11.9K)-b-PEO(2K) and PTMC(11.2K)-b-PEO(2K). There is a clear
big drop of glass transition temperature from 62.7 °C (PEO-b-PCL) to 40-50°C for TMC
containing

polymers

P(CL-co-TMC(29mol%))

(12.4K)-b-PEO(2K),

P(CL-co-

TMC(49mol%)) (11.9K)-b-PEO(2K) and PTMC(11.2K)-b-PEO(2K). The thermal
transition properties of the polymer blends made from different ratios of P(CL-coTMC(49 mol%)) (12.4K)-b-PEO(2K), P(CL-co-TMC(29 mol%)) (11.9K)-b-PEO(2K)
and PCL(12K)-b-PEO(2K) are also measured as shown in Figure 4.17, Figure 4.18, and
Figure 4.19. Again, by including TMC in the hydrophobic block, a decrease of glass
transition temperature was observed. In addition, the glass transition temperature
decreased with increasing the TMC content in the polymer blend.
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Figure 4.16 DSC data of: (a) PEO (2K); (b) PEO(2K)-b-PCL(12K); (c) PEO(2K)-bP(CL-co-TMC(29mol%)) (12.4K); (d) PEO(2K)-b-P(CL-co-TMC(49mol%)) (11.9K);
and (e) PEO(2K)-b-PTMC(11.2K).
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Finally, we used micropipette aspiration to probe the rheological properties of
giant polymersomes. The meso-scale polymersomes prepared from PCL(12K)-bPEO(2K) , P(CL-co-TMC(49 mol%)) (12.4K)-b-PEO(2K) / PCL(12K)-b-PEO(2K) 50:50
blend, and two different molecular weight PEO-b-PBD diblock copolymers OB2 and
OB18 were progressively aspirated into a micropipette at stress rates of 0.1 pN nm -1 sec-1
up to the point of rupture. Values of the lysis tension for the TMC polymer blend as well
as the three nonblend polymersomes studied are shown in Figure 4.20. The results
generally showed that for soft PEO-b-PBD polymersomes, increasing molecular weight
led to an increase in stability, consistent with general ideas of mesophase stability for
strongly segregated copolymers. For highly crystallized PEO-b-PCl polymersomes that
have solid membranes, they were unable to be aspirated and did not lyse at any pressure,
as has been previously reported.27, 86 However, for the PEO-b-PCL/PEO-b-P(CL-co-TMC)
polymer blend, they could easily lyse at a much lower tension compare to the soft PEO-bPBD polymersomes. This implicates the possible applications of using this PEO-bPCL/PEO-b-P(CL-co-TMC) blend to prepare quantitative polymersomes vesicles that are
soft and amorphous and will facilitate their location and transportation to cells in vivo.
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Diblock copolymers

Lysis Tension
(mN/m)

PEO(2K)-b-P(CL-co-49mol%TMC)(11.9K)
/PEO(2K)-b-PCL(12K) 50: 50

2.92 + 1.10

PEO(2K)-b-PCL(12K)

does not lyse at any pressure

PEO(1.3K)-b-PBD(2.5K)

14

PEO(3.6K)-b-PBD(6.8K)

18

Figure 4.20 Micropipette aspiration study results of different polymers. The optical
microscopy images represents the lysing process of polymersomes prepared from
PEO(2K)-b- PCL(12K) / PEO(2K)-b-P(CL-co-TMC(49mol%))(11.9K) 50/50 blend.
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4.4.5. Vinyl Sulfone Functionalization of PEO-b-PCl Diblock Copolymer
Various ways exist to generate functionalities on the surface of the hydrophilic
leaflets of amphipilic block copolymer membranes to attach peptides and proteins for tumor

targeting and drug delivery.91 However, very few work has been done towards the
biodegradable polymersomes. Herein, we reported the successfully development of a
functionalization method for modification of the biodegradable PEO-b-PCL diblock
copolymer by attaching the vinyl sulfone group. The vinyl sulfone functional group has
been previously employed to attach peptides to chain ends of non-degradable PEO-bPBD92 and degradable poly(ethylene oxide)-block-poly(γ-methyl-ε-caprolactone) PEO-bPMCL76, 92 polymersome-forming systems. Using similar strategy to functionalize PEOb-PCl diblock copolymers and subsequently conjuagate with peptides or proteins, we will
be able to make ligand-conjugated PEO-b-PCL biodegradable polymersomes.
The reaction route to prepare peptide-conjugated biodegradable polymersomes is
shown in Scheme 4.7. After silver(I) oxide-mediated tosylation of PEO, the resulting
product was analyzed by 1H NMR spectroscopy, and we determined that an average of
about 90% of PEO chains had a tosyl group installed (Figure 4.21A). The tosylated PEO
polymer was then reacted with an excess of potassium thioacetate in DMF to displace the
tosyl groups with thioacetates. The tosyl groups were displaced to form the thioacetate
and then hydrolyzed to thiol-PEO as confirmed by 1H NMR analysis (Figure 4.21B).
Vinyl sulfone functionalized PEO polymer are synthesized via conjugate addition
reaction between thiols and divinyl sulfone, and the unreacted divinyl sulfone is
separated by repeated precipitation into ice-cold diethyl ether. As determined by 1H NMR
spectroscopy (Figure 4.21C), the vinyl sulfone addition reaction has a nearly quantitative
reaction yield toward thiol groups. After installation of vinyl sulfone, the hydroxyl end
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groups of VS-PEO were used as initiation sites for polymerization of CL. The most
commonly used method for PEO-b-PCL polymerization is in presence of FDA-approved
SnOct2 catalyst at high reaction temperature (130 ºC). However, we found the vinyl
sulfone functionality in PEO is not very stable at such high reaction temperature, and the
functionalization degree in the final VS-PEO-b-PCL polymers is significantly decreased
by using this method. Therefore, a different ring-opening polymerization method was
developed with a highly effective AlEt3 catalyst at room temperature. Minimal loss of
vinyl sulfone (from 81% to 61-68%) was detected by 1H NMR spectroscopy under this
polymerization condition (Figure 4.21D). Vinyl sulfone functionalized diblock
copolymers with various different molecular weights were synthesized in Table 4.10,
with the polymerization proceeded at a well-controlled fashion: PCL block molecular
weight is linearly dependent on the amount of CL monomer added to the polymerization
reaction (Figure 4.22). By controlling the mole ratio of CL monomer with VS-PEO, the
PCL block molecular weight can be precisely tuned.
To verify that the aggregate morphology was unaffected after inducing vinyl
sulfone groups, functionalized PEO(2K)-b-PCL(11.7K) were self-assembled into mesoscale polymersomes. The polymersomes formation were in a comparative yield to the
PEO(2K)-b-PCl(12K) diblock copolymer. Although the meso-scale polymersomes selfassembling yield from the other functionalized diblock copolymers in Table 4.10 is
relatively lower, we would expect all of them to have a high nano-sized polymersomes
formation yield based on our previous nano-sized PEO-b-PCL polymersomes analysis.
Therefore, we have synthesized and characterized the vesicle-forming block polymer VSPEO-b-PCL which can be used to develop a degradable, targeted drug delivery system.
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Scheme 4.7 A. Synthetic routes to VS-terminated PEO-b-PCL diblock copolymer. B.
Michael type addition of cysteine-contained antibody to VS-functionalized PEO-b-PCL
polymersomes.
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Figure 4.21 1H NMR spectra (CDCl3) of (a) PEO tosylate, (b) PEO thiolate, (c) PEO
vinyl sulfonate and (d) VS-PEO-PCL.
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Figure 4.22 Correlation of VS-PEO(2K)-b-PCL molecular weight to the mass of CL
monomer.

Table 4.10 Molecular weight and functionalization degree of vinyl sulfone functionalized
PEO-PCl diblock copolymers.

Functionalized Polymers

fPEO

Vinyl Sulfone Functionalization %

VS-PEO(2K)-b-PCL(6.3K)

24.1%

67.1

VS-PEO(2K)-b-PCL(7.8K)

20.4%

63.4

VS-PEO(2K)-b-PCL(8.5K)

19.0%

70.2

VS-PEO(2K)-b-PCL(9.4K)

17.5%

62.0

VS-PEO(2K)-b-PCL(10.0K)

16.7%

67.7

VS-PEO(2K)-b-PCL(11.7K)

14.6%

61.5

VS-PEO(2K)-b-PCL(14.1K)

12.4%

62.9

VS-PEO(2K)-b-PCL(17.7K)

10.1%

60.2
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4.5. Conclusions
A series of PEO-b-PCL diblock copolymers varying in PEO block size (Mn: 750,
1100, 2000 and 5000), fPEO (0.08-0.33), and Mn (3.6-57K) were synthesized by ringopening polymerization of ε-caprolactone monomer using commercially available
MePEO as the macro-initiator. Anionic living polymerization was also employed to
synthesize PEO-b-PCL copolymers with a wider range of controlled PEO block sizes (Mn:
1500, 2600, 3000, 3800, and 5800), CN as the PEO block terminal group, fPEO = 0.100.23, and Mn ranging from 7.8 to 47K. All copolymers were isolated by GPC and
possessed narrow molecular weight distributions (PDI: 1.14-1.37). The PEO-b-PCL
diblock copolymers were subsequently screened for the ability to assemble into various
aqueous morphologies via two separate preparation methods: film hydration and organic
co-solvent/water injection/extraction. Meso-scale polymersomes were obtained from a
PEO(2K)-b-PCL(12K) diblock copolymer (PDI = 1.21) in nearly quantitative yield by
both methods, while a much broader range of diblock copolymer varying in both the
hydrophilic fraction (fPEO: 0.14-0.21) and PEO chain length 1.1-3K can self-assemble into
a very high yield of nano-sized polymersomes upon hydration of a dry thin film deposited
on Teflon. Without the addition of co-solvent, the thin film hydration method enables
controllable, large-scale synthesis, and avoids the presence of residual organic solvent
which may be toxic for in vivo applications. Therefore, this is a pioneer work provides
the entire gate of a roadmap of biodegradable PEO-b-PCL diblock copolymer
compositions that can self-assemble into meso- and nano-scale polymersomes as
biomaterials for future cosmetic, imaging, and drug delivery applications. This work also
demonstrates that if nanoscale bilayer vesicles are desired, convincingly screening the
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ability to form meso-scale polymersomes is inappropriate. Furthermore, we can expect by
simply varying the PCL chain length or hydrophobic fraction, the biodegradable
hydrophobic membranes of the nano-scale polymer vesicles can be tuned to enable the
precise control of encapsulated drug release based on the effect of PCL/PEO molar ratios
on the biodegradation kinetics. 93-96
However, the thermal properties of these PEO-b-PCL-based biodegradable
polymersomes as measured by DSC indicate that they are highly crystallized at room
temperature. Recognizing the need to develop highly elastic, soft polymersomes from
non-toxic, biodegradable polymers, we further designed and characterized vesicles
assembled from a series of PEO-b-PTMC and PEO-b-P(CL-co-TMC) polymers by
copolymerize CL with a second TMC monomer, an elastomeric aliphatic polyester with
excellent flexibility and poor mechanical strength. The thermal properties of these
polymers were studied by using DSC and micropipette aspiration; both indicate that we
formed a soft based material. The introduction of TMC provides a route to significantly
alter membrane rheological properties. Furthermore, the morphology of nano-scale selfassemblies from these TMC containing polymers varying in PEO molecular weight (2K,
3.8K and 5K), PEO weight fraction (0.15-0.20) and TMC mole fraction (30%, 50%,
100%) was examined by Cryo-TEM. Interestingly, these polymers formed either 100%
polymer vesicles in much smaller sizes compare to traditional polymersomes or 100%
uniformly distributed micelles structures with very large hydrophobic cores in aqueous
solution; these novel and unique structures has a great deal of potential for in vivo and
drug delivery applications.

256

Finally,

we

synthesized

functionalized

vesicle-forming

VS-PEO-b-PCL

biodegradable diblock copolymers varying in number-average molecular weight (Mn: 9.8
- 16.1k) and PEO weight fraction (fPEO: 12.4 – 20.4%). These functionalized block
copolymers self-assemble in water to form polymersomes with high reactivity and
specificity toward cysteine containing proteins under a mild conjugate reaction condition.
A precise control of VS-PEO-b-PCL molecular weight is achieved by ring-opening
copolymerization of VS-PEO and CL with a highly effective AlEt3 catalyst. The VS
functionalization groups on the exterior of the vesicles are capable of reacting with thiolcontaining targeting proteins under very mild conditions in advantageous for reaction
rates, yields, and stability. By including VS-PEO-b-PCL as the minority component prior
to self-assembly, we anticipate it to serve as a versatile platform for specific delivery of a
variety of therapeutic payloads with enhanced targeting due to ligand bound to vinyl
sulfone groups.
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CHAPTER 5. Quantitative Membrane Loading of Quantum
Dots into Polymersomes
5.1. Summary
Multi-functional materials that combine both hydrophilic and hydrophobic agents
with novel, exceptional properties gained increasing attention in recent years for their
potential applications in nanobiotechnology. By incorporating inorganic, strongly
fluorescent hydrophobic quantum dots (QDs) of exceptional photostability into the
bilayer membrane of polymer vesicles, we developed a new imaging system with wideranging potential for biomedical applications. The hydrophobic shell of diblock
copolymer vesicles was successfully loaded with highly fluorescent CdSe/ZnS QDs as
hydrophobic model substrates. The nano- and micro-scopic effects on the resultant
vesicles‟ structural and material properties were studied.

The combination of

fluorescence microscopy studies to examine the meso-scale morphology of CdSe/ZnS
QD incorporated polymersomes and cryogenic transmission electron microscopy (CryoTEM) experiments to observe nano-scale morphology of gold nanoparticle incorporated
polymersomes showed that the nanoparticles were located within the hydrophobic
interior of the shell bilayer, introducing curvature of the copolymer layers around the
guest nanoparticles. In addition, to investigate whether incorporation of nanoparticles into
polymersome bilayers impact physical properties of the polymer vesicles, fluorescent
CdSe/ZnS QDs of two different sizes (average diameter = 2.1 and 5.2 nm, as determined
by TEM) were selected as hydrophobic model substrates and quantitatively enclosed into
the vesicles with polymersome membranes fabricated from three different diblock
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copolymers

poly(ethylene

oxide)-block-poly(butadiene)

PEO30-b-PBD46

(OB2,

membrane thickness 9.6 nm), PEO80-b-PBD125 (OB18, membrane thickness 14.8 nm) and
poly(ethylene

oxide)-block-poly(ε-caprolactone)

PEO45-b-PCL107 (OL,

membrane

thickness 27.2 nm) at various QD concentrations. The self-assembled polymersome
bilayer structures remained essentially unchanged, in appearance of some multilayered
and aggregated structures when hydrophobic CdSe/ZnS QDs were incorporated within
the vesicle shell. To note, the morphology of OL polymersomes incorporating CdSe/ZnS
QDs changed from a highly crystalline, rigid vesicle structure to a noncrystallized,
amorphous vesicle structure. Both the QD size and concentration impact this
phenomenon. For small 2.1 nm CdSe/ZnS QDs, the vesicle structure remains crystalline
at low QD concentrations, and the morphology change only happened in appearance of a
high QD concentration. However, for larger 5.2 nm CdSe/ZnS QDs, vesicle morphology
changes were evident at both low and high concentrations. Ongoing studies are now
carried out to examine vesicle mechanical properties as a function of QD size and
concentration via micropipette aspiration experiments.
Furthermore, we demonstrate the reproducible and quantitative loading of various
sized hydrophobic CdSe/ZnS QD molecules within synthetic polymersome membranes.
The limits for QDs incorporation inside the polymersome hydrophobic shell was
systematically evaluated; revealed how far the bilayer can curve before different
structural assemblies are favored. The polymersomes have a large capacity to solvate
these large hydrophobic QDs within their thick membranes. These aqueous-insoluble
QDs can be readily dispersed at high solution concentrations via membrane incorporation
within aqueous vesicle suspensions. Due to membrane incorporation, hydrophobic
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CdSe/ZnS QDs encapsulants were effectively prevented from self-aggregation, and
successfully shielded from deleterious environmental interactions. Together, these studies
present a generalized paradigm for the generation of promising multifunctional inorganicorganic hybrid materials suitable for in vivo biomedical applications.

5.2. Introduction
The incorporation of nanoparticles into artificial membranes is very important in
medical science and nanotechnology, featuring a wide range of applications in drug
delivery and sensor technologies.1 Of utmost interest in this context are polymersomes
because of their unique ability to form a variety of polymer-based, biocompatible
nano/microstructures. Amphiphilic block copolymers tend to self-assemble into
polymersomes2-4 with hydrophobic bilayer membranes and hydrophilic inner corona
similar to liposomes.5 Such block copolymer vesicles in aqueous media have attracted
increasing interest due to their enhanced stability compared to classical liposomes and
due to the potential to control vesicle properties such as bilayer thickness, permeability,
and surface functionalities by appropriate chemical copolymer adjustment.2 These
properties of polymersomes offer a powerful route to the formation of multifunctional
nanosized materials for imaging and drug delivery applications.6-8
Currently, there are two different approaches for incorporation of nanoparticles
into the vesicles: (1) nanoparticles are formed in situ within the polymersomes (2)
nanoparticles are induced into the vesicle during self-assembling. In the first approach,
metal salts are usually solubilized within the vesicle, followed by chemically reduction
and production of the final metal nanoparticles at the same sites where they initially
present.9-15 The main disadvantage of this process is that the vesicles may be decomposed
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and less stable during the chemical modification steps to produce metal nanoparticles,
thus limits the applicable chemistry and the nanoparticles growth within the vesicles may
not be well controlled. In the second approach, by providing hydrophobic properties
within their high capacity hydrophobic bilayer membranes, the polymersomes enable the
incorporation of large nanoparticles into the vesicle shell during self-assembly processes.
Preformed nanoparticles of a specific size with defined structure and solubilizing surface
groups are directly incorporated into vesicular structures via interfacial interaction. In this
case, the nanoparticles have a better defined shape, size and morphology since they are
preformed and characterized. In addition, interfacial interaction between the
nanoparticles and the membrane can be tuned much more efficiently, enabling the
controlled loading of nanoparticles into polymer vesicles.
To date, not much work has been done on nanoparticle incorporated
polymersomes via self-assembling that are suitable for in vivo applications. Lots of
nanoparticles and diblock copolymers hybrids form micelles16-18, oligolamella “onionlike” structures19 or or irregular polymer/nanoparticle aggregates17, 20 rather than vesicle
structures. In addition, the present nanoparticle and diblock copolymer systems that form
polymersome vesicles are based on cosolvent method21-23 which involves use of organic
solvents during the preparation which can lead to in vivo toxicity. The only study that
incorporated quantum dots and gold nanoparticles in diblock copolymers by the film
rehydration method didn‟t show direct province of nanoparticles locating in the bilayer
membrane. The authors claimed the self-assembly structures are polymersomes, however,
the vesicle structure was difficult to discern and appear to have micellar properties as
measured by TEM.24, 25
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To the best of our knowledge, this report is the first to describe well-defined
meso-scale and nano-scale polymersomes packed with nanoparticles in the bilayer
membrane formed by thin-film hydration method. Specifically, QDs were chosen as the
hydrophobic model substrate to be induced into the polymersomes. Semiconductor
crystallites (known as QDs)26-28 are excellent probes for bioimaging applications due to
their broad excitation spectra, narrow emission spectra, tunable emission peaks, long
fluorescence lifetimes and negligible photobleaching.

29-31

However, they must maintain

three properties under aqueous biological conditions: efficient fluorescence, colloidal
stability, and low nonspecific adsorption. Besides, the use of QDs in biological cells
always poses concerns about potential cytotoxicity. QDs tend to aggregate, resulted in
poor colloidal stability32 and toxicity in live cells33. Consequently, the use of QDs in
biological applications is still limited and primarily confined to in vitro studies. By
incorporation of hydrophobic QDs into the polymersome membranes, we developed a
generic method for making QDs water-soluble and biocompatible, well dispersed and
separated in the vesicles for greatly increased colloidal stability and decreased toxicity.
Our first work involves preparation of meso-scale CdSe/ZnS QD incorporated
polymersomes with three different diblock copolymers OB2, OB18, and OL at various
QD concentrations. As observed by confocal microscopy, classic bilayer vesicle
structures coexist with some multilayered and aggregated vesicle structures for all
polymersome samples composed with different diblock copolymers, and the vesicles
sizes decreased with increasing QD concentration in the vesicle shell. Very interestingly,
we noticed a morphology transition of QD encapsulated OL diblock from highly
crystalline vesicles to non-crystalline vesicles after nanoparticle incorporation,
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underscoring the importance of the self-assembly structure and nanoparticle arrangement.
Moreover, Cryo-TEM experiments were performed for the visualization of the nanosized nanoparticle incorporated polymersomes. Due to the low dynamic contrast of these
CdSe/ZnS QDs, gold nanoparticles were loaded into the hydrophobic membranes. The
cryo-TEM results correspond well with confocal microscopy studies, indicate the
consistency of the vesicle properties in both meso- and nano-dimensions.
To explore the capacity of polymer vesicles to stably incorporate nanoparticles
non-covalently within their thick lamellar membranes, polymersomes self-assembled
from three diblock copolymers with CdSe/ZnS QDs incorporated in prescribed molar
ratios within their membranes were generated and characterized. The extent of vesicle
membrane loading of QDs was quantitative measured by optical verification via steady
state absorption. We demonstrate that polymersomes can be loaded with sizes ranging 25 nm QDs below a critical saturation point without significantly compromising the robust
thermodynamic and mechanical stabilities of these synthetic vesicle assemblies. Abover
the saturation point, there are strong aggregation interactions in-between the QDs as well
as between the QDs and dibock copolymers, resulted in a low QD uptake efficiency.
Finally, steady-state fluorescence spectroscopic studies were employed for delineation of
intermembranous interactions of QDs and diblock copolymers. As expected, at identical
membrane concentrations, the emission intensity per QD is higher for thicker membranes
and smaller QDs, both accounts for the strong aggregation effect in a thin membrane and
for larger QDs.
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5.3. Experimental Methods
5.3.1. Preparation of Nanoparticle Incorporated Polymersomes
PEO(1300)-b-PBD(2500)

(OB2)

and

PEO(3600)-b-PBD(6800)

(OB18)

copolymers under study were custom synthesized by Polymer Source, Inc (Dorval,
Quebec Canada).

PEO(2K)-b-PCL(12K) copolymers was synthesized following

established ring opening polymerization methodology as described in 4.3.1. CdSe/ZnS
QDs with hexadecyl amine ligand at sizes of 2.1 nm and 5.2 nm were purchased from
Evidentdot Inc. 2-4 nm gold nanoparticles with oleic amine ligand were purchased from
Sigma-Aldrich. Formation of giant (> 1 um) and small (< 300 nm) diameter emissive
polymersomes followed thin-film hydration procedures. Briefly, diblock copolymer and
nanoparticles species in toluene were combined at different molar ratios and uniformly
coated on the surface of a Teflon plate, followed by evaporation of the solvent under
vacuum for > 12 h. The Teflon plate consisted of a l/16" thick sheet of Teflon cut in
small squares and roughened by sand paper to create macroscopically uniform digitations.
Addition of aqueous solution (DI water) and heating at 60 °C for 48 h led to spontaneous
budding of giant (5-50 μm) emissive polymersomes (membrane loaded at prescribed
polymer:nanoparticle molar ratios) off of the Teflon and into the aqueous surroundings.
Small (< 300 nm diameter) unilamellar polymersomes that possess appropriately narrow
size distributions were prepared via procedures analogous to those used to formulate
small lipid vesicles (sonication, freeze-thaw extraction, and extrusion). Free nanoparticles
were removed by dialysis using a 1000 kDa membrane (SpectrumLab, Inc).
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5.3.2. Morphology characterization of Nanoparticle Incorporated Polymersomes
Confocal Laser Scanning Microscopy: All confocal images were collected on a
Leica SP5 laser scanning confocal microscope (Wetzlar, Germany). A 405 nm diode laser
source was coupled to an inverted Leica DM16000CS microscope with a 40× oilimmersion objective (Leica Plan NeoFluor, NA=1.25). An acousto-optic beamsplitter
(AOBS) with a collection bandwidth of 20 nm served as a dichroic mirror to allow the
405-nm excitation light to reach the sample and to allow selection of emission
wavelengths. The emission bandpass for integrated fluorescence intensity measurements
was set to 500-750 nm. Cooled photomultiplier tubes (PMTs) were used to measure
fluorescence through a 121 μm pinhole in a confocal arrangement with a theoretical axial
resolution of 2 μm. Images were line averaged (16× per line) for improved image quality.
Leica LAS AF 1.8.2 software was used for data acquisition.
Cryo-TEM: Specimens were prepared in a Controlled Environment Vitrification
System (Vitrobot). Approximately 10 μL of solution were deposited on a holey carbon
film supported on a TEM grid (200 mesh, Ted Pella). Blotting the excess solution
produced 100-300 nm thick films suspended in the void spaces of the holey film. Rapid
immersion in liquid ethane (-180 °C) vitrified the solutions, which were then transferred
to a liquid nitrogen cooled Cryo-TEM holder (Gatan 626). High magnification images
were obtained using a FEI Tecnai G²Twin TEM at 200 kV.
5.3.3. Quantification of QD Incorporated Polymersomes
Aqueous suspensions (in DI water) of small nano-sized CdSe/ZnS QDs emissive
polymersomes were transferred to a glass vial, frozen in liquid N2, and lyophilized
(FreeZone 4.5 L Benchtop Freeze Dry System, Labconco Corporation, Kansas City, MO;
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Model 77500) for 24 hours to destroy the vesicles and dry the polymer and fluorophore
species. The mass of the dry samples were measured. The dry samples were then taken
up in toluene and their absorption spectra recorded on a Shimadzu UV-1700
Spectrofluorimeter (Varian Inc, USA) . The concentrations of CdSe/ZnS QDs in the
original polymersome solutions were calculated via Beer's Law using the toluene
absorption spectra and the previously determined average molar extinction coefficients
for each CdSe/ZnS QDs in this solvent.

The mass of the recovered polymer was

calculated by subtracting the mass of QDs from the mass of dry sample mixture.
5.3.4. Emission Profiles of QD Incorporated Polymersomes
Fluorescence spectra of emissive CdSe/ZnS QD incorporated polymersomes were
obtained with Edinburge FL920 spectrophotometer (Edinburgh Instruments Ltd, UK).
Emission spectra were corrected using the spectral output of a calibrated light source
supplied by the National Bureau of Standards. QD incorporated polymersome solutions
were produced from thin-film formulations of polymer and QDs deposited at various
molar ratios. Steady state electronic absorption spectra of the solutions were obtained
prior to dilution to yield fluorophore absorptions less than 0.05 ABS units in each sample.
Steady state fluorescence spectra were recorded and normalized by fluorophore
absorption to yield the relative fluorescence per molecule in each of the various vesicle
formulations. This value was then multiplied by the number of QDs per polymersome
and reported as the relative fluorescence intensity per vesicle.
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5.4. Results and Discussion
5.4.1. Generation of Nanoparticle Incorporated Polymersomes in Micro- and
Nano- Dimensions
Figure 5.1A depicts the steps involved in the fabrication of nanoparticle
incorporated polymersomes. A solution of nanoparticles and polymers in toluene is dried
on a thin teflon film to form a multilamellar polymer film, from which vesicles are
spontaneously formed by hydration under water and sonication. We investigated three
diblock copolymers (different hydrophobic blocks, various block lengths, etc.), as well as
nanoparticle with different sizes and surface ligands and their impact upon bilayered
vesicle formation. We found that the nanoparticle incorporation into polymersomes is not
limited to any particular class of polymer, polymer size regime, or set of NP surface
ligands. For observation by confocal microscopy, we constructed giant vesicles (1-50 m)
by classical swelling. Figure 5.1B shows representative confocal images of meso-scale
vesicles, which appear as spherical emissive circles with a more intensive fluorescent
perimeters. This result demonstrates that the hydrophobic CdSe/ZnS QDs are integrated
in the hydrophobic bilayer of the vesicle, and a high yield of giant unilamellar vesicles
was obtained. Figure 5.1C shows Cryo-TEM images of 2-4 nm gold nanoparticle
incorporated into the membranes of nanoscale vesicles. The scattering contrast of gold
nanoparticles is much higher compared to the diblock copolymer, enabling the gold
nanoparticles to be clearly seen as dark spots inside the vesicle structure. The
polymersomes are frozen in a thin water film during Cryo-TEM experiments, resulted in
the projection of the three-dimensional vesicle into the two-dimensional imaging.21 Those
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gold nanoparticles appearing in the aqueous inner core are therefore also enclosed in the
vesicle shell due to the projection.
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Figure 5.1 A. Steps involved in the formation of nanoparticle incorporated
polymersomes.
B. Confocal fluorescence images of 2.1 nm CdSe/ZnS QD incorporated OB18
polymersomes by hydration swelling. Left column: optical microscopy images; central
column: fluorescent microscopy images; right column: overlapped images.
C. Cryo-TEM images of 2-4 nm Gold nanoparticles with oleic amine ligand incorporated
nanosized OB18 polymersomes by hydration, sonication and extrusion.
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5.4.1.1. Confocal Microscopy Characterization of QD Incorporated Meso-scale
Polymersomes
Confocal microscopy studies demonstrate dispersion of numerous highly emissive
CdSe/ZnS QDs within the polymersome hydrophobic membranes, and show that the
vesicles maintain an aqueous interior free of nanoparticles with potential for heterofunctional utility such as hydrophilic drug delivery. The accumulation of CdSe/ZnS QDs
within polymersome membranes is strongly driven by their hydrophobicity. In addition,
there is neither detectable leakage of nanoparticles to the external aqueous solution or
internal core as observed by confocal microscopy over weeks at room temperature.
Furthermore, the morphology of QD incorporated polymer self-assemblies was
studied with various QD concentrations in the copolymer bilayer membrane. For OB2
polymersomes, we observed smaller vesicles and more multilayered and aggregated
structures with increasing QD concentrations (Figure 5.2 and Figure 5.3). Besides, the
vesicle sizes varied considerably between the two OB molecular weights. Following
hydration we observed mostly 5-10 μm with some 20 μm vesicles for lower molecular
weight QD incorporated OB2 polymersomes, and 1-2 μm with some 10 μm vesicles for
QD incorporated OB18 polymersomes.
OL diblock copolymer was also used to self-assemble into μm-sized
polymersomes with CdSe/ZnS QDs. Confocal microscopy studies of this system show
very interesting results. A significant phase transformation of the vesicle structure with
increasing nanoparticle concentration was observed. As shown in Figure 5.4, for OL
polymersomes with a small amount (0.08 mol%) of 2.1 nm CdSe/ZnS QDs, the vesicles
remained as crystalline, irregular structures. However, when the incorporated 2.1 nm
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CdSe/ZnS QDs concentration was increased to 0.5 mol%, the vesicle structures was more
amorphous and appears as sphere vesicles. For larger 5.2 nm CdSe/ZnS QDs, at both low
(0.08 mol%) and high (0.5 mol%) QD incorporation concentrations, the morphology
changed to noncrystalline, spherical vesicles. The polymersome morphology of 2.1 nm
CdSe/ZnS QD incorporated OL polymersomes at a low nanoparticle concentration of
0.08 mol% is very similar to the unincorporated OL polymersomes (Figure 5.5).
Therefore, by simply incorporating QDs into the OL polymersomes, we achieved the
transition of OL polymersome membrane from rigid crystallized membranes to soft
elastic membranes as ideal candidates to successfully passivate tumor tissue in vivo (as
described in 4.2). The surface membrane of a giant 5.2 nm CdSe/ZnS QD incorporated
polymersome was also measured by Z-section confocal microscopy. The distribution of
CdSe/ZnS QDs in the bilayer membrane was mostly uniform with some aggregation as
observed in Figure 5.6.
This morphology transformation phenomenon in QD incorporated OL
polymersomes can be explained by the interaction of the QDs with the polymersome
hydrophobic membrane. The QDs are in dynamic state in the vesicle bilayer membrane,
and the motion of QDs would disturb the crystalline structure of bilayer, resulting the
decrease of phase transition temperature (Tc) and the increase of the fluidity of bilayer,
thereby cause the phase transition of OL polymersomes.
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Figure 5.2 Capacity of OB18 polymersome membranes to stably incorporate and solvate
CdSe/ZnS QDs.
(A) Polymersomes containing equal aqueous concentrations of polymer but with different
amounts of 2.1 nm CdSe/ZnS QDs, as indicated by the molar ratios of polymer:QD; (B)
Polymersomes containing equal aqueous concentrations of polymer but with different
amounts of 5.2 nm CdSe/ZnS QDs, as indicated by the molar ratios of polymer:QD.
Aggregated and multilayered structures are shown for both 2.1 nm and 5.2 nm CdSe/ZnS
QD incorporated OB2 and OB18 polymersome compositions.
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Figure 5.3 Capacity of OB2 polymersome membranes to stably incorporate and solvate
CdSe/ZnS QDs.
(A) Polymersomes containing equal aqueous concentrations of polymer but with different
amounts of 2.1 nm CdSe/ZnS QDs, as indicated by the molar ratios of polymer:QD; (B)
Polymersomes containing equal aqueous concentrations of polymer but with different
amounts of 5.2 nm CdSe/ZnS QDs, as indicated by the molar ratios of polymer:QD.
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Figure 5.4 Overlapped confocal fluorescence images of different sized CdSe/ZnS QD
incorporated OL polymersomes by hydration swelling.
A. OL to 2.1 nm CdSe/ZnS QD molar ratio: 1200:1; B. OL to 2.1 nm CdSe/ZnS QD
molar ratio: 200:1; C. OL to 5.2nm CdSe/ZnS QD molar ratio: 1200:1; D. OL to 5.2nm
CdSe/ZnS QD molar ratio: 200:1.
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Figure 5.5 (A) Overlapped fluorescence confocal microscope image of 2.1 nm CdSe/ZnS
QD incorporated OL polymersomes at OL to 2.1 nm CdSe/ZnS QD molar ratio: 1200:1
by hydration swelling. (B) Nonincorporated optical microscope image of OL
polymersomes.
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Figure 5.6 Z-section confocal fluorescence confocal images of 5.2nm CdSe/ZnS QD
incorporated OL polymersomes by hydration swelling.
OL to 5.2nm CdSe/ZnS QD molar ratio: 1200:1. Total Z-sectioning was 12 µm in depth.
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5.4.1.2. Cryo-TEM Characterization of Gold Nanoparticle Incorporated Nano-scale
Polymersomes
The morphology of CdSe/ZnS QD incorporated polymer self-assemblies in mesodimensions was studied by confocal microscopy and showed successful incorporation of
nanoparticles into polymersome bilayer membranes. Furthermore, we want to study the
morphology of nanoparticle incorporated polymer vesicles in nano-dimensions. Since
these CdSe/ZnS QDs have a very low electron density, and are not able to be observed
after incorporating into the polymer membranes by Cryo-TEM. The electron-dense gold
nanoparticles were used to incorporate into the polymer bilayer membranes and the
morphologies were subsequently examined by Cryo-TEM.
Similarly to μm-sized CdSe/ZnS QD incorporated polymersomes, gold
nanoparticles with a different surface ligand (oleic acid) also self-assemble into the
bilayer membrane of nano-sized polymersomes, as observed by Cryo-TEM, suggests that
the surface ligands on the nanoparticles have minimal effect on the self-assembling
process. In nm-sized gold nanoparticle incorporated polymersome samples, a mixture of
bilayered, multilayered and aggregated structures was also observed (Figure 5.7).
However, the amount of multilayered and aggregated structures was less than that seen in
μm-sized vesicles. As visually estimated from Cryo-TEM experiments, approximate 7090% of the gold nanoparticle incorporated OB18 polymersomes are single bilayered
normal vesicle structures, with small amount multilayered and aggregated structures;
while in μm-sized polymersomes, over 50% vesicles are multilayered and aggregated.
This phenomenon may be caused by the sonication step that decreased the aggregation of
nanoparticle incorporated vesicles during the self-assembling process for nano-scale
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polymersomes formation. Also, as expected based on μm-sized CdSe/ZnS QD
incorporated polymersomes results, with an increase in loading concentration of gold
nanoparticles, much smaller and more aggregated polymersomes were formed (Figure
5.8). The membrane thicknesses of three different polymersomes with and without gold
nanoparticle incorporation were also measured from Cryo-TEM (Figure 5.9), and were
found to be consistent before and after gold nanoparticle incorporation.
This gold nanoparticle incorporated polymersome system is a well-defined
example of hydrophobic vesicle shell loading, with only hydrophobic interactions
between copolymer and nanoparticle. The copolymer bending around the guest
nanoparticles as a function of membrane thickness, incorporated nanoparticle diameters
and concentrations was examined. A mechanism hypothesis (Figure 5.10) is proposed
based the observed phenomena that aggregation of nanoparticles affects its incorporation
into block copolymers self-assembled polymersomes. Usually, the assembly of the
vesicles is driven by hydrophobic/hydrophilic (or interfacial) effects,34-37 but there are
also important secondary effects38-40 such as curving of membranes, budding of vesicles
or fission and fusion of vesicles upon the interaction of nanoparticles with the interface or
surface of the membrane. The interaction energy between the nanoparticles and the
polymer vesicle membrane determines the polymer self-assemblies structures and the
physical properties of the polymersome membrane. The size and number of the
nanoparticles also play an important role for curving effects to or from the membrane,
fusion or fission of the vesicles or even embedding of the nanoparticle within a
membrane occurs.24 Therefore, the change of interfacial interactions of the QDs and
diblock copolymers at various QD concentrations or different QD sizes, causes the
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aggregation effect and induces the change of the membrane mechanical properties. At a
low nanoparticle concentration, the nanoparticle aggregation effect is small and most
nanoparticles are uniformly distributed with the diblock copolymers. Thus, upon selfassembly, we observed a large amount of single dispersed bilayer vesicle structures
together with a small portion of the multilayered and aggregated structures. With an
increasing of the nanoparticle concentration, there will be more aggregation from the
nanoparticles and more multilayered and aggregated vesicle structures were observed.
Finally, at a very high nanoparticle concentration, most nanoparticles tend to aggregate
together and instead of incorporation into the polymersome bilayer membranes, they
formed large aggregates and directly precipitated out of the aqueous solution during selfassembling, leaving behind polymersomes with very low nanoparticle concentrations in
the bilayer membranes. The observed vesicle size decreased with increasing nanoparticle
concentrations can also be explained using this hypothesis. With increasing nanoparticle
concentration in the polymersome bilayer membrane, the interaction energy of
nanoparticles with the hydrophobic membrane increases, resulted in increased interfacial
curvature, or decreased membrane bending rigidity of the membrane and thus the smaller
and more aggregated structures. In addition, the membrane thickness does not change
much after nanoparticle incorporation, indicating that the nanoparticles are densely
compacted within the hydrophobic membrane of the polymersomes.
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Figure 5.7 Cryo-TEM images of 2-4 nm gold nanoparticle incorporated OB18
polymersomes show multilayered and aggregated vesicle structures.
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Figure 5.8 Cryo-TEM images of 2-4 nm gold nanoparticle incorporated polymersomes
with increasing nanoparticle concentration, as indicated by the molar ratios of
polymer:gold nanoparticle (left to right).
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Polymersomes
composition

Membrane thickness

Polymersomes
composition

Membrane thickness

OB2-Gold

9.31 ±1.32 nm

OB2

9.6 ±1.61 nm

OB18-Gold

14.5 ±2.17 nm

OB18

14.8 ±1.96 nm

OL-Gold

26.77 ±4.62 nm

OL

27.2 ±6.23 nm

Figure 5.9 Cryo-TEM images of 2-4 nm gold nanoparticle incorporated polymersomes
with different polymer environments, and membrane thickness of the polymersomes with
or without 2-4 nm gold nanoparticle incorporation.
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Figure 5.10 Hypothesis for CdSe/ZnS QD incorporated polymersomes formation process
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5.4.2. Quantitative Loading of CdSe/ZnS QDs in Polymersomes
To correlate changes in the packing of hydrophobic QDs encapsulates with the
extent of membrane loading and their relative sizes to the thickness of the polymersome
membrane, further characterization is carried by steady-state absorption and fluorescence
spectroscopic studies. Aqueous suspensions of small (<300 nm diameter) emissive
polymersomes were formed from thin-film formulations deposited at various mole ratios
of three different diblock copolymers (OB2, OB18, OL) and two different sizes emissive
CdSe/ZnS QDs (2.1 nm and 5.2 nm). Since the polymer (λabs.max.= 255 nm) and 2.1 nm
CdSe/ZnS QDs (λabs.max. = 428 nm) or 5.2 nm CdSe/ZnS QDs (λabs.max. = 515 nm) have
non-overlapping absorption in aqueous vesicle suspensions, the electronic absorption
spectra of the redissolved solution of lyophilized QD incorporated polymersomes in
toluene were monitored and the concentrations of CdSe/ZnS QDs were calculated using
Beer's Law.
Very different from porphyrin fluorophores incorporated polymer vesicles which
can incorporate large payloads of porphyrin chromophores up to 20 mol% for a varies
sizes of porphyrins,41 there is a saturation point for QD incorporation. When the molar
ratio of polymer:QD deposited on Teflon were below that saturation point, which is 75:1
for OB2, 50:1 for OB18, 35:1 for OL with 2.1 nm CdSe/ZnS QDs; or 600:1 for OB2,
400:1 for OB18, and over 200:1 for OL with 5.2nm CdSe/ZnS QDs, there was a near
perfect correlation with the resultant polymer:QD molar ratio composing the vesicles‟
membrane structures (Figure 5.11), as well as a greater than 80% uptake of the mass of
Teflon-deposited fluorophore into the membranes of the water-soluble polymersomes
(Figure 5.12A). However, when the QD concentration is above the saturation point, the
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final QD concentration in vesicle membranes and the uptake efficiency significantly
decreases.
The theoretical maximum QD concentration within polymersome membranes can
be calculated by assuming the vesicular hydrophobic volume is completely filled up with
QDs. Therefore, the maximum 2.1 nm CdSe/ZnS QD concentration (mole ratio of
polymer:QD) that can be incorporation in polymersomes is: 24.8:1 for OB2, 15.3:1 for
OB18, 9.1:1 for OL; while for 5.2 nm CdSe/ZnS QDs, it is 198.7:1 for OB2, 122.4:1 for
OB18, and 74.9:1 for OL. Interestingly, these numbers are all about 3 times multiplex of
the experimental data. It is known that there is a critical interaction between nanoparticles
and diblock copolymers, below the critical value, there is significant aggregation and
above it there is almost no aggregation.42 Therefore, our study demonstrated that the
critical value for CdSe/ZnS QDs incorporation into polymersomes is 1/3 of the
theoretically calculated maximum loading concentration. This determined critical value
can be used to guide the quantitative loading of any nanoparticles with specific sizes into
the polymersome membrane.
The membrane-uptake of QDs into solution corresponds well with the maximum
QD loading concentration within vesicle membranes; the uptake of QDs is as high as ~
70-90% below the saturation concentration and greatly decreased to 10-20% above the
saturation concentration. The vesicle yields for 2.1 nm CdSe/ZnS QDs incorporation
follow the same trend with the membrane-uptake ability of QDs in vesicles; there is
minimal aggregation of QDs and polymers below the saturation point with a high vesicle
yield and more aggregation above the saturation point, resulted in the decreased vesicle
yield. However, the vesicle yields of 5.2 nm CdSe/ZnS QD incorporated polymersomes
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changes differently, without much decreasing above the saturation point as seen in
Figure 5.12B. A possible explanation for this phenomenon is described in our hypothesis
(Figure 5.10) that the formation of CdSe/ZnS QD incorporated polymersome is mainly
affected by the aggregation effect. The interactions between QDs and the interactions
between QDs and segments of the block copolymer both have strong aggregation effect.
Above the saturation concentration, the CdSe/ZnS QDs and diblock copolymers form
large aggregations which precipitate out of solution (as observed during the sample
preparation of 2.1 nm CdSe/ZnS QD incorporated polymersomes ), resulted in decreased
vesicle yield. Therefore, for larger CdSe/ZnS QDs that are saturated at quite low QD
concentration, very few polymers were co-precipitated with the CdSe/ZnS QDs and
resulting in small change of the vesicle yield.
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Figure 5.11 Capacity of polymersome membranes to stably incorporate and solvate 2.1
nm and 5.2 nm CdSe/ZnS QDs.
(A) The polymer:QD ratio composing the vesicles' membranes as a function of the
polymer:QD molar ratio originally deposited on Teflon, as determined by electronic
absorption spectroscopy. Experimental conditions: T = 23 °C, DI water.
(B) Solution vials containing equal aqueous concentrations of polymer but with
decreasing amounts of CdSe/ZnS QDs, as indicated by the molar ratios of polymer:QD
(left to right), under both room light and UV light.
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Figure 5.12 Polymersomes accommodating hydrophobic CdSe/ZnS QDs of various sizes.
(A) The membrane-uptake of CdSe/ZnS QDs into aqueous vesicle suspensions and (B)
the yield of emissive polymersomes in aqueous solution as a function of the polymer:QD
molar ratio originally deposited on Teflon, as determined by electronic absorption
spectroscopy. Experimental conditions: T = 23 °C, DI water.
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Upon further quantitative examination, the solutions of CdSe/ZnS QD
incorporated polymersomes were diluted, in order to obtain concentrations of QDs within
the linear range of fluorescence detection (i.e. less than or equal to 0.05 absorbance units),
and their fluorescence spectra were recorded (Figure 5.13). Spectrophotometer analysis
of aqueous solutions of QD incorporated polymersomes verified strong fluorescence
emission from large numbers of membrane-soluble nanoparticles, indicating excellent
QD dispersion and light-harvesting characteristics. Nanoparticles manifest photophysical
properties within the polymersomal matrix that are similar to those previously established
in organic solvents. In addition, increasing QD concentrations augments the absorption
oscillator strength and shifts the emission maximum progressively to longer wavelengths.
By spectral comparison, emissive polymersomes formed from increasing QD
concentrations showed marked decreases in their respective fluorescence signal
intensities, when normalized by the total number of QDs per vesicle. The reduced
photoluminescence intensity per QD and bathochromic shift of photoluminescence band
with increasing QD concentration both indicate aggregation of QDs. Nanoparticle
aggregation results in attenuated fluorescence due to self-absorption and augmentation of
non-radiative decay channels, therefore both segregation of the nanoparticle and control
of their microenvironment are imperative.
In order to explore the relative distribution of 2.1 nm and 5.2 nm CdSe/ZnS QDs
within the polymersome membrane, we compared concentration-dependent fluorescence
emission of each QD when loaded within vesicles of different membrane corethicknesses. By increasing membrane thickness, the relative fluorescence emission of
both 2.1 nm CdSe/ZnS nanoparticles and 5.2 nm CdSe/ZnS nanoparticles displayed a
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linear increase in relative fluorescence signal intensity at identical fluorophore membrane
concentrations (Figure 5.13), indicating a change in the relative distribution of the QD
fluorophore when incorporated in the thicker polymersome membrane. In addition, this
increase in the relative emission per molecule was more pronounced in the case of 5.2 nm
CdSe/ZnS QDs relative to 2.1 nm CdSe/ZnS QDs (Figure 5.14) and indicates that the
larger QDs experience, as expected, a greater number of aggregation effect, resulting in
loss of fluorescence emission. These results suggest that the diminished QD emissive
output with increasing vesicle membrane-loading derives mainly from the QDs emission
quenching dominated by loading-dependent aggregation.
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Figure 5.13 Fluorescence spectra of CdSe/ZnS QD incorporated polymersomes
dependent on the molar ratios of polymer:QDs constituting the vesicles' membranes.
Spectra were normalized by QD concentration and plotted on a relative scale of emission
intensity.
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Figure 5.14 Comparison of relative fluorescence signal intensity per CdSe/ZnS QD in
aqueous polymersome suspensions as a function of membrane mol% loading
(experimental conditions: T = 23 ºC, DI water).
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5.5. Conclusions
In this chapter, we report an interesting observation of wide-ranging potential for
cellular imaging and manipulation by readily disperse aqueous-insoluble nanoparticles at
high solution concentrations via membrane incorporation within aqueous vesicle
suspensions. The hydrophobic shell of diblock copolymer vesicles was successfully
loaded with highly fluorescent QDs and gold nanoparticles as hydrophobic model
substrates, which suggests that polymersome incorporation is an effective way to make
nanoparticles water-soluable and biocompatible. The combination of independent
methods of characterization by fluorescence microscopy imaging and Cryogenic TEM
both confirmed that the hydrophobic substrates were enclosed inside the hydrophobic
vesicle shell. Further experiments with differently sized nanoparticles and different
diblock copolymers determined the limits for particle enclosing inside the vesicle shell,
revealing how far the double-layer can curve before different structural assemblies are
favored. Moreover, we described the fabrication and controlled quantitative loading of
CdSe/ZnS QDs to the polymersomes membranes, and outlined a basic protocol for
determining loading-dependent effect of different sized nanoparticles when confined into
the synthetic vesicle membranes. Compared to other systems, they simultaneously
provide efficient fluorescence, a great reduction in photobleaching and the augument of
QDs colloidal stability with tunable size and switchable physical properties. These results
indicate that vesicle-encapsulated QDs fulfill the promise of generating novel
intracellular fluorescent probes to revolutionize bioimaging of living cells and tissues
both in vitro and in vivo.
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CHAPTER 6. Major Results and Future Directions for the
Development of NIR-Emissive Polymersomal Markers

6.1. Chapter 2: Synthesis, Characterization and Properties
Conjugated

(Porphinato)zinc(II)

Compounds

of

Featuring

Benzothiadiazole Spacer Units
6.1.1. Major Results
We synthesizied a class of quinoidal spacer conjugated (porphinato)zinc(II)
(PZn-(BTD-PZn)n, (PZn)2-(BTD-(PZn)2)n) and (BTD-(PZn)n-BTD) complexes that
featuring conjugated BTD spacer with varying degrees of porphyrin conjugation. The
performance of electronic and optical devices based on these conjugated species is
optimized by reducing and tuning energy gaps between the highest occupied molecular
orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO). These
compounds possess very high emission dipole strength with great enhancement of
emission intensity and tremendous luminescence quantum yields (18% to 38% in THF,
and 18%-49% in toluene) in the NIR region (700–1100 nm), make them extremely bright
NIR emitters as electrooptic materials in a range of photonic applications, especially for
optical imaging purpose after incorporation into polymersomes. The synthesis, optical
spectroscopy, potentiometric studies, and electronic structural calculations are reported
and show that the magnitudes of the potentiometric HOMO−LUMO gap (Ep) and
quantum yields in conjugated organic materials can both be modulated.
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6.1.2. Future Directions


Study the solvent relaxtion pathways that augment excited-state polarization and

cause an increasing of quantum yield in nonpolar solvent toluene than polar solvent THF.


Incorporate these BTD conjugated porphyrins into polymersomal vesicles and

engineering the optical properties of these emissive polymersomes.
6.1.3. Papers Related To This Chapter
Synthesis,

Characterization

and

Properties

of

Conjugated

(Porphinato)zinc(II)

Compounds Featuring Benzothiadiazole Spacer Units
Wei Qi, Jaehong Park, Ian Stanton, Michael J. Therien. In prepration.

6.2. Chapter

3:

Antibody

Conjugated

Near-Infrared

Emissive

Polymersomes for Active Targeting
6.2.1. Major Results
We have established targeted NIR-emissive polymersomal structures that emit
over the 700-950 nm spectral domain. These nanoscale, NIR-emissive bilayered vesicles
feature hundreds-to-thousands copies of a single member of a larger family of conjugated
multi(porphyrin) structures engineered to possess high emission dipole strength. And the
hydrophilic PEO terminus is functionalized with selected activated functional groups to
enable conjugation to proteins and proteins. This is the first work that systematically
studies the functionalization chemistries for direct antibody conjugation to polymersomes.
Six different coupling procedures were developed and we evaluated all these method in
terms of antibody conjugation degree and polymersomes recovery yield to find the
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optimized universal method for antibody attachment. The surface functionality degree
and antibody concentration effect is also studied for controlled antibody conjugation on
surface of polymersomes.
Based on the functionalization techniques we developed for direct conjugation of
antibody to polymersomes surface, we have created a universal method to make
immunopolymersomes for tumor cell targeting and cell tracking. Two different tumor
cells are studied. Anti-ErbB2 NIR emissive polymersomes is developed to enable
efficient intracellular delivery for HER2 breast cancer cells targeting with these optical
probes. And a few different NIR emissive immunopolymersomes are also prepared for
detecting of prostate cancer cells. NIR imaging allows quantitative, repetitive, in vivo
detection of fluorophore-laden cells, at centimeter tissue depths without disturbing
cellular function. Flow cytometry and confocal microscopy results indicate that antiErbB2 immunopolymersome polymersome delivery to HER2 cells is concentration and
time dependent, resulting in punctate intracellular localization. We observe significant
uptake of NIR emissive polymersomes when conjugated to the peptide, with a lower
detection limit of 5000 labeled cells. The extent of polymersome delivery is estimated to
be 86,000 ± 2,500 vesicles/ cell with the uptake efficiency as high as 37%. Further,
loading prostate cancer cells with different immunopolymersomes showed specific
delivery of the immunopolymersomes to the tumor cells. Our studies will enable future in
vivo tracking of labeled tumor cells by NIR fluorescence based imaging.
6.2.2. Future Directions
More studies on comparison of the coupling procedures and find the optimized
antibody density on polymersomes surface for targeted cell binding:
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Polymer concentration (mM) effect on antibody coupling efficiency.



Effect of chemical manipulation of antibody on its antigen binding activity.



Efficiency of antibody-conjugated polymersomes (ACP) on target binding for

different coupling procedures.


Effect of Ab surface density on ACP on target binding.
For Anti-ErbB2 polymersomes (AEP), there are a lot of further characterizations

we need to carry out. And also we can load drugs such as DOX to these AEP for targeted
delivery:


Pharmacokinetics of AEP.



Stability of AEP-dox in Vivo.



Antitumor Efficacy of AEP-dox against HER2 Human Breast Cancer Xenografts.



Toxicity of AEP-dox.



Antitumor Efficacy of AEP-dox versus Combination Therapy.

6.2.3. Papers Related To This Chapter
Antibody Conjugated Near-Infrared Emissive Polymersomes for Active Targeting
Wei Qi, Diane Fels, Mark W. Dewhirst, Michael J. Therien. In prepration.
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6.3. Chapter 4: Synthesis, Characterization, Polymersome Preparation,
Morphology Assessment and Functionalization of Biodegradable
Diblock Copolymers
6.3.1. Major Results
A series of FDA-approved, biodegradable PEO-b-PCL diblock copolymers
varying in PEO block size (Mn: 750-5000), fPEO (7.7%-33.3%), and Mn (3.6k-57k) were
synthesized by ring-opening polymerization and anionic living polymerization. The PEOb-PCL diblock copolymers were subsequently screened for the ability to assemble into
nano-scale and meso-scale polymersomes morphologies by different preparation methods.
We found that only PEO-b-PCL diblock copolymers possessing a PEO block size of 2k3.8k, and fPEO ranging from 11.8-18.8%, were found to assemble into meso-scale
biodegradable polymersomes. And meso-scaled polymersomes were obtained uniquely in
nearly quantitative yield from a PEO(2k)-b-PCL(12k) diblock copolymer (PDI:1.21).
However, very interestingly, these diblock copolymer form nano-scale vesicle
morphologies in nearly quantitative yield on a much broader range. The compositions
that form none or very little meso-scale polymersomes could form ~100% nano-scale
polymersomes, which implicts a various applications for this diblock copolymers as
nano-sized dilvery vesicles.
To improve the mechanical properties of these highly crystalized polymersomes
made from degradable PEO-b-PCL diblock polymers, we copolymerized with a flexible
and elastic TMC to make PEO-b-PTMC diblock copolymers and PEO-b-P(CL-co-TMC)
diblock tripolymers. The thermal properties of these polymers are studied by using both
DSC and micropipette aspiration. Both experiments indicates that we formed a soft based
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material by using this polymer blend. Althought these polymers have a low yield on
forming meso-scaled vesicles, we expect they will show a similar trend on formation of
nano-scaled polymersomes to PEO-b-PCL diblock copolymers, study on the ability of
these polymers to self-assembly into nano-scaled vesicles is now undergoing.
We functionalized this biodegradable PEO-b-PCL diblock copolymer with
reactive vinyl sulfone groups at the terminus of the corona-forming PEO block. These
groups are capable of tethering high concentrations of a thiol-containing targeting peptide
after self-assembly of vesicles in mild conditions.

This is the first example of

functionalized biodegrdable diblock copolymers, and this system should serve as a
versatile platform for specific delivery of a variety of therapeutic payloads in a carrier
capable of utilizing a wide range of targeting moieties.
6.3.2. Future Directions
1. Study the ability of TMC-based diblock copolymer to self-assemble into nano-sized
polymersomes.
2. Use these vinyl sulfone functionalized biodegradable PEO-b-PCL polymers to
prepare nano-scale polymersomes, and conjugate peptides to the surface of these
biodegradable polymersomes while incorporating drugs in the aqueous inner core to
achieve targeted drug delivery.
6.3.3. Papers Related To This Chapter
1. Nano- and Meso-Scale Polymersomes, Based on Biodegradable Poly(ethylene
oxide)-block-Polycaprolactone (PEO-b-PCL) Copolymers
Wei Qi, Guizhi Li, Peter Ghoroghchian, Daniel A. Hammer, Michael J. Therien. In
preparation.
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2. Synthesis of Highly Elastic Biodegradable Polymersomes Featuring a Soft Segment
of Trimethylene Carbonate (TMC)
Wei Qi, Guizhi Li, Michael J. Therien. In preparation.
3. Functionalized biodegradable polymersomes: a new approach to targeted drug
delivery
Wei Qi, Ying Ma, Michael J. Therien. In preparation.

6.4. Chapter 5: Quantitative Membrane Loading of Quantum Dots into
Polymersomes
6.4.1. Major Results
1. Successful incorporation of hydrophobic highly fluorescent quantum dots and gold
nanoparticles into the bilayer membrane of both meso-scale and nano-scale polymer
vesicles based on PEO-b-PBD and PEO-b-PCl diblock copolymers.
2. Interestingly, the mechanical properties of PEO-b-PCl polymersomes change with
incorporated nanoparticle concentration and incorporated nanoparticle sizes.
3. Quantitative loading of quantum dots into nano-sized polymersomes is studied. The
loading process shows very different trend compare to the porphyrin incorporation in
polymersomes, which could be explained by our loading mechanism hypothesis.
Together, these studies present a generalized paradigm for the generation of complex
multi-functional materials that combine both highly emissive quantum dots and polymers
through cooperative self-assembly.
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6.4.2. Future Directions


Study the interesting photoluminescent properties of the quantum dots after

incorporation into polymersomes.


Use these quantum dots incorporated polymersomes for cell imaging and compare

them to porphyrin based emissive polymersomes.


Incorporate up-converting nanoparticles in the bilayer membrane of polymersomes to

make UV-degradable polymersomes for controlled drug releasing.
6.4.3. Papers Related To This Chapter
1. Nanoparticles Incorporation into nano- and meso-Scale Polymersomes
Wei Qi, Michael J. Therien. In preparation.
2. Quantitate loading of Quantum dots into Polymersomes
Wei Qi, Michael J. Therien. In preparation.
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